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Centralised monitoring: Data collected through an electronic data capture and 
queries identified by monitor that may need further attention to alleviate 
problems. 
Data quality monitoring: the oversight and review of research processes, 
procedures, records, data reporting, appropriate conduct and ongoing evaluation. 
Double data entry: Entering the data twice and comparing differences between 
datasets. 
Logic, range and consistency checks: Flag indicator results that fail common-
sense comparisons to other indicators or other disaggregation. 
On-site monitoring: All monitoring activities undertaken at the clinical trial site. 
Source data verification: Comparing source data (original or certified copy) 
documents to data recorded or entered to a case report form or electronic record or 
database. 
Statistical techniques: For example, cluster and outlier analyses.  
Remote monitoring: Data monitored off-site, includes delivering documents via 
email, fax or snail mail to monitoring personnel to conduct source data 
verification. 
Risked-based targeted monitoring: Focus on certain data points that have been 
identified to have the most risk.  
Risked-based triggered monitoring: After certain events like a large number of 





To learn about human health, clinical research studies are conducted. A 
substantial concern for all clinical research studies is the failure to collect, process 
and present good quality data. Poor data quality may stem from error. 
International guidelines have identified that it is an essential need to monitor 
study activity to ensure that the rights, safety and wellbeing of participants are 
protected. However, the guidelines provide limited insight on how to perform 
monitoring procedures including the nature and extent of monitoring needed to 
ensure quality. Without clear guidance, this leaves clinical researchers confused 
about the most appropriate quality assurance and control procedures.  
The central hypothesis of this thesis is that despite the wide variations, 
exploration and evaluation of appropriate data quality monitoring procedures in 
clinical research studies will provide guidance toward developing a “fit-for-use” 
data quality monitoring framework (DQMF). This hypothesis was tested in five 
key studies using an explanatory sequential design guided by the Data-
Information-Knowledge-Wisdom (DIKW) model as the theoretical framework. 
A systematic literature review and meta-analysis were conducted to explore the 
current evidence regarding the variability of data quality monitoring procedures in 
clinical research studies (study 1). The review showed that there has been an 
increase in new approaches (i.e. risk-based and centralised monitoring) to 
monitoring data quality but there does not appear to be a “one-size-fits-all” 
approach that could be utilised for ‘best practice’. The majority of included 
articles were associated with large multi-site intervention trials, suggesting 




review identified that centralised monitoring was conducted more frequently 
(25.91 per 365 person-days) when compared to source data verification (SDV) 
(1.70 per 365 person-days), on-site (1.62 per 365 person-days) and remote (3.17 
per 365 person-days) monitoring procedures.  
In order to gather information about current data quality tools and procedures that 
are used within Australian clinical trial sites, a feasibility study of n=20 clinical 
trials was completed using an online survey (study 2). Results from the survey 
found that centralised monitoring (65%) was the most common procedure, despite 
50% of sites still completing traditional approaches (e.g. 100% SDV), a labour-
intensive and cost-inefficient method. The survey revealed that only 50% of the 
trial sites had a data management plan in place. Thus, clinical trial sites were 
implementing ad-hoc procedures pragmatically to ensure data quality.   
The findings of the feasibility study informed a national survey to explore, in 
detail, the procedures that are implemented for ensuring data quality in Australian 
clinical studies (study 3a). A national survey with n=547 study respondents 
revealed of 67% clinical studies followed national and/or international guidelines 
for data monitoring. Over half (55%) of the clinical studies applied SDV 
compared to risk-based targeted and triggered monitoring (10-11%). There was a 
borderline significant association between intervention trials and a definition for 
protocol deviation and/or violation (odds 3.065, p = 0.096). This may suggest 
when clinical trials are provided with additional guidance and resources, they are 
more likely to implement the required procedures. This study confirmed that 
small single-site clinical studies were continuing to conduct more traditional 
approaches (i.e. SDV) to monitor data quality instead of using more optimal risk-




Given the previous studies had identified heterogeneity in Australian clinical 
research data monitoring approaches, an opportunity sample of clinical 
researchers who had completed the quantitative national survey were invited to 
participate in a semi-structured interview (study 3b). Interviewees described their 
experiences with data quality monitoring in clinical studies. This study 
highlighted that Australian intervention clinical trials were implementing a variety 
of monitoring procedures tailored to their situation and context. Barriers to the 
design and conduct of data monitoring included meeting the demands for 
excessive monitoring set by regulatory agencies, a lack of funding and inadequate 
infrastructure which were keenly felt by independent, non-commercial and 
academic small scale researchers. It was a common phenomenon for all clinical 
studies to lack guidance, education and training, in relation to relevant data 
quality monitoring procedures.  
The findings from studies 1 to 3 were used to generate ideas to guide the 
development of a “fit-for-use” data quality monitoring framework (DQMF) for 
clinical research (study 4). The framework contains three key components of data 
quality, data quality monitoring, and data quality management. The components 
are presented in a nested concentric network to illustrate the relationships and 
hierarchy; and provides a single consolidated framework for monitoring data 
quality of individual clinical research studies with reference to key international 
documents. Each layer of the framework contains important procedures and 
concepts to be undertaken. The importance of training and education spans all 
layers of the DQMF. Stakeholder evaluation established common terminology 
and definitions as crucial to the success of the DQMF. The utility of this DQMF 




adaptations according to study context and data availability.  
This thesis offered early evidence of a novel DQMF to aid in the development of 
a long-term strategy to increase efficacy for clinical research data quality 
monitoring while acknowledging that a “one-size-fits-all” approach is not 
appropriate. The evidence suggests that not all Australian clinical research studies 
follow the GCP guidelines. Despite regulatory agencies endorsing new 
monitoring approaches, which represent an opportunity for effective and efficient 
monitoring, the application of the current guidelines are challenging for some 
studies due to the requirements of technology. Guidance should not be limited to 
suit multi-site drug-intervention trials. In order to improve clinical research 
studies, data monitoring training and education need to be accessible to all clinical 
study types, large and small. The findings from this thesis have implications for 
not only clinical researchers, but regulatory agencies to provide guidance and 



















1.1 Overview  
Clinical research is a branch of medical science that is vital to the discovery of new 
treatments, disease prevention, diagnosis/screening and disease risk reduction in 
humans1. Studies involving human volunteers (or participants), known as ‘clinical 
research studies’ are carried out to learn about human health. Clinical research 
studies are, therefore, an important way to advance the care and treatment of people 
and are crucial to the discovery of new health and disease outcomes. Clinical 
research studies can be divided into two main study types: observational studies 
(also referred to as epidemiological studies) or intervention trials (also called 
clinical trials or experimental studies). In observational studies there is no attempt to 
intervene and instead the researchers prospectively or retrospectively observe the 
natural relationships between factors and outcomes in a non-controlled 
environment2. On the other hand, intervention trials are prospectively assigned to 
participants and compared with an assigned placebo or control treatment to evaluate 
its effect on health-related biomedical or behavioural outcomes3. 
Intervention trials and observational studies require appropriate planning, design and 
analysis to minimise error and increase the validity of the study results. A well-
designed study will ensure that the results of the research with the sample 
population are of a high quality and are generalisable to the wider population of 
interest. Therefore, regardless of the study type, all health decisions should be based 
on high quality scientific data. The evidence has linked poor data quality to incorrect 
conclusions and recommendations;4-7 therefore, data quality is of paramount 
importance for acquiring reliable research findings from clinical studies8,9. Poor data 
quality may stem from error; consequently, preventing data error is just as important 
as the development, design, and collection of clinical study data10. To minimise 
 
 




error, it is essential that study activity is monitored to comply with regulatory 
requirements while ensuring that the rights, safety and wellbeing of the participants 
are protected.  
The International Council for Harmonisation (ICH) developed the Good Clinical 
Practice (GCP) E6 guideline which is considered the international “gold standard” 
to conduct, monitor and report a clinical study involving human participants11,12. 
However, the GCP E6 guideline was written with an emphasis on drug intervention 
trials13-15 and as a result, drug intervention trials predominately make up most of the 
existing literature related to data monitoring. Consequently, non-drug intervention 
trials such as behavioural (i.e. food, social and psychological) intervention trials and 
observational studies are left with little guidance on how to perform data monitoring 
activities. In the Australian context, the research setting of this thesis, clinical 
researchers also have to follow the National Statement on Ethical Conduct in 
Human Research (National Statement) which provides guidance on the ethical 
design, conduct, review and dissemination of results of all studies involving 
humans16. For this reason, this thesis will include both intervention trials and 
observational studies.  
This chapter provides an overview of the definition of data quality and the impact 
that poor quality data can have on clinical research study findings. The chapter also 
focuses on the recommended regulatory requirements and how data is governed, 
managed and monitored to ensure continuous quality improvement throughout a 
clinical study. Additionally, data quality education and training are considered. This 
chapter exposes gaps in the literature which will be addressed in the subsequent 








1.2 Defining data quality  
High data quality is crucial to organisational success in research, while poor data 
quality (often referred to as ‘dirty data’) can significantly impact the credibility of 
a business or institution17. To date, there has been a lack of a precise unified 
definition for data quality. The term ‘data quality’, sometimes referred to as 
information quality18, is a multidimensional and hierarchical concept19,20. The 
World Health Organization (WHO)21 defines data quality as “ …the ability to 
achieve desirable objectives using legitimate means. Quality data represents what 
was intended or defined by their official source, are objective, unbiased and 
comply with known standards” [pg.10]. An alternate definition from Kerr et al.22 
suggested that good data quality is data that is “fit for use” [pg.5] in regards to the 
objectives set out in the study protocol.  
Given the multi-component nature of data quality there is often ambiguity in its 
use as the term may refer to either a single or subset of data quality dimensions. In 
a review of the data quality literature, there were 49 different data quality 
dimensions (referred to as attributes) identified4. Although there have been a large 
number of dimensions determined within the published literature, the majority of 
studies provide no useful definition or are unclear in the definition used which 
creates further uncertainty for researchers. Consequently, different data users 
including, researchers, regulatory authorities and information scientists may 
highlight or exclude different dimensions of data quality. Within clinical research 
reliability, accuracy, validity and completeness have been considered to be the 
most commonly reported dimensions23. By comparison, regulatory authorities 
tend to focus on the verification and attribution of data quality dimensions, whilst 
the information technology (IT) sector concerns are with measuring the agreement 
 
 




of data definitions in relation to the rules outlined by an organisation24. Together 
clinical researchers must comply with the regulatory authorities who promote the 
use of IT systems. This adds to the confusion for researchers in determining 
which data quality dimensions are of the highest priority and how they should be 
defined and measured.  
It is evident that the discipline of informatics and the concept of data quality are 
inseparable25. This relationship has been previously described by Nahm25 who 
illustrated the way in which data definition, collection, processing and 
representation are each handled, and how these impact data use which in turn 
impacts on data and information quality. On the contrary, data and information 
quality also impact use, see Figure 1-1. When determining data quality, all 
probable sources of error need to be considered, this includes the development, 
design, recording, abstraction, transcription, data entry, coding and/or cleaning 
processes. Thus, the sources of the data are essential to minimise errors, as a 









Figure 1-1: Figure reproduced from Nahm, M. (2012) titled, impacts of data 
generation and handling features on data and information quality. The way data 
and information are handled impacts the quality of that data and information. The 
quality of data and information impacts our willingness and ability to use it. Use 
of data and information causes more care to be taken in their handling, increasing 
the quality25.  
 
1.3 Errors exist  
No dataset is perfect and, therefore, no clinical study is perfect. In fact, pursuing 
data quality to a greater extent than is needed within the context of the study is 
deemed unnecessary and costly in terms of time and resources. There is a general 
agreement within the research community that error-free data is an unrealistic 
goal10,26. Hypothetically, even if the data were 100% accurate, consideration 
would need to be given to the study design, precise endpoints, participant safety 
and assurance of unbiased findings. To overcome this issue, it has been accepted 
within the published literature that if greater than 10% of data is missing or 
incorrect, analysis of the data is considered to be unreliable27,28. Further, a much-
debated question is whether a 10% error acceptance level is too large to draw 
reliable and valid results from electronic datasets. This has been challenged in 
 
 




recent times whereby a study has suggested that an error acceptance level should 
depend on the type of dataset, for example paper-based versus electronic data 
collection and storage29.   
Regardless of whether you employ a paper-based or electronic approach, human 
error is inherent to a study. In addition, there are many common types of errors 
within clinical studies which include; design, procedural, recording (systematic, 
random and fraudulent) and analytical30. Multiple issues such as the type of error, 
the extent of the error and the variables where the errors are found all play an 
important role in the data analyses and determining the overall quality of 
individual datasets31. At a minimum, pragmatic (validation) checks of critical data 
points should be applied across all clinical studies. However, the reason why 
randomised controlled trials (RCT) are considered the “gold standard” is so that 
error randomly occurs in both study arms and therefore the errors cancel each 
other out. Although evidence suggests that random data errors have little impact 
on the overall results of clinical studies, this excludes fraudulent data which is 
often rare and isolated32. Errors caused by fraud violation may be more difficult to 
detect and, therefore, standardised procedures need to be appointed to measure 
error. 
There is no universally accepted method for measuring error31. Error rates are 
typically used to quantify data quality in clinical studies, which allows for a 
uniform comparison between studies and are commonly expressed as a rate of 
errors per 10 000 data fields. The Society of Clinical Data Management has 
reported up to seven different methods were being used to calculate error rates 
which led to different outcomes31. Of note, the error rate reported in the literature 
is commonly not a ‘true’ or ‘total’ error rate as it is simply an estimate of database 
 
 




errors that are introduced during data entry and cleaning28. There is a need for a 
clear method to measure error rates to avoid ambiguity and ensure the reliability 
of the data. However, it has been suggested that it is unlikely that a universally 
acceptable error rate can be established26.  
1.4 Impact of error on data quality in clinical research studies 
Preventing errors from occurring, rather than retrospectively fixing the errors, is 
considered to be best practice to ensure data quality within a study25. In the 
context of clinical research, poor data quality is a major problem that can 
seriously affect data integrity and the generalisability of the research findings7,33. 
Therefore, minimising poor quality data is considered to be crucial for clinical 
research to produce accurate and reliable evidence for improved patient care. To 
achieve this, guidance needs to be provided to clinical research studies on the 
collection, processing and handling of the data.  
Unfortunately, there is no “one-size-fits-all” approach for data quality due to the 
many different study designs, clinical objectives and requirements for data. As 
there are no regulations to provide a standardised or minimum acceptable data 
quality level several challenges arise, mainly because individual organisation’s set 
their own strategies and methods10. In clinical studies, many strategies have been 
developed, such as written standard operating procedures (SOPs), personnel 
training, data monitoring or auditing and the careful design of case report forms 
(CRF). However, current international and national guidelines lack consistency 
creating uncertainty for clinical researchers. Therefore, in order to optimise data 
quality and minimise data error, effective data governance is needed within 
clinical studies to assist the staff to document, structure, manage and control the 
 
 




use of their data whilst making sure users can trust their findings.  
1.5 Data governance 
Data governance encompasses people, processes and IT systems to formally 
manage and exercise control over the methods used by data stewards and 
custodians in order to improve data quality34. Therefore, a data governance 
structure ensures an organisation has defined an individual’s role, their rights and 
their responsibilities associated with a data set. This includes establishing specific 
guidelines and formal policies or standards for data quality management. The 
main difference between data ‘governance’ and ‘management’ is that governance 
refers to those who make the decisions that are required to guarantee the effective 
use of resources and management35, whilst, management is the implementation of 
the decisions36. Therefore, data management is closely influenced by data 
governance.  
1.5.1 Guidelines and regulatory authorities – oversight for clinical studies 
As a result of historical evidence documenting unethical experiments and 
misconduct, guidelines have been developed to assist clinical researchers to 
conduct ethical research37,38. Over the years, ethical advances in human protection 
have shaped human experimentation, including several milestones such as the 
Hippocratic Oath (460 BC), Nuremberg Code (1947), Declaration of Human 
Rights (1948), Kefauver-Harris Amendment to the United States (US) Food, 
Drugs and Cosmetic Act (1962), Declaration of Helsinki (1964, last revised 2013) 
and the Belmont Report (1979)39.  
During the 1960s and 70s there was a rapid increase in the number of ethical, 
safety and quality guidelines and regulations for conducting, reporting and 
 
 




evaluating clinical trial data40. By the late 1970s the majority of countries had 
their own guidelines and regulations for clinical trial conduct. To overcome the 
divergence in procedures between countries, there was a need to harmonise the 
regulations which led to the development of the ICH guidelines on the specific 
categories of safety, quality and efficacy. In April of 1990, the ICH had its first 
meeting attended by representatives from industry and regulatory agencies from 
Europe, Japan and the US41. Since this first meeting the ICH has focused its 
attention beyond these founding regions and as of May 2020 includes 17 
members and 31 observers from industry and regulatory agencies across 54 
countries42. To date, there are four ICH guideline categories; quality, safety, 
efficacy and multidisciplinary. The multidisciplinary category was first 
introduced in 1994 to include important topics that did not fit into the original 
three categories. Each of the four categories are made up of a number of topics 
and this thesis will largely focus on the efficacy guideline E6 GCP, that is 
concerned with the design, conduct, safety and reporting of clinical trials. 
1.5.1.1 ICH GCP  
The original GCP E6 guideline11 was published in July 1996, and updated in 
November 2016. The GCP E6(R2) guideline is the ethical and scientific quality 
standard for designing, conducting, recording and reporting clinical trials that 
involve human participants12. The guideline states that, “quality control should be 
applied to each stage of data handling to ensure that all data are reliable and have 
been processed correctly” [pg.22]. However, the guidelines are not specific about 
the amount of monitoring that is needed to ensure quality and give flexibility in 
their interpretation43,44. Concerns regarding the broad guidelines were identified 
amongst clinical research centres responding to a survey of data quality 
 
 




management in Europe45. The concerns related firstly to the limited freely 
available clinical data management guidelines and secondly, data management 
systems did not comply with guidelines, including GCP and the International 
Organization for Standardization (ISO) for independent validation by an external 
auditor45. Furthermore, to address the application of the GCP E6(R2) guideline to 
the increasingly diverse types of clinical trials and data sources, and provide 
flexibility where needed to facilitate technological innovations, a GCP E6(R3) 
working group has been endorsed by the ICH in June 201946. The working group 
anticipates November 2022 as the GCP E6(R3) adoption date.  
1.5.1.2 National Statement on Ethical Conduct in Human Research  
Complementing the GCP guideline in the Australian context is the National 
Statement 2007 (updated 2018)16. The National Statement provides guidance to 
researchers about their responsibilities related to the ethical design, conduct, 
review and dissemination of results of human research. This includes human 
research undertaken by private individuals, organisations, industry and the 
government. Therefore, the National Statement is one of the main standards 
applicable for all human research in the Australian context. By following the 
National Statement, researchers can feel confident about the research process and 
participant safety and wellbeing. This highlights the importance of providing 
standardised guidance to all researchers, not just those conducting large multi-
centre drug intervention trials.  
1.5.2 Role of policy and standard operating procedures  
Policies in clinical research generally do not specify individual responsibilities or 
tasks and are high level statements of organisational intentions. On the other hand, 
SOPs help to define the specific and routine procedures of a study47 to ensure 
 
 




tasks are performed within a basic framework to comply with organisational 
policies, and national and international regulatory requirements. However, SOPs 
do not replace regulatory guidance, but rather they are intended to comply with 
the guidelines of the local site and ethics committee48. The SOP related to quality 
assurance and quality control is one of the most generic, reusable and important 
documents within a clinical study49. How an organisation’s quality policy and 
SOPs (quality assurance and quality control) fit into the overall structure of a 



















Figure 1-2: The hierarchy of data in a clinical research study quality system. 
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1.6 Data management  
Data management includes developing and implementing policies and procedures 
throughout a sequence of stages. Also known as the data lifecycle, this includes 
the planning before and execution of protocols in the data capture and analysis 
stages through to the archival or deletion of data. Data management needs to be 
consistent, effective and efficient10,49. Regardless of the method used to collect, 
handle and store the data collected within clinical studies, a rigorous management 
system is essential. For academic clinical studies, developing and maintaining a 
data management system is a challenge50. This is largely due to the requirements 
for individual trials, such as the need to implement specific frameworks and/or the 
cost to develop and maintain the software which may not be resourced51. 
Academic clinical trials are less likely to implement sophisticated clinical data 
management systems such as those utilised within the pharmaceutical industry 
(e.g. Oracle Clinical); instead they often implement specialised, in-house smaller 
systems (e.g. REDCap)45. Kuchinke 45 found that considerable heterogeneity 
exists in data management. Similarly, the Association of Academic Health 
Centers (AAHC) highlighted that a lack of resources, systems, and procedures are 
barriers to clinical trial operations52. However, there is no GCP-compliant 
standard and/or IT system infrastructure available which is applicable, practical 
and accessible to multinational clinical research studies.  
The interest in standardisation within the clinical research community has grown 
in recent years, however, there is no GCP standard for data management that is 
applicable to all clinical studies. As established by Ohmann et al.50, Figure 1-3 
highlights the importance of the GCP guidelines within clinical research at an 
international level and within the US and the European Union (EU) directives. 
 
 




The image links regulations and guidelines that are relevant to the GCP-compliant 
data computer systems and data management practices connecting important 
references from one document to another. The image does not include the 
regulations or guidelines from Australia. However, Australia’s unique position 
warrants inclusion, as the latest report by the Australian New Zealand Clinical 
trial Registry (ANZCTR) has found that the number of registered intervention 
(clinical) trials and observational studies conducted in Australia was 12 329 per 
capita, ranking Australia tenth out of 25 countries over the last decade53. In the 
top 10 countries, only three (including Australia) were not part of Europe and 
further Australia ranked above the US who are in 19th place. The ANZCTR report 
also stated that 33% of Australian registered clinical studies recruit participants 
from multiple countries53. A more global and inclusive approach to clinical study 









Figure 1-3: International, European and United States regulations and 
guidelines50. 
21 CRF Part 11: Title 21 of the Code of Federal Regulations Part 11; CPMP: Committee for 
Proprietary Medical Products; CSUST: Computerized Systems Used in Clinical Trials; ECRIN: 
European Clinical Research Infrastructure Network; EU-Dir: European Union Directive; FDA: 
Food and Drug Administration; GAMP: Good Automated Manufacturing Practice; ICH-E6 GCP: 
International Conference on Harmonisation-E6 guideline Good Clinical Practice; ISO: 
International Organization for Standardization; HIPAA: Health Insurance Portability and 
Accountability Act; PIC/S: Pharmaceutical Inspection Co-operation Scheme.  
 
1.7 Data monitoring 
In order to comply with the GCP E6 guideline clinical study researchers must 
effectively monitor study procedures, conduct stringent data checks and provide 
sufficient oversight to ensure a robust clinical study is completed. Therefore, 
monitoring is an integral part of GCP to ensure that a study is conducted in line 
with international regulations, standards and guidelines, and the analysis is based 
on high-quality data54. Regardless of the study design, location or resources, the 
importance of monitoring does not change. However, the published literature 
suggests that standardised and more specific procedures need to be adopted. In 
accordance with this notion, a survey conducted by the Clinical Trials 
 
 




Transformation Initiative (CTTI) in the US found that there is heterogeneity 
within and between organisational monitoring practices across 
academic/government, clinical research organisations and industry55. This has led 
researchers to explore new avenues to monitor data quality in clinical research 
settings. Within clinical research, data quality monitoring can be separated out 
into two main concepts; quality assurance and quality control.  
1.7.1 Quality assurance and quality control 
Quality assurance is the process to “prevent” data errors, which includes methods 
such as audits and monitoring to ensure data integrity. Auditing is a recognised 
quality assurance method that has been used for many years to assess and develop 
the quality of information56,57. Quality assurance audits within clinical and 
healthcare settings are extensively used and are the major strategy to ensure high-
quality data28,31,43,58. Quality assurance activities include examining the design of 
CRFs, analysing the data collection techniques and regular training of data entry 
personnel and data management27,59. On the other hand, quality control is the 
process to “alleviate” or “remove” the impact of errors that have occurred during 
data collection and/or analysis49. This refers to the operational techniques used to 
fulfil requirements for quality. Recognised methods of quality control include 
conducting periodic monitoring (daily, weekly, and monthly) through pragmatic 
data range and consistency checks, query management, and double data entry to 
minimise error10. Therefore, quality control is a continuous quality assurance 
activity undertaken to verify trial-related processes to meet the agreed standards.  
However, the terms of quality assurance and quality control are often used 
inaccurately and interchangeably10. Within academic research settings, published 
on-site audits that include quality assurance are infrequently reported. This may 
 
 




be due to unclear auditing methods, a lack of time and funding, audits possibly 
perceived as unnecessary for unregulated studies and the publishing of SOPs not 
seen as a ‘value-added’ activity60-62. There is general agreement among leading 
clinical trial management that establishing reliable guidelines for monitoring 
strategies are needed to help determine risk-adapted monitoring for individual 
trials43. It is recognised that different strategies need to be tailored for different 
types of clinical studies to determine adequate and appropriate monitoring63,64. 
However, published methodology papers are warranted to promote routine 
auditing and monitoring within academic and commercial research settings. 
Further, research grants do not include funding for such programs65.  
1.7.2 Data monitoring methods 
The original GCP E6 guideline11 recommend on-site monitoring and the method 
of source data verification (SDV). SDV involves staff manually verifying the 
individual data points29. The first reflection and guidance documents promoting a 
new approach, risk-based monitoring (RBM) were published in 201366,67. 
Following this, in 2016 new regulatory guidance in the updated GCP E6(R2) 
guideline12 suggested a reduction of on-site monitoring, and replaced it with “a 
systematic, prioritised, risk-based approach to monitoring” [pg.29] or “a 
combination of on-site and centralised monitoring” [pg.29]. These 
recommendations allow for more flexible, efficient and effective monitoring 
procedures in accordance with the available resources26,32,67,68.  
Despite the promotion of a RBM approach, clinical studies continue to apply 
SDV monitoring. In 2019 Fougerou-Leurent et al.69 compared targeted1 SDV with 
                                                          
 
1 Targeted SDV: only key data verified for all patients. 
 
 




100% SDV and found that four times more queries were identified by the former 
approach. However, a limitation of implementing targeted SDV was an estimated 
increased workload due to handling time, whilst also maintaining a small 
proportion of error (<1%) on the key data2. Another relevant study compared 
partial3 SDV with 100% SDV and found the completion of 100% SDV to only 
have a marginal error reduction of 0.26%70. In line with these findings two studies 
conducting 100% SDV compared with a centralised review found little difference 
on the primary study outcome and, therefore, challenged the need to conduct 
SDV71,72. Most recently, the Strategic Timing of AntiRetroviral Treatment 
(START)73 monitoring sub-study concluded that the value of on-site monitoring 
in addition to localised and centralised monitoring is limited when compared with 
localised and centralised monitoring only. In particular, on-site monitoring 
reported a greater number of primary and serious events more than six months 
from their occurrence as compared to no on-site monitoring. The START sub-
study estimated that the cost of on-site monitoring was over US$2 million, 
limiting its value73. Finally, a recent review comparing various SDV methods 
reported wide variances between studies and could not determine a uniform SDV 
method to be used for ‘best practice’74. It appears that clinical studies continue to 
apply SDV monitoring due to a lack of sound evidence about the advantage of 
applying ‘newer’ methods over the more traditional ones26. 
There is emerging evidence to support risk-based approaches, but it remains 
sparse. To date, on-site monitoring and/or SDV have only been compared RBM 
                                                          
 
2 Key data verified by the targeted SDV: informed consent, inclusion and exclusion criteria, main 
prognostic variables at inclusion, primary endpoint and Serious Adverse Events. 
3 Partial SDV: partly monitored data, participants or sites (not 100%).  
 
 




in two completed studies. The first study, the ADApted MONitoring 
(ADAMON)68 study compared intensive on-site monitoring and risk-adaptive 
monitoring. The results of this study found a small improvement (8.2%) in 
completing intensive on-site SDV while RBM utilised less than half of the 
resources (<50%) and adhered to the same level of GCP compliance. More 
recently, the TargetEd Monitoring: Prospective Evaluation and Refinement 
(TEMPER) study75 assessed the ability of targeted and triggered RBM. The 
findings suggest that triggered monitoring may be potentially useful but it needs 
improvement and warrants further investigation. One other study is still ongoing, 
the OPTI-misation of MONitoring (OPTIMON) study76, though the first results 
have demonstrated that a risk-adapted strategy was reasonably equivalent to an 
intense strategy in detecting critical errors though it lacked statistical power77. 
Finally, in a systematic review, Hurley et al.78 identified a total of 24 different 
tools or techniques to guide RBM, despite concluding that a standardised 
approach could not be determined. Therefore, RBM may be of potential use but 
warrants further improvement. 
1.7.2.1 Changes due to COVID-19 
Due to the coronavirus 2019 (COVID-19) pandemic, clinical research sites have 
had to reduce or restrict on-site monitoring visits. This has caused a significant 
challenge to clinical studies which were still conducting 100% SDV as they have 
had to shift quickly to remote monitoring which relies heavily on IT systems 
being in place79-81. This has required site staff and sponsors to find alternative 
approaches to maintain participant safety, whilst ensuring data quality and 
integrity. Alternative approaches for communication have included telephone 
contact and real-time video conferencing meetings (e.g. Zoom and WebEx 
 
 




Teams) to review study procedures, participant status and study progress 
remotely. Studies have also had to modify their existing protocols to allow for 
participant virtual visits, telehealth and electronic consent. In light of the recent 
disruptions, researchers have been triggered to consider if it is time to implement 
a RBM approach and IT system that complies with the GCP guideline and the 
Australian National Statement.  
1.7.2.2 Changes due to technology  
The application of IT systems in clinical studies has seen the emergence of a suite 
of data checking and aggregating packages82 that has transformed the method for 
data monitoring. It has allowed for real time data checking, quicker identification 
of missing data and statistical monitoring32,83. In response to the increased use of 
IT solutions, the most recent GCP guideline encourages clinical studies to 
incorporate RBM approach underpinned by an IT component84.  
Despite the growing support for IT and RBM, a recent survey reported that 
clinical research coordinators were resistant to a RBM approach. Reasons for 
resistance included the approach increased workload, did not improve speed and 
even reduced data quality85. Further, a lack of education was also the greatest 
barrier to implementing a RBM approach. Due to limited research, it is largely 
unknown what challenges clinical studies and researchers face in implementing 
data quality monitoring approaches using IT systems. These IT systems require 
additional training specific to how they will be used to maximise their efficiency.  
1.8 Data quality education and training  
Education and training in data quality monitoring has the potential to provide 
immense benefits to clinical studies. Despite the recognition that clinical 
 
 




researchers can benefit from completing GCP training, this training is not a legal 
requirement though it is recommended to be updated every 3 years86. In addition, 
the current training presents as a “one-size-fits-all” approach, which cannot meet 
the needs of individual clinical research projects. In 2016, a study87 highlighted 
that site staff who participate in multiple clinical trials are often required to 
complete GCP training multiple times within the certification period which is 
burdensome and an inefficient use of resources. Other limitations reported for 
GCP training included the time consuming nature88, redundant concepts87,89, 
discrete to research validity43, lacks specificity90 and alone it is not sufficient to 
prepare an inexperienced staff member91. To date, there is a paucity of evidence 
to suggest that clinical data managers in both academic and industry settings have 
received either on-the-job training or self-paced learning that is focused on 
specific work procedures92. This doesn’t necessarily mean that GCP training is 
not being conducted. Commonly, in-house training on SOPs and project specific 
Manual of Procedures (MOPs) are conducted but are not published. Without clear 
guidance on evidence-based practice (EBP) or adequate training that is tailored to 
a specific clinical context, clinical researchers can only rely on their own 
judgements to monitor data, which is a sub-optimal operation.  
1.9 Summary of evidence and identifying gaps in the literature  
As medical recommendations rely on the outcomes of research data, good quality 
data is integral to the success of clinical research. However, the lack of a 
universally accepted definition of data quality remains problematic. Even though 
existing definitions have common elements, differences in the definitions relate to 
the multidimensional concepts of data quality which also has unclear definitions. 
The definition of data quality will continue to evolve as the scientific and 
 
 




healthcare landscape shifts towards a self-service model for data including big 
data, machine learning and artificial intelligence. Currently, the lack of a standard 
definitions causes confusion and uncertainty within the research community. 
Moreover, the interest in standardisation within the clinical research community 
has grown in recent years and has important benefits. Although, consideration 
needs to take into account that a single definition for data quality is not possible, 
but rather needs to be multi-faceted and all-encompassing.  
From the current body of literature, it can be said that international clinical data 
quality guidelines lack uniformity. In recent years there has been a push from 
regulatory agencies to implement newer procedures to monitor data quality, such 
as RBM. There is a paucity of evidence to support the guidelines, and therefore 
they are flexible in their interpretation. Most importantly, much of the research in 
the published literature is from quantitative studies showing the effectiveness of 
monitoring procedures in large multi-site RCTs. Only limited evidence exists in 
small single-site intervention trials or observational studies. This may reflect the 
additional funding and resources available to larger studies. However, it is 
recognised that many organisations collect and analyse data for their own benefit, 
to ensure quality and to meet SOPs. Within the academic and small research 
settings, published methodology papers are not often reported. This could be due 
to the unclear procedures, lack of funding, monitoring perceived as unnecessary 
for unregulated studies or they are not seen as a value-added activity. In 
particular, it has been recognised that different monitoring strategies need to be 
tailored for different types of clinical studies. Unpublished monitoring procedures 
leave a gap within the published health and clinical research literature.  
Finally, the evidence suggests that there is a lack of formal and relevant data 
 
 




quality training for different clinical contexts. This may reflect that the current 
GCP training is based on the international guideline which was written to follow 
pharmaceutical industry standards and are predominately for drug-intervention 
trials. Therefore, little is currently known about how clinical researchers from 
different organisations and other study types receive data quality training, or if the 
current training is relevant and useful. To be able to fully understand the 
facilitators and barriers to training and implementing monitoring procedures, the 
lived experiences of researchers need to be considered through qualitative inquiry. 
To date, the results from quantitative studies alone have only been measured, 
mostly focusing on which procedure is the most time and cost-efficient.  
This chapter has identified the following gaps in the evidence, which will be 
addressed through the studies of this thesis: There is 
 a paucity of research to determine what data quality monitoring 
procedures are implemented in clinical studies;  
 no account of clinical researchers lived experiences with implementing 
data quality monitoring procedures or maintaining data quality; 
 little research on the current procedures and approaches used for education 
and training related to data quality; 
 a lack of standardised definitions and frameworks for monitoring data 









1.10 Aim and hypothesis  
The central aim of this thesis was, therefore, to explore and understand the 
varying data quality monitoring procedures used in clinical research studies and to 
develop a data quality monitoring framework (DQMF). The central aim was 
examined via five key studies. An overview of the five studies and their 
relationship to the central thesis concept is illustrated in Figure 1-4.  
 
Figure 1-4: Main thesis concept and the studies supporting the investigation of 
the thesis aims. 
 
The individual study aims were:   
1. Study 1: to explore the evidence regarding the variability of data quality 
monitoring procedures in clinical research studies; 
2. Study 2: to gather information about current data quality tools and 
procedures used within Australian clinical trial sites; 
3. Study 3a: to further explore the procedures that are implemented for ensuring 








4. Study 3b: to describe Australian researchers’ experiences with data quality 
monitoring in clinical studies; and 
5. Study 4: to develop a “fit-for-use” DQMF for clinical research. 
The central hypothesis of this thesis was that despite the wide variations, 
exploration and evaluation of appropriate data quality monitoring procedures in 
clinical research studies will provide guidance toward developing a “fit-for-use” 
DQMF. The individual hypotheses are addressed in each of the chapters as 
appropriate.  
1.11 Research questions 
The individual study research questions were:  
1. Study 1: How are clinical research studies implementing data quality 
monitoring procedures?; 
2. Study 2: What data quality tools and procedures are currently used within 
Australian clinical trial sites?; 
3. Study 3a: What data monitoring procedures are implemented for ensuring 
data quality nationally in Australian clinical studies?; 
4. Study 3b: What motivating factors and barriers do Australian researchers’ 
experience with data quality monitoring in clinical studies?; and 
5. Study 4: Can a “fit-for-use” DQMF be developed for clinical research? 
1.12 Thesis structure 
Chapter 1 has described an overview of clinical research studies and the 
importance of ensuring data quality to produce valid and reliable conclusions and 
recommendations. It has also briefly addressed data governance, data 
 
 




management, monitoring methods, and training undertaken in clinical studies to 
allow for continuous quality improvement.   
Chapter 2 will introduce the theoretical framework and methodology that is 
employed within this thesis. It will also include an overview and discussion on 
each of the methods implemented throughout the thesis.  
Chapter 3 (study 1) outlines a systematic review and meta-analysis to explore 
what data quality monitoring procedures clinical research studies are 
implementing. This chapter explores the difference between recommendations 
made by regulatory agencies and procedures reported in the literature. This was 
relevant to support the development of the feasibility study.  
Chapter 4 (study 2) will outline the results from a feasibility survey which 
gathered information about the tools and procedures Australian clinical trials use 
to monitor data quality. The findings from this feasibility survey were used to 
determine the validity and practicality of a national survey. This study found that 
a different sampling approach would be needed to administer the national survey 
to improve coverage and a higher response. 
Chapter 5 (study 3a) presents the findings obtained from an Australian national 
survey which builds on in more detail the feasibility study. This chapter will 
detail the procedures implemented in both intervention (clinical) trials and 
observational studies to ensure high quality data. The analysis investigates how 
clinical studies define, collect, store, manage, process and represent data. It also 
addresses the data quality education and training that is provided to data entry and 
data monitoring staff.  
 
 




Chapter 6 (study 3b) provides the results of clinical researcher’s experiences with 
monitoring procedures, staff training and the motivating factors and barriers to 
ensure quality of clinical research data before, during and after a study. The 
findings of this study provide a deeper meaning to the quantitative results 
obtained in the previous study 3a.  
Chapter 7 (study 4) is a culmination of the findings of the previous chapters and 
incorporates thesis findings into a framework. The framework developed in this 
study will guide new clinical studies or identify procedures in existing studies to 
improve data quality monitoring. 
Chapter 8 will summarise the key findings of all studies and discuss 
recommendations for future research. 
1.13 Significance of the research  
To produce evidence-based medicine, high-quality data is crucial to clinical 
research, as conclusions and recommendations drawn from such research rely 
solely on the outcomes of the data. However, inconsistencies exist between 
national and international guidelines and also the literature regarding “best 
methods” to monitor clinical study data. While regulatory agencies provide 
overarching guidance as to what is “best practice” for data quality monitoring, the 
majority of research has focused on pharmaceutical standards or large, multi-site 
international drug trials. Therefore, the same regulations are required regardless of 
the study design or clinical focus, overlooking observational studies and non-drug 
intervention trials.  
Clinical research is a data-driven domain and error can be introduced during all 
 
 




stages of a clinical study. This thesis is, to the candidate’s knowledge, the first to 
explore the procedures implemented by researchers to monitor data quality within 
Australian clinical studies. This necessitated identifying the gaps between the 
procedures recommended by national and international regulatory agencies in 
comparison to the procedures applied at a study level. This thesis highlights the 
ad-hoc procedures implemented and limited data quality education and training 
provided to clinical researchers by utilising data collected from cross-sectional 
surveys. Further, qualitative methods conducted with a small sample of survey 
respondents identified numerous motivating factors and facilitators to 
implementing data quality monitoring procedures. This is also the first known 
thesis to collect qualitative data from Australian clinical researchers regarding 
their lived experiences with data quality monitoring and meeting regulatory 
requirements. 
As a result, emphasising the importance of overall study quality, including how 
data is defined, collected, processed and represented may provide “big picture” 
guidance to clinical researchers. Previously, the focus has been on specific data 
quality dimensions, the validity of data collection tools and statistical approaches 
to overcome missing data. A novel addition to the literature is applied in the 
present thesis to improve clinical research study practices, which currently 
consists of complex, isolated and independent tools, procedures and frameworks. 
Using a mixed-methods approach, this thesis will contribute to the evidence by 
providing an easily integrated knowledge development tool for clinical research 
practice. This thesis is the first to provide a framework that will support clinical 
research as a value-added function by providing oversight and guidance on the 
complex area of data quality monitoring; providing clear definitions of concepts 
 
 




are key to the frameworks’ success. Finally, this thesis contributes new 






















As highlighted in Chapter 1, fundamental to clinical studies is the quality and 
integrity of the data that is generated. In the context of Australian clinical studies, 
the varying data quality monitoring procedures implemented and the reasoning for 
why clinical researchers use or do not use certain procedures is not fully 
understood. Further research is needed to compare the differences between the 
procedures recommended by the regulatory agencies, procedures reported in the 
literature and the procedures implemented at the clinical research sites. In order to 
address the central hypothesis of this thesis and explain in detail the concepts of 
data quality monitoring, theoretical and methodological issues in the current body 
of literature must also be considered. To test the central hypothesis a number of 
different approaches will be used. This chapter presents a critique of the methods 
utilised and outlines the rationale behind the study design and the methods that 
were applied. An overview of the thesis studies and the methodology applied in 





































Figure 2-1: Conceptual framework of research program design. 
2.1 Theoretical framework  
As health informatics focuses on solving problems through the application of 
information and communication technologies in health care, it draws on theories 
from other disciplines. Therefore, this thesis has used an information theory 
perspective to guide the inquiry process and the interpretation of the findings. 
Information theory has several meanings but in general, it is the communication 
or reception of knowledge or intelligence93. Within information theory is the data-
information-knowledge-wisdom (DIKW)93, which evolved from the original 
In-depth interview  
Chapter 3 
Exploring the procedures 
reported by clinical studies 




Systematic review and 
meta-analysis 
Cross-sectional study  
(Feasibility survey) 







Gathering information about 
the use of tools or procedures 
to monitor data quality 
Chapter 5 
Exploring the procedures 
used in clinical studies to 
monitoring data quality 
Chapter 6 
Lived experiences of clinical 
researchers with data quality 
monitoring  
Chapter 7 
Designing a “fit-for-use” 
data quality monitoring 









theoretical model by Blum94 and Graves95 (Figure 2-2). The model overlaps and 
interrelates the concepts of DIKW, suggesting that one concept can affect another 
and even be transformed into another96,97. Throughout this process increasing 
interactions and interrelationships overlap and increase in complexity. The model 
illustrates the full pathway from defining and collecting raw data, through to 
transforming data into wisdom which is added to the scientific literature. For the 
purpose of this thesis, the four concepts of DIKW provide a structure for the 
development of the DQMF described in study 4 (Chapter 7).   
Specifically, data refers to the data elements collected and organised in the 
systematic review (study 1, Chapter 3), quantitative (study 2 and 3a, Chapters 4 
and 5) and qualitative (study 3b, Chapter 6) studies, which were defined by the 
research questions. Within each study, the data was then processed into 
information to create meaning, in which new data items and information were 
created. After the data and information were formalised, knowledge was then 
generated. By interpreting the data and information in the aforementioned studies, 
new knowledge was created in this thesis through the development of the DQMF. 
Finally, wisdom is used to understand and apply knowledge to practice, though 
wisdom was not addressed in this thesis as the DQMF was not applied to a 
clinical research study for real world use. 
 
 






Figure 2-2: Data-information-knowledge-wisdom model 93.  
 
2.2 Methodological approach  
This thesis utilised an explanatory sequential design98 involving a qualitative 
phase (Study 3b, Chapter 6) to explain the initial quantitative results (Study 3a, 
Chapter 5). The two phases were distinct yet connected99.  
This approach was considered to be ideal to firstly, gain a general understanding 
of what data quality monitoring procedures were used in clinical studies and 
secondly, to help to explore the participant’s experiences, or elaborate on, the 
quantitative findings. In the context of clinical practice, a study by Shneerson and 
Gale100 reported that an explanatory sequential design allows researchers to refine 
qualitative research questions, explore the reasons for quantitative answers and 
ensure findings were meaningful. Similar advantages of an explanatory sequential 
design have also been described elsewhere99,101,102. Therefore, combining several 
 
 





research techniques is powerful in that it facilitates validation of data through 
cross-checking from more than one source. 
Further, reasoning for incorporating a qualitative component into the study design 
of this thesis was related to the limited number of published qualitative studies on 
data quality monitoring in clinical study settings. To date, there are only four 
qualitative studies published in the literature on data monitoring procedures in 
clinical study settings103-106. This is of particular interest to this thesis as two of 
the articles focus solely on RBM approaches, the newly recommended GCP 
E6(R2) approach. Whilst updated guidelines have recommended new approaches 
there is limited evidence on the clinical researcher experience with implementing 
and working with such approaches, and their impact on data quality, warranting 
further investigation.  
2.3 Methods used in this thesis  
The quantitative methods used in this thesis include cross-sectional studies, while 
in-depth interviews were used to collect qualitative data.  
2.3.1 Systematic reviews and meta-analyses  
Systematic reviews are a rigorous assessment of all the published literature related 
to a specific research question and inclusion criteria. The purpose of conducting 
systematic reviews is to pool and synthesise the relevant literature to guide 
clinical decisions and promote EBP107. In order to support EBP it is recommended 
that studies are appraised according to their study design which determines a level 
of evidence108. In rating the evidence, systematic reviews of relevant RCTs are 
ranked the highest (level I) within the evidence hierarchy. Additionally, statistical 
methods (meta-analysis) can be used to integrate and analyse results of included 
 
 





studies in a systematic review109. To reduce duplication and the opportunity for 
reporting bias, systematic review and meta-analyses protocols are publicly 
registered on the Prospective Register of Systematic Reviews (PROSPERO)110.  
In a meta-analysis, the results of individual studies are pooled together to 
contribute to the combined summary (pooled) effect estimate111. The importance 
of conducting a meta-analysis is that it may increase power and include a more 
precise estimate of the ‘effect’ outcome. In this thesis, the first study (Chapter 3) 
involved a systematic review and meta-analysis of the relevant literature to 
explore if clinical research studies are implementing data quality monitoring 
procedures. All relevant studies that met the inclusion criteria were pooled. In 
clinical research, meta-analyses are valuable as they seek to report consistency 
between the included studies and they can help to establish statistical significance 
across the studies that may have had conflicting results.  
Despite the recognised strengths of systematic reviews and meta-analyses, there 
are a few limitations to their use. Firstly, conducting a meta-analysis on studies 
from different populations, studies using different methods for measuring 
outcome variables or studies with high levels of bias may lead to misleading 
results111,112. Secondly, publication bias may exist as publishing significant or 
positive results is more likely than publishing non-significant or negative 
results113. Consequently, negative results are underreported in meta-analyses. To 
address these limitations and ensure systematic reviews and meta-analyses are 
transparent and conducted in a reproducible way it is recommended researchers 
follow an official guide such as the Cochrane Handbook for Systematic Reviews 
of Interventions111, in conjunction with the Preferred Reporting Items for 
Systematic reviews and Meta-Analyses (PRISMA) statement, checklist and flow 
 
 





diagram109. Additionally, as part of the reporting process, assessing the risk of 
bias is necessary to assess the quality and validity of each individual study 
included in the review. Assessment of risk of bias is essential in aiding the 
explanation of results included in the systematic review and meta-analysis. 
2.3.2 Cross-sectional studies   
Cross-sectional, case-control and cohort studies are collectively referred to as 
observational studies; however, cross-sectional studies are the simplest of the 
three study designs114,115. Cross-sectional studies differ from case-control and 
cohort studies in that the outcome and the exposure are simultaneously 
measured116. Cross-sectional studies are a ‘snapshot’ of the outcome of interest at 
a given time point117 and are relatively quick and easy to conduct118. Despite the 
recognised strengths, cross-sectional studies are limited in confirming causality 
and are prone to selection and information bias119. Data collection of cross-
sectional studies typically involves questionnaires or surveys120. Cross-sectional 
surveys allow for data collection in a standardised format and can be self-
administered (paper and pencil or web-based) or interview-administered (face-to-
face or telephone)121. Within self-administered surveys, web-based surveys are 
more cost effective than paper-based surveys122. In addition, web-based surveys 
are beneficial in that they provide a good coverage of large populations, are 
flexible and have been found to generate honest responses regarding research 
areas which are considered highly confidential, such as data quality, the topic of 
this thesis. On the other hand, interview administered surveys can result in under 
reporting of undesirable behaviours such as inappropriate data monitoring 
procedures121.  
In this thesis two web-based cross-sectional surveys were designed in study 2 
 
 





(Chapter 4) and study 3a (Chapter 5) to explore the aspects of data quality 
monitoring procedures implemented in Australian clinical studies. Cross-sectional 
survey design is useful for health planning, monitoring and evaluation116. This 
enabled the findings of this thesis to identify different clinical study types that 
were more likely to meet or not meet the recommended national and international 
guidelines. Additionally, the use of a web-based cross-sectional survey design 
allowed for the collection of real-world observations from a large sample of 
respondents who were located across Australia. To ensure the quality of reporting 
for web-based surveys the Checklist for Reporting Results of Internet E-Surveys 
(CHERRIES) statement is recommended to researchers123,124.  
2.3.2.1 Tailored design 
A well-known method for improving survey design and increasing response rate 
is the tailored design approach125. This approach was applied for study 3a 
(Chapter 5) to understand what survey procedures were effective and/or 
ineffective within the specific survey context. Therefore, the tailored design in 
study 3a (Chapter 5) refers to customising of the survey procedures to the 
population (clinical researchers), situation (Australia) and topic (data quality) in 
question. A tailored design strategy was also applied to account for all sources of 
survey error (coverage, sampling, nonresponse and measurement) that could 
undermine the quality of the survey. This approach involves developing a survey 
that interacts and works together (including the recruitment and the 
questionnaire). Thus, attention was given to the following aspects to contact and 
communicate with respondents: reduce sampling error by inviting all clinical 
studies that met the inclusion criteria; reduce coverage error by contacting 
respondents via postal delivery and e-mail (using organisational letterhead and 
 
 





signature); reduce nonresponse error by making multiple contact attempts which 
varied in contact timing; and reduce measurement error by conducting think-aloud 
cognitive interviews to better understand how respondents understand and 
interpret the survey items, visual design, presentation and navigation problems. 
How each of the four sources of error were addressed is further explained in 
Chapter 5 of this thesis. If a tailored design had not been applied there was the 
potential to affect the internal and external validity of the survey. This could have 
had a potential negative effect on how respondents reacted or viewed the survey 
and the overall response rate126. Therefore, the tailored design approach was 
considered necessary to motivate all respondents to participate within the resource 
and time constraints of the survey. 
 2.3.2.2 Social exchange theory 
Social exchange theory was utilised in the design of study 3a (Chapter 5). The 
social exchange theory is a general model for understanding how people behave 
in their interactions with one another, and to understand how social norms 
develop to guide those interactions127-129. This model can be used to explain 
human desire to achieve self-interests from which individuals draw satisfaction. It 
should be noted that social exchange relies on goodwill or trust and is different to 
economic exchange which typically involves legal obligations130. Economic 
exchange is similar between persons, is over a set, short time frame and demands 
specific rewards or costs. Conversely, social exchange is individualised, flexible 
in time and leaves costs and rewards open. Therefore, social exchange was 
applied to encourage respondents to participate in the survey. This was done by 
effectively communicating to respondents why they had been asked to respond 
with the aim that the perceived benefits and trust outweighed the perceived time-
 
 





cost of completing the survey. 
2.3.2.3 Mixed mode multi-contact survey 
A mixed-mode multi contact approach was developed to improve the survey 
response rates by providing an opportunity to effectively balance the surveyor 
needs and the respondent concerns125. Mixed-mode designs can be combined in 
varying orders depending on factors including; reducing error and costs, 
increasing benefits and gaining trust with respondents. In this thesis, study 3a 
(Chapter 5) applied a mixed-mode multi-contact survey design which provided 
opportunities to reach different kinds of respondents and to inform and build trust 
with the respondents131,132. A mixed-mode design was selected over a single-
mode design because single-mode is difficult to develop respondent trust as 
invitations of web-based surveys sent via e-mail are likely to be ignored, deleted 
or not be received altogether125. However, there are many recognised limitations 
of mixed-mode multi-contact surveys including the complexities in their design 
and implementation, which may be affected by the overall study design and target 
population. Depending on the combination of methods, various limitations arise 
such as measurement error when respondents complete a survey using different 
modes of data collection133. To reduce the measurement error in Study 3a, 
multiple modes of communication were implemented, however, only one mode 
was used to collect the responses. This included a postal letter on an 
organisational letterhead for legitimacy, followed by e-mail invitations which 
included an electronic link to the web survey thereby removing known barriers to 
response. 
2.3.2.4 Think-aloud cognitive interview 
Think-aloud cognitive interviews allow survey designers to determine whether 
 
 





respondents comprehend and answer questions accurately and as intended134,135. 
Think-aloud cognitive interviews are considered appropriate to evaluate surveys 
by providing insights where a pilot study cannot125. In particular, think-aloud 
cognitive interviews allow for the surveyors to evaluate whether respondents were 
firstly, interpreting the question wording in the same way and secondly, to 
determine if the respondents were able to navigate through the web-designed 
questions correctly. For these reasons, study 3a (Chapter 5) incorporated think-
aloud cognitive interviews. However, it is important to recognise the 
shortcomings of the think-aloud cognitive interviews. Conducting interviews tend 
to be a labour intensive activity which is unnatural, difficult and places a 
significant burden on the participants135. Additionally, the interviews usually 
include only a small sample size (e.g. <20) and the participants typically tend to 
be through personal recruitment125. Despite these limitations, conducting think-
aloud cognitive interviews are an evidence-based tool that provide greater 
confidence to overall survey quality.  
2.3.3 In-depth interviews  
In-depth interviews provide greater detailed information when compared to other 
data collection methods such as surveys. However, they are a time-consuming 
activity, prone to bias, not generalisable and rely on an appropriately trained 
interviewer. By comparison focus groups differ from interviews as an emphasis is 
placed upon participant interactions and group dynamics136. Focus groups require 
more participants, are difficult to schedule and require more time and resources 
than interviews. For these reasons, in-depth interviews were used in study 3b 
(Chapter 6) to collect qualitative data from Australian clinical researchers who 
had experience with data quality monitoring. A semi-structured interview 
 
 





framework was chosen over a structured or unstructured interview framework as 
it allow for a conversation with another person using a small number of prepared 
questions permitting participants to elaborate on their responses137. In qualitative 
health research (in-depth interviews and focus groups) to promote clear and 
comprehensive reporting it is encouraged researchers follow the COnsolidated 
criteria for REporting Qualitative research (COREQ) guidelines and checklist138.  
2.3.3.1 Guided phenomenological approach  
A guided phenomenological approach was undertaken in study 3b (Chapter 6). 
Phenomenology has been widely used to understand human phenomena in health 
science research139. In phenomenology there is a strong emphasis on lived 
experiences or how things appear in our experiences140,141. Phenomenology has 
evolved as a philosophical context and a research method within health research 
and consists of two varied approaches, descriptive and interpretive 
phenomenology142. The primary differences between the descriptive and 
interpretative approaches are how the findings are generated and used to argue 
professional knowledge143. 
The approach used within the in-depth semi-structured interviews was a 
descriptive approach which guided the investigation and the questions explored 
focusing on a detailed narrative of participants lived experiences. In this thesis 
lived experience was from the perspective of clinical researchers describing their 
approaches to monitoring data quality. When researching lived experiences, the 
researcher must maintain an open mind, which includes being attentive, observant 
and sensitive to others experiences139. Thus, a “bracketing” strategy was utilised. 
By bracketing the investigator acknowledges their personal beliefs, theories or 
other assumptions139. This ensured that participants’ experiences were explained 
 
 





as opposed to the pre-understandings of the researcher.  
2.3.3.2 Thematic analysis   
Whilst a number of techniques exist for the analysis of in-depth interview 
transcript, Study 3b (Chapter 6) utilised ‘thematic analysis’, as described by 
Braun and Clarke144. This approach is widely used in health research145. Thematic 
analysis aims to understand the complexity of meaning and focuses on how to 
organise patterns of meaning from data of lived experiences into themes. This 
type of analysis involves six phases: familiarising yourself with your data; 
generating initial codes; searching for themes; reviewing themes; defining and 
naming themes; and producing the report. The findings are organised in a 
meaningful text way to explain the themes, descriptive text and associated 
quotes144.   
2.3.4 Design-oriented approach  
For the purpose of (study 4, Chapter 7), a holistic design-oriented approach was 
applied to design and develop the framework. Empirical- and practitioner-based 
approaches were not used as they are retrospective-driven (hypothesis-driven) and 
only provide after the fact support for developing quality criteria of information 
systems146. While a design-oriented approach is forward-driven (data-driven) and 
provided guidance to the researchers to create the framework (artefact) and 
further understand the apparent reality of different stakeholders (clinical research 
trials) of the framework147. This provided further guidance to the researchers by 
helping to recognise data failures by developing the framework against a real-
world state148.  
Design science is considered a problem-solving paradigm and seeks to extend the 
 
 





boundaries of the human and organisational capabilities by creating new and 
innovative artefacts149 arguing that human knowledge and an understanding of the 
problem and the solution are acquired in the ‘building’ and the ‘application’ of an 
artefact. Therefore, this research followed the conceptual framework proposed by 
Hevner et al.149 as listed below: 
1. “Design as an artifact: Design-science research must produce a viable 
artifact in the form of a construct, a model, a method, or an instantiation. 
2. Problem relevance: The object of design-science research is to develop 
technology-based solutions to important and relevant business problems.  
3. Design evolution: The utility, quality and efficacy of a design artifact 
must be rigorously demonstrated via well-executed evaluation methods.  
4. Research contributions: Effective design-science research must provide 
clear and verifiable contributions in the areas of the design artifact, design 
foundations and/or design methodologies.  
5. Research rigor: Design-science research relies upon the application of 
rigorous methods in both the construction and evaluation of the design 
artifact.  
6. Design as a search process: The search of an effective artifact requires 
utilising available means to research desired ends while satisfying laws in 
the problem environment.  
7. Communication of research: Design-science research must be presented 
effectively both to technology-oriented as well as management-oriented 
audiences”.  
In conclusion, this chapter has defined the methodological framework utilised 
throughout this thesis. Multiple methods were required in order to address the 
 
 





central hypothesis. Therefore, this framework has considered several aspects of 
study designs including a systematic review and meta-analysis, quantitative, 
qualitative and design-oriented approaches. A detailed overview of the premise 
behind each method has been provided in this chapter. The subsequent chapters of 








CHAPTER 3 DATA QUALITY MONITORING A CHANGING 
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A substantial proportion of this chapter is under review for publication in the 
peer-reviewed publication: 
Houston, L, Yu, P, Martin, A and Probst, Y. Data quality monitoring a changing 
landscape in clinical research studies: A systematic literature review and meta-
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To safeguard the well-being of human participants and ensure accurate and 
complete data collection procedures, the 1996 GCP E6 guideline recommended 
on-site monitoring and SDV11. On-site monitoring including 100% SDV is time 
consuming, expensive and does not guarantee patient safety nor data 
quality60,72,150-153. For these reasons, SDV was not recommended in the updated 
GCP E6(R2) guideline in 201612. Regulatory agencies in Europe154, the US155 and 
Japan156 implemented the original ICH guideline; however, these regulations did 
not include the nature, extent or frequency of on-site monitoring which was left to 
the discretion of the study sponsor.  
The updated GCP E6(R2) guideline recommends a RBM approach, which has 
been implemented by regulatory agencies across the US, Europe, Japan, Canada, 
Switzerland, Singapore, China, Chinese Taipei and Brazil157 with endorsement in 
the US, Europe and Australia66,67,158 provided through guidance documents or 
reflection papers. In RBM, activities are focused on either targeted or triggered 
risks to data quality and how these risks could be prevented to ensure study 
integrity. RBM may include focusing monitoring activities on primary data 
endpoints, calculation of specific levels of monitoring required; or conduct 
monitoring off-site by sending documents flagged as potential risks for 
centralised review. However, the literature to support RBM is sparse, and its 
effectiveness and usability cannot be confirmed78. A barrier to implementing a 
RBM approach has been a lack of staff education and training during the 
transition to the updated GCP E6(R2) guideline103. Furthermore, a recent review 
concluded that centralised monitoring which utilises statistical tests may be a 
promising alternative but has limitations as a stand-alone procedure26. Therefore, 
 
 




the primary aim of this study was to explore the evidence for the variability of 
data quality monitoring procedures in clinical research studies. The secondary aim 
was to analyse the frequency of monitoring reported by the clinical research 
studies.  
3.2 Methods 
A systematic review was conducted in accordance with the PRISMA statement109 
and checklist (see Appendix A). The Cochrane Handbook for Systematic Reviews 
of Interventions was consulted for guidance111. The review was not registered with 
PROSPERO (International prospective register of systematic reviews) as it does not 
have a health-related outcome to meet the registration criteria110. The review 
addressed the research question in the PO (population/phenomena, outcome) 
format159: ‘How are clinical research studies [population/phenomena] implementing 
data quality monitoring procedures [outcome]?’  
3.2.1 Study selection  
A systematic search of the scientific databases CINAHL, Cochrane, MEDLINE and 
PubMed (all years to 29 May 2020) was conducted. Both MEDLINE and PubMed 
were searched to ensure that recent studies were identified160,161. Where possible, 
Medical Subject Heading (MeSH), free-text search terms and Boolean operators 
were used in the search strategy160. The search strategy used for the initial search 
was as follows: (data accuracy OR data quality OR data integrity OR data quer* OR 
data error* OR data reliability OR data validity OR data completeness) AND 
(clinical research OR clinical protocol* OR clinical stud* OR clinical trial* OR 
intervention stud* OR intervention trial* OR observation stud*) AND (double data 
entry OR logic check* OR range check* OR consistency check* OR statistic* OR 
 
 




risk-based monitor* OR risk-based triggered monitor* OR risk-based targeted 
monitor* OR remote monitor* OR central* monitor* OR on-site monitor* OR on-
site monitor* OR source data verification OR process* method* OR clinical audit* 
OR quality control OR quality assurance OR total quality management OR quality 
improvement OR data monitor*). Although this review focuses on monitoring 
procedures, the keywords ‘quality assurance’ and ‘quality control’ which are 
associated with the terms auditing and monitoring, respectively, were included; due 
to their interchangeable use. 
Eligible articles were all primary research studies including intervention trials, 
observational studies and qualitative studies. Included articles needed to provide 
details on data monitoring procedures on an ongoing basis in a clinical study setting 
with human participants of all ages. Therefore, articles conducting audits over 
multiple time points were considered as monitoring for the purpose of this review 
and included. There was no date restriction.  
Interventional trials, observational studies and qualitative studies were excluded if 
they: (i) did not report the results in the English language; (ii) were animal or 
cellular studies; (iii) were review articles, book series, editorials, errata, theses, 
methodological studies, conference abstracts or proceedings; (iv) proposed 
implementing new software/IT system(s) for data management/monitoring; and/or 
(v) reported results of a single/cross sectional audit, including only one point in 
time. 
Duplicate articles were removed using EndNote referencing software (version X9, 
2018; Thomas Reuters). Initial screening was based on title and abstract by reviewer 
(LH). A second independent reviewer (EN) screened 20% titles and 5% abstracts. If 
 
 




the abstract was unavailable or did not provide sufficient information, the full-text 
articles were obtained. Reviewers (LH and YP) screened all full text articles. Any 
discrepancies were discussed between until consensus was reached. Reference lists 
of the included articles were manually searched to identify additional articles.  
3.2.2 Data extraction  
Data extraction was performed by reviewer (LH) in a tabular format from each 
article including: citation, study design, funding, article topic, study location, 
number of countries, number of studies, number of study sites, study size, study 
duration, data collection platform, data storage, study monitor(s) level and details of 
the monitoring procedure(s) implemented. The study design was extracted as 
reported by the authors and cross-checked using the Evidence Analysis Manual’s 
glossary of terms related to research designs162. Where no design was reported the 
Evidence Analysis Manual was used. Where an included article reported the 
monitoring of data from another or multiple primary research studies, the associated 
study was also retrieved. Thus, the term ‘article’ as used in this review refers to the 
retrieved articles from the critical appraisal and the term ‘study’ refers to the 
associated primary studies. The following description from the Evidence Analysis 
Manual was used to differentiate descriptive studies due to the variety of methods 
(case study, case series or other descriptive studies)162. In addition, study authors 
were contacted where data was not provided.   
Although not included in the main findings, articles reporting the results of a 
single/cross-sectional SDV audits were collated and included in Appendix B as our 
research team had recently summarised SDV audits74. Therefore, any articles 
meeting the 2018 review selection criteria had the following data extracted: citation, 
SDV method, source (data, files, sites or participants) selected, amount of data, 
 
 




number of variables, key data, data coding, coding defined, total error calculation 
and details on study outcome.  
3.2.3 Data analysis  
Data analysis was performed to visually represent the extracted data of the articles 
included in the qualitative synthesis. Box plots and were created using IBM SPSS 
software (Version 22, IBM Australia, Lane Cove, NSW, Australia) to visualise 
the characteristics of the articles including the distribution of study sites, sample 
size and duration, and the percentage of sites, files, participants, indicators or 
endpoint packages that were selected for monitoring based on the monitoring 
procedure(s) and additional check(s) conducted. Data was also presented visually 
to summarise the quantitative elements of the included articles using Microsoft® 
Excel v 16.26 (2019, Washington, DC, USA) database. A scatter plot was used to 
summarise the number of monitoring procedures accumulating over time 
compared to the implementation of nine national and international regulatory 
guidance documents. The year of implementation for each document was 
extracted from government or reputable websites (e.g. ICH GCP and International 
Standards Organization (ISO)). A bar chart was used to compare articles that 
reported monitoring procedural designs and the reason for implementation and to 
visualise the number of study data variables included in monitoring procedures 
compared to the sample size. 
3.2.4 Statistical analysis  
A meta-analysis was performed to analyse the number of times monitoring was 
conducted over study duration in RStudio using the meta package (RStudio version 
3.6.2: Integrated Development for R. RStudio, Inc., Boston, MA, USA; meta 
package version 4.13-0)163. To calculate the frequency of monitoring, the number of 
 
 




monitoring events reported for a monitoring procedure was divided by study 
duration (days). The analysis was completed for the monitoring procedures: SDV, 
on-site, centralised and remote monitoring. To assess heterogeneity between 
individual articles, Q test and I2 statistics were calculated. An I2 more than 50% is 
considered to be substantial heterogeneity and 75% considerable heterogeneity164. A 
random effects model was used due to the significant heterogeneity associated with 
study design and duration. For all analyses, a random effects model was used to 
calculate the pooled effect summary rate of the outcome data and the associated 
95% confidence intervals (CI). Sensitivity analysis was performed by excluding 
articles were the article’s CI did not overlap with the CI of the pooled effect165. 
P<0.05 was considered to be statistically significant. 
3.2.5 Risk of bias  
Included articles were assessed for risk of bias in methodological quality using the 
Quality Criteria Checklist for primary research of the Academy of Nutrition and 
Dietetics Evidence Analysis Manual by one reviewer (LH)162.  Articles were rated as 
positive, neutral or negative according to the defined criteria. The Checklist was 
deemed appropriate as it was validated and took into consideration the 
heterogeneous study designs reported. Other tools were inappropriate as the majority 
were specific to a single study design and only a few were validated166.  
3.3 Results  
3.3.1 Study characteristics 
The search strategy identified 14860 articles of which 56 articles were included in 
this review: 52 reported quantitative data describing 85 studies (including 11 
articles reporting multiple studies, ranging from 2 to 11 studies), two articles 
 
 




reported qualitative data and two articles reported mixed methods of 44 studies 
(one article included 43 studies) (Figure 3-1).  
The 56 included articles are summarised in Table 3-1. 52 articles provided 
quantitative data from six experimental studies (three RCTs68,69,73 and three quasi-
experimental trials167-169) and 45 observational studies (16 descriptive studies170-
185, eight pre-post studies29,62,72,186-190, eight surveys55,85,191-196, six case series71,197-
201, four cohort studies58,75,202,203, two historical control28,204, one post hoc 
analysis70 and one retrospective review205). The two articles providing qualitative 
data,105,106 and the two mixed-method articles103,104 reported heterogeneity in the 
study designs. The articles were published between 1986 and 2020, although a 
majority (n=45, 80%) were published in the last 10 years and 37 (66%) received 
research funding. Articles represent studies conducted across continents, 
including Europe68,69,72,75,103,104,173,176,181,194,196-198,204,205, North America28,55,58,167-
169,172,180,189,199-201, South America170, Asia85,106,179,182,185,195, Africa62,184,186,202 and 
Australia29,171,191. Fourteen (25%) articles included studies conducted across 
multiple continents70,71,73,105,174,175,177,178,183,187,188,190,193,203 and one article did not 
report its location192. The studies varied widely (Figure 3-2) in the number of 
countries (ranged from one to 50), the number of study sites (one to 1040 sites), 
the sample size (18 to 94 000 participants) and the duration of studies (10 days to 
11 years). The 54 (96%) articles collecting quantitative data (including the mixed-
method studies) used data collection instruments including paper-based28,29,58,69-
73,75,168-172,175-177,179,180,182-184,187,188,197,198,200-205, electronic 
platforms55,62,103,178,181,185,190-196 or a combination of both68,85,173,174,186,199; with 
three not reporting their data collection instrument104,167,189. Of the quantitative 
studies, 40 out of 45 (89%) articles (excluding eight surveys and one mixed-
 
 




method article survey) reported using an electronic software system or 
database28,29,58,62,69-73,75,104,168-171,173-188,190,197-203,205. These 45 articles described 120 
studies (Appendix C) including 85 intervention trials, 22 observational studies 
and two pilot studies. Eleven studies did not specify the design (see Appendix C, 








Figure 3-1: Flowchart of study selection.  
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Abbreviations: AF, atrial fibrillation; CRA, clinical research associate; CRF, case report form; CTU, clinical trials unit; CV, cardiovascular; CVD, cardiovascular disease; DMSC, 
Data Management and Statistical Core; eCRF, electronic case report form; eCTR, electronic clinical trial record; EDC, electronic data capture; EMR, electronic medical record;  
FDA: Food and Drug Administration; HIV: Human Immunodeficiency Virus; IWSR: Interactive Web Response System; MR: medical record; NA: not applicable; NR: not recorded; 
PI, principal investigator; RBM, risk-based monitoring; wk, week. 
Study size: n refers to the total number of participants reported to complete the study and included in the final analysis.  
 
 




a 551 randomised participants from baseline and early-treatment visit data.  
b 3787 patients included in the four audit cycles. The total number of patients included in the central database was NR.  
c 3 year sub study carried out within a large multi-site case control study conducted over 10 years.  
dTotal number of participants randomised for the four included RCTs.  
e 428 participants enrolled in study.  
f 3102 patients were randomised 
g Study size in this article is referred to as number of medical charts not participants.  
h 9385 participants enrolled in the study  
i 24-month trial duration, however monitoring reports were selected from a 12-month period.  
j 12000 patients had started on antiretroviral treatment from a registry of 27000 adult patients as of December 2011 (post EMR) 
k 13 879 (81.4%) breastfeeding mother-infant pairs were followed up between January 2008 and December 2010, 17 046 were enrolled in 1996 and 1997 initial study.  
l 222 facilities, number of participants not recorded.  
m 6 sites included in SDV-1 and 7 sites included in SDV-2. The total number of sites include in the registry was NR.  
n 1 study including 2 networks (Network A: ARDs network; Network B: ChiLDREN network) 
o A researcher spent 2 weeks with each case study (n=2).  
p Combined total of 6871 subjects randomised in the three RCTs.  
q Two studies with a combined total of 3442 participants 
r 1-year period of observations collected from the two studies. 
s Quantitative survey and semi-structure interviews. 
t Quantitative retrospective analysis and semi-structured interviews.  
u Interviews were conducted before and after the 60 day RCT. 
v 20 (14%) out of the invited 142 clinical trial staff members completed the survey.   
w Trials planned accrual >1000.  
x Total number of participants combined from the six included studies.  
y 500 patients were randomised into two treatment groups. 
z 12 wk double-blind treatment and 40 wk longitudinal 
* Audited number (n) of participants, files or centres not available in publication. Only percentage provided.  
** Total number of participants, files or centres not available in publication, therefore unable to calculate percentage.  
*** Study site and study size, include the number of sites and participants reported to complete each study, unless otherwise specifie
 
 




              
     
Figure 3-2: Box plots showing the distribution of study sites (A), sample size (B) 
and duration (C) reported in the included articles.  
Excluding: A = 12 articles; B = five articles; and C = five articles due to data not 









3.3.2 Data quality monitoring procedures and additional checks 
A wide variety and combination of data monitoring procedures and checks were 
identified across the 56 articles (Table 3-2), with 27 (48%) articles reporting only 
one monitoring procedure28,29,62,69,70,85,104-106,168-171,173,177,181-183,186-
188,193,195,197,198,203,204, of which seven also included at least one additional check 
(double data entry and/or range, logic and consistency checks)28,69,168,170,173,177,181. 
Three articles (5%) mentioned all five monitoring procedures55,185,191, in which 
two were cross-sectional surveys55,191. Monitoring data quality by a SDV 
procedure was the most commonly applied or explored procedure reported in 32 
(57%) articles28,29,55,58,62,68-73,75,167,169,171,172,176,178,181,184-188,190,191,196,197,199,202,204,205. 
Although RBM was only reported in 15 (27%) articles, 13 of these were 








Table 3-2: Overview of all included studies reporting on monitoring procedure(s) 
and additional check(s) in order of publication date.   
  Monitoring procedures Additional checks 
Author, year  RBM RM 
CM/ 
CSM 
OSM SDV DDE 
RLC 
checks 
Bagniewska et al. 1986      a a
Barrie et al. 1992     b   
Weiss et al. 1993     b   
Pradhan et al. 1994       
Verweij et al. 1997     b   
Caloto et al. 2001    b   
Dennis et al. 2003       
Reisch et al. 2003       
Soran et al. 2006  c     
Van den Broeck et al. 2007       
Nahm et al. 2008     b  
Andrianopoulos et al. 2011     b   
Krzych et al. 2011  c      
Liddy et al. 2011       
Morrison et al. 2011*        
Tolmie et al. 2011        
Bakobaki et al. 2012     a a 
Castelnuovo et al. 2012        
Duda et al. 2012     b   
Guthrie et al. 2012     a  a
Mphatswe et al. 2012     b   
Tuder Smith et al. 2012        
Verhulst et al. 2012     b   
Kirkwood et al. 2013        
Mealer et al. 2013   a      
Pogue et al. 2013        
Chantler et al. 2014#        
Edwards et al. 2014       
Lindblad et al. 2014      a   
Mitchel et al. 2014   a a a   
Andersen et al. 2015        
Houston et al. 2015     b   
Knepper et al. 2016*        
Kumar et al. 2016*        
Rao et al. 2016        
Ruiz et al. 2016       
Timmermans et al. 2016        
Aceituno et al. 2017       
Brosteanu et al. 2017   a  a   
Diani et al. 2017   a  a   
Fox et al. 2017        
Hossman et al. 2017   a    
Hurley et al. 2017§        
Von Niederhausern et al. 2017^        
Zhang et al. 2017#        
Houston et al. 2018*       a
Rahbar et al. 2018       
Stenning et al. 2018   a  a   
 
 




Beever et al. 2019*        
Embleton-Thirsk et al. 2019       a
Fougerou-Leurent et al. 2019       
Jeong et al. 2019*        
Engen et al. 2020     a   
Higa et al. 2020  a a a a   
Kim et al. 2020*        
Love et al. 2020*          
Total 15 14 24 23 33 10 15 
CM: Centralised monitoring; CSM: Centralised statistical monitoring; DDE: Double data entry; 
OSM: On-site monitoring; RBM: Risk-based monitoring; RLC checks: Range, logic and 
consistency checks; RM: Remote monitoring; SDV: Source data verification.  
a Monitoring procedure and/or additional check mentioned in article but not described in detail. 
Therefore, procedure not included in relevant summary table in Appendices D, F or G.  
b Monitoring procedure described in article as an audit.  
c Referred to as centralised monitoring in article. However, remotely conduct monitoring activities 
that were previously conducted on-site. This includes delivering documents via email, fax or snail 
mail to satisfy monitors’ queries and conduct source document verification. 
* Cross-sectional survey, therefore monitoring procedure(s) and/or additional check(s) not 
implemented to clinical study. 
# Qualitative study, therefore monitoring procedure(s) and/or additional check(s) not implemented 
to clinical study.  
§ Mixed-method study (survey and interviews), therefore monitoring procedure(s) and/or 
additional check(s) not implemented to clinical study. 
^ Mixed-method study, therefore monitoring procedure(s) and/or additional check(s) only 










Figure 3-3: Double y-axis scatter plot showing the number of monitoring procedures reported in articles accumulating over time and 
the implementation status of nine national and international regulatory guidance documents. 
DH: Department of Health; EC: European Commission; EMA: European Medicines agency; GCP: Good Clinical Practice; HC: Health Canada; ICH: 
International Council for Harmonisation; ISO: International Organization for standardization; J: Japanese;  K: Korean; MFDA: Ministry of Food and Drug 
safety; MHRA: Medicines and Healthcare products Regulatory Agency; MRC: Medical Research Council; PMDA: Pharmaceuticals and Medical Devices 
Agency; Q&A: Questions and Answers; R1: revision 1 R2: revision 2; R3: revision 3; RBM: risk-based monitoring; V1: version 1; V2: version 2; V3: version 
3; U: Updated; US FDA: United States Food and Drug Administration 
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The 45 (80%) articles implementing data monitoring procedure(s) are summarised in 
Figure 3-4. The articles reported to either implement a prospective monitoring 
design28,29,62,68,69,73,75,167,170-185,187,188,190,199,202,203, a retrospective monitoring design58,70-
72,104,168,169,189,197,200,201,204,205 or a combination of prospective and retrospective 
monitoring186,198 are summarised. The majority (n=29, 64%) of articles assessed the 
quality of data collected and the reliability of the findings29,62,104,168-180,182-184,186-
188,197,199,201-204. The monitoring procedures within the 16 (36%) articles which assessed 
the performance/value of a procedure(s) varied (see Appendix D), though ten evaluated 
on-site monitoring (include SDV)58,68-70,72,73,189,190,205.  
 
Figure 3-4: Overview of the included articles monitoring procedural designs and 
the reason for implementation (n=45)*. 
Quality: Articles assessed the quality of data collected and the reliability of study findings. 
Performance: Articles assessed the performance/value of monitoring procedure(s).  
* Excluded cross-sectional surveys, qualitative studies and the qualitative component of the mixed 
method study. Such studies were excluded due to not prospectively or retrospectively 
implementing a monitoring procedure in a clinical study. 
** Prospective monitoring design conducted concurrently throughout study alongside data 
collection.  
*** Retrospective monitoring design conducted after data collection is completed, database lock, 
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3.3.2.1 Source data verification  
Of the 33 (59%) articles reporting SDV, 21 (38%) described the application of 
SDV monitoring procedures28,29,58,62,69-72,169,171,172,178,181,184,186-188,190,197,202,204 
(Appendix E, Table 1). Comparing source documents to a database was the most 
common procedure reported in 12 (57%) out of the 21 
articles28,29,62,71,169,171,178,181,184,186,187,197. The characteristics and scope differed 
depending upon the clinical setting, study design, amount of data collected, 
amount of acceptable error and requirements to meet GCP compliance28,187,190,202. 
Two articles implemented standard audit codes and categorisation from the 
European Organisation for the Research and Treatment of Cancer (EORTC)29,187. 
The use of the term ‘audit’ was common among nine articles conducting SDV 
over multiple time points and were considered as monitoring for the purpose of 
this review28,29,62,169,171,187,188,197,204. Of the articles reporting multiple SDV audits, 
two found an increase in error between audits29,188 and five an improvement in 
data quality over time28,62,169,186,204. Four of the five articles that reduced the 
number of discrepancies or missing data reported improvements to the 
interventions28,62,186,204. An additional 13 single/cross-sectional SDV audits are 
summarised in Appendix B. In brief, the majority of articles (69%) compared 
source data to a database. The proportion of files, sites, participants or ICU 
encounters (1-100%) and the number of variables (3-140) included for auditing 
varied. Dissimilarities in methods confirmed the heterogeneity in single/cross-
sectional SDV audits.  
3.3.2.2 On-site monitoring  
Fourteen (25%) articles described an on-site monitoring procedure, though an 
additional 23 (41%) articles mentioned its use in this review68,73,168,170,173-
 
 




175,179,180,184,189,200,201,205 (Appendix E, Table 2). The on-site monitoring activities 
were vastly different, with none reporting standardised or published procedures. 
In addition to checking data variables for errors or discrepancies, on-site 
monitoring activities included checking protocol compliance, patient safety and/or 
consent forms68,73,168,175,184,189,200,201,205. During on-site monitoring visits, SDV was 
performed in three articles, with no additional details provided68,73,205. Two 
articles which applied only an on-site monitoring procedure found that frequent 
on-site monitoring activities in addition to staff training successfully allowed for 
early data corrections and ongoing quality improvement168,170. Details on the 
reporting structure were absent in a further three articles180,189,200, but feedback 
and discussions with study staff and management, alongside monitoring reports 
were commonly reported68,73,168,170,173-175,179,184,201,205.  
3.3.2.3 Remote monitoring  
Remote monitoring procedures were described in seven articles (13%) from the 
14 (25%) reporting the procedure172,177,179,183,190,201,203 (Appendix E, Table 3). The 
nature and extent of remote monitoring procedures were dependent upon study 
size190 and the geographical spread of the study sites183,203. Three articles reported 
the use of a tracking system172,183,203 which simultaneously identified incomplete 
records, data inconsistencies and missing data. This timely submission process 
allowed studies to continuously raise data queries. The timeframe for data capture 
and sending files varied (7 – 30 days)172,179,203. All articles reported that data was 
checked at a coordinating centre, where files were sent by posting/fax (original or 
copies)172,177,183,201,203, on encrypted flash drives179 or online190. The majority of 
articles carried out a similar reporting structure when data inconsistencies or 
missing data were found including directly contacting the sites or returning files 
 
 




to the site to resolve queries172,177,179,183,201,203. One article stated that additional 
training was done for sites with missing data190.  
3.3.2.4 Centralised monitoring (including centralised statistical monitoring) 
The use of a centralised monitoring procedure (including centralised statistical 
monitoring (CSM)) was reported in 24 (43%) articles and described in 13 
(23%)71-73,174-176,178,180,182,189,198,200,205 (Appendix E, Table 4). Of these, two articles 
implemented both centralised monitoring and CSM175,176, six used only 
centralised monitoring71-73,174,180,205 and five applied CSM178,182,189,198,200. A 
centralised monitoring procedure was applied in six articles to guide on-site 
visits174-176,180,189,200, six replaced on-site monitoring visits72,73,178,182,198,205 and one 
conducted centralised monitoring independently71. The centralised monitoring 
procedures were heterogeneous, with no article reporting published or similar 
methods180. Six articles suggested that centralised monitoring was a worthwhile 
alternative to intensive on-site monitoring from an efficiency and cost saving 
perspective72,73,182,189,198,205. Data queries and issues identified via centralised 
monitoring were reported back to site staff for clarification and resolution in the 
majority (77%) of articles73,174-176,178,180,182,189,198,205. 
3.3.2.5 Risk-based monitoring  
Of the 15 (27%) articles reporting RBM procedures, only six (11%) articles 
described their procedure68,75,104,167,185,199 (Appendix E, Table 5). Of these, a RBM 
procedure was used to guide only on-site visits75,104 or both centralised and on-site 
visits68,167,185,199. A RBM procedure was either implemented to target certain data 
points167,185,199 or both targeted and triggered monitoring68,75,104. Triggered 
monitoring referred to the use of predefined indicators to trigger the action of 
monitoring75. Published monitoring procedures were reported in two articles68,104, 
 
 




one applied monitoring prospectively 68 and the other retrospectively104. The 
RBM procedures varied for the other four articles75,167,185,199. Although the risk 
assessment categories varied, all six articles mentioned subject safety and 
protocol compliance as common risk categories and the use of a grading system 
for risk classification. High risk or flagged sites received a more intensive 
monitoring strategy68,104,185,199. Only one included article did not recommend on-
site monitoring, centralised monitoring and systematic review of the risk 
profile167. Articles comparing multiple monitoring procedures included, 
Brosteanu et al.68 who found RBM required less than 50% of resources compared 
to extensive on-site monitoring, while Stenning et al.75 found that triggered 
monitoring did not satisfactorily distinguish sites with higher and lower levels of 
major and critical findings. 
3.3.2.6 Double data entry  
Ten (18%) articles reported the use of double data entry to accompany monitoring 
procedures though only eight (14%) described the 
procedures69,170,173,177,178,180,201,202 (Appendix E, Table 6). Double data entry was 
not completed on all data points as it was considered cost-inefficient177,180. 
Manual double data entry of a sample was considered adequate to ensure the 
results collected were of acceptable quality173. The timeframe (1 week) to resolve 
data discrepancies was stated in only one article170. The majority of articles 
reported that discrepancies were reported and sent to other study 
personnel69,173,178,180,202. Only two articles calculated an error rate173,202.  
3.3.2.7 Range, logic and consistency checks  
Of the 15 (27%) articles reporting range, logic and consistency checks, 11 (20%) 
described the application in addition to monitoring procedures28,168,172-
 
 




175,177,181,184,201,202 (Appendix E, Table 7).  Checks were applied at the time of data 
entry with an automated system which used predefined rules28,168,172-174,181,184,201. 
Of these articles, inconsistent and discrepant data were identified instantly and 
corrected prior to the use of other data quality monitoring procedures. Otherwise, 
range, logic and consistency checks were performed after data collection and 
entry using a standard query process175 or manually scanning for incomplete or 
inconsistent data177. All articles stated the reporting structure. Additionally, data 
inconsistencies and discrepancies flagged during range, logic and consistency 
checks were followed up during on-site monitoring procedures174,181.  
3.3.3 Amount, variables and frequency of procedures and checks  
Applying 100% monitoring to a dataset has been considered time-consuming, 
expensive and does not guarantee error free data58,70,72,171,184. A total of 62 
monitoring activities and additional checks from 31 articles provided data on the 
percent of sites, files, data, participants, indicators or endpoints monitored 
(Appendix E)29,57,58,62,68-73,168,170-175,177-180,182,184,186,190,198,200-204. There was 
variability in the choice included (Figure 3-5). By comparison range, logic and 
consistency checks were consistent with all nine articles reporting to check 100% 
of the files or data28,172,174,175,177,181,184,201,202. Figure 3-5 also indicates the median 
number of studies that conducted SDV was much lower (32.5%) than the other 
monitoring procedures and checks (≥55%).  
 
 





Figure 3-5: Box plot of the percentage of sites, files, participants, indicators or 
endpoint packages selected for monitoring based on monitoring procedure and 
additional check conducted. Data is shown after outliers were removed by a 
standard inter-quartile method (1.5 x interquartile).  
CM: Centralised monitoring; CSM: Centralised statistical monitoring; DDE: Double data entry; 
OSM: On-site monitoring; RBM: Risk-based monitoring; RLC checks: Range, logic and 
consistency checks; RM: Remote monitoring; SDV: Source data verification.  
 
Information on the number of study variables monitored were reported in 18 
(32%) articles (Appendix E) of which five specified the inclusion of key or 
primary data variables (four to 144 variables)69,71,180,184,190 and 15 articles included 
other data variables (three to 1095 variables)62,69-72,168,171,173,175,176,186,188,198,200,203. 
There was no association between the number of study variables and study sample 
size (Figure 3-6) though two articles published in 2019 included both a small 
number of key variables and a larger sample of other variables69,71.  
 
 





Figure 3-6: Double y-axis graph showing the number of key (solid shaded 
symbols) and other (no fill symbols) data variables included in monitoring in 
comparison to the study sample size (shaded columns).  
Sample size: n refers to the total number of participants reported to complete the study and 
included in the final analysis. 
Symbols: diamond = on-site monitoring; triangle = centralised monitoring; circle = source 
data verification; cross = remote monitoring.  
* Van den Broeck et al. 2007: Represented twice in graph as publication monitors a different 
number of data variables for the two monitoring procedures conducted (source data verification 
and on-site monitoring).  
^ Andrianopoulos et al. 2011: Three source data verification audits monitoring a different number 
of data variables at each time point.  
 
Twenty-eight (50%) articles were included in the meta-analysis reporting on the 
number of times monitoring was conducted using SDV (n=12), on-site (n=11), 
remote (n=6) and centralised (n=5) monitoring (Figure 3-7, Figure 3-8, Figure 
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frequency, the pooled effect summary rate for monitoring utilising a SDV 
procedure was 1.70 per 365 person-days (95% CI: 0.70 - 4.10; p < 0.01; I2 = 90%; 
Figure 3-7), on-site monitoring 1.62 per 365 person-days (95% CI: 0.38 - 6.86; p 
< 0.01; I2 = 97%; Figure 3-8), remote monitoring 3.17 per 365 person-days (95% 
CI: 1.52 - 6.61; p < 0.01; I2 = 91%; Figure 3-9) and centralised monitoring 25.91 
per 365 person-days (95% CI: 4.60 - 145.80; p < 0.01; I2 = 100%; Figure 3-10) 
using a random effects model. The monitoring frequency was much higher and 
varied more for centralised monitoring in comparison with the other procedures. 
Considerable heterogeneity was observed for all four procedures (I2 ≥ 90%). The 
specific monitoring requirements within organisations may account for the reason 
some studies have higher rates of monitoring events in comparison to other 
studies who conducted the same monitoring procedure. 
The sensitivity analysis performed on each of the four monitoring procedures 
identified articles that had a much higher rate of monitoring event than the other 
articles. Removing these studies (Ruiz et al. article from SDV; Dennis et al. and 
Caloto et al. articles from OSM; Tolmie et al. and Fox et al. articles from RM; 
Engen et al. and Bakobaki et al. articles from CM) did change the overall 
summary statistic for each of the four procedures: SDV 1.36 per 365 person-days 
(95% CI: 0.82 - 2.25; p = 0.03; I2 = 49%; Appendix F, Figure 1); OSM 1.07 per 
365 person-days (95% CI: 0.72 - 1.60; p = 0.49; I2 = 0%; Appendix F, Figure 2); 
RM 1.08 per 365 person-days (95% CI: 0.36 - 3.22; p = 0.02; ; I2 = 70%; 
Appendix F, Figure 3); and CM 9.36 per 365 person-days (95% CI: 5.89 - 14.89; 









Figure 3-7:  Forest plot illustrating the number of times of monitoring was 
conducted over the duration of a clinical research study using source data 
verification for all articles (n=12). Rate (times monitoring was applied/365 
person-days).   




Figure 3-8: Forest plot illustrating the number of times of monitoring was 
conducted over the duration of a clinical research study using on-site monitoring 
for all articles (n=11) (A). Rate (times monitoring was applied/365 person-days).  
Abbreviations: CI, confidence interval. 
 
 





Figure 3-9: Forest plot illustrating the number of times of monitoring was 
conducted over the duration of a clinical research study using remote monitoring 
for all articles (n=6). Rate (times monitoring was applied/365 person-days).   





Figure 3-10: Forest plots illustrating the number of times of monitoring was 
conducted over the duration of a clinical research study using centralised 
monitoring for all articles (n=5). Rate (times monitoring was applied/365 person-
days).   
Abbreviations: CI, confidence interval. 
 
 
3.3.4 Included cross-sectional surveys and qualitative studies 
Eight (14%) cross-sectional surveys55,85,191-196 and one (2%) mixed-methods 
survey103 (18 to 607 participants) were included in this review (Appendix G). 
Four (7%) surveys aimed to identify the current methods, tools and procedures 
used to monitor data quality and detect data anomalies55,191,192,196 and of these, 
three surveys concluded that a wide variety and ad-hoc monitoring procedures 
were employed55,191,196. Centralised monitoring was considered the most common 
 
 




procedure55,191,196 and on-site monitoring was the most common strategy192. The 
remaining five (9%) surveys specifically focused on RBM practices and 
researcher perceptions and attitudes85,103,193-195. Two surveys published in 2013 
and 2016 found that 40-50% of survey respondents were not aware or had not 
heard of RBM85,193. While, in 2017 a survey reported only 14% of respondents 
were not familiar with RBM103 and two surveys (2019, 2020) found the vast 
majority of respondents were using RBM194,195. The RBM procedure was believed 
to increase workload and require greater IT demands85,103 though has the potential 
to be more efficient and reduce monitoring costs194. Kumar et al.193 found that 
clinical researchers from developing countries had more favourable responses and 
were more confident with RBM. The heterogeneity between clinical researcher’s 
responses regarding their attitudes and perceived barriers towards implementing 
different monitoring procedures were revealed. There was a need for further 
education, training, development and reflection to understand and implement the 
necessary data quality monitoring procedures85,103,191,193-196.  
Two (4%) qualitative studies105,106 and two (4%) mixed-methods studies103,104 
used a combination of interviews, focus groups and observations (Appendix H). 
The study population and setting of the four articles were diverse and 
heterogeneity between study aims was apparent. No main common themes from 
the articles could be determined though well trained and motivated study 
personnel were deemed crucial to the overall success of a study104,105. Involving 
staff early in a study was beneficial for staff teamwork, trust, responsibility and 
feedback allowing for continuous improvement. Increasing the frequency of 
monitoring was suggested to improve data quality but could not be adapted to all 
cases due to different financial environments (e.g. academic settings)104. 
 
 




Therefore, the cost-effectiveness of RBM was questioned with concerns that 
infrequent on-site monitoring could miss queries of systematic error103,104. A lack 
of expertise and insufficient training prevented clinical researchers from 
implementing RBM. Though Zhang et al.106 found that the implementation of a 
mobile system allowed the quality of the data to be monitored remotely, which 
considerably reduced workload.  
3.3.5 Quality assessment  
Methodological quality was assessed under various categories such as clarity of 
the research question; selection bias; comparability of study groups, handling 
withdrawals; blinding of participants; validity of outcome measures and 
intervening factors; quality of statistical analysis; and conclusions were made 
considering study limitations and sponsorship bias. Thirty-nine (70%) articles 
were rated as positive 28,29,55,58,62,68-73,75,85,103,169-171,175-177,180,183,184,186-188,190-
196,198,200,202-205 and the remaining 17 (30%) articles were neutral 104-106,167,168,172-
174,178,179,181,182,185,189,197,199,201 (Appendix I). The lack of negative quality ratings 
implies a moderate to high study validity, which may be explained as the majority 
of articles were associated to large RCTs.  
3.4 Discussion  
This review demonstrated that there has been an increase in new approaches to 
monitoring data quality (i.e., centralised monitoring and RBM) but there does not 
appear to be a “one-size-fits-all” procedure. The majority of articles were from 
large multi-site intervention trials, suggesting that existing guidelines might be 
more suited towards such trials. These findings imply that new approaches may 
represent an opportunity for more effective and efficient data quality monitoring, 
 
 




though evidence-based guidelines are limited and are currently not tailored to suit 
all clinical research study designs. 
The 2016 GCP E6(R2) guideline prioritised a risk-based approach or a 
combination of on-site and centralised monitoring12 for clinical studies. 
According to our findings, the effectiveness and efficiency of RBM cannot be 
confirmed as published data for this method is limited. Inconsistent findings 
reported that RBM reduces study costs, staff workload and improves data quality 
and patient safety. In line with this, a review by Hurley et al.78 indicated that there 
are a variety of RBM tools and no gold standard approach suggesting an evolving 
area and one of the challenges researchers face. This may explain why clinical 
researchers continue to apply SDV as recommended by the 1996 GCP 
guideline11. Recently, the START monitoring sub-study concluded that the value 
of on-site monitoring in addition to local and central monitoring is limited in 
value (increasing study cost and reporting time) when compared to local and 
central monitoring only73. To date, on-site monitoring and/or SDV to RBM have 
only been compared in three articles; two finding the approach needs 
improvement68,75. The final study is still ongoing, though demonstrated non 
inferiority of a RBM approach to detect severe errors77. Thus, further evidence 
supporting the safety and effectiveness of RBM is warranted. Despite this 
evidence gap, GCP compliant clinical studies are advised to implement RBM to 
monitor their study data206.  
This literature review has identified that monitoring procedures varied and no 
“one-size-fits-all” approach could be recommended. These findings are similar to 
two reviews which focused on only one monitoring procedure43,78. The current 
systematic review extends on those findings by demonstrating that funded 
 
 




intervention trials with more than four sites, greater than 500 participants made up 
a vast majority of the associated studies, albeit differences in publication topic 
and study location. Although the GCP E6(R2) guideline has highlighted the 
importance of flexibility in the extent and nature of monitoring12, regulatory 
guidance is broad and open to interpretation207. Unfortunately, a lack of detail and 
instruction related to the GCP guideline means that clinical researchers are unsure 
about what monitoring procedures is best for their study. This review has revealed 
that performing 100% monitoring compared to partial monitoring offers only a 
marginal total error rate reduction of <1%70,190 while remote monitoring could not 
locate 0.44% of data values58. Conversely, monitoring targeting key data 
increased the workload (up to 50%) due to the additional and heterogeneous 
queries generated69. Increased time spent addressing queries increased study 
costs, which questioned the performance and value of the approach.  
Adding to this confusion, it is apparent that the GCP E6(R2) guideline falls short 
in dictating the frequency of monitoring required and there is only limited 
additional evidence to guide researcher decisions55,208,209. Our systematic review 
showed that centralised monitoring was conducted more frequently over a 365 
person-day period when compared to SDV, on-site and remote monitoring; albeit 
substantial heterogeneity was found for all procedures (I2>90%). This review 
showed that a “one-size-fits-all” monitoring approach is impractical. Meanwhile 
small single-site intervention trials and observational studies are underrepresented 
in this review, suggesting that they may find it difficult to meet the current 
recommendations and thus have been less likely to publish their data monitoring 
approaches.  
Our work suggests that organisations conducting data monitoring procedures, 
 
 




appeared to appreciate resources, such as IT systems and staff members, as they 
were both key to identifying, minimising and resolving data discrepancies. This is 
similar to previous articles which have reported the use of computer-aided 
validation to be more reliable for real-time edit checks and statistical 
monitoring32,83,153. Furthermore, clinical studies are required to comply with 
regulatory agencies promoting a RBM approach which rely largely on an IT 
platform84. This systematic review demonstrated the majority of articles do utilise 
IT systems to minimise inconsistent or missing data, however there was no one IT 
system which was recognised as “best fit”. The majority of articles included in 
this review were large multi-site intervention trials which reported to have 
funding and may be the reason for the common adoption of sophisticated IT 
systems. Therefore, our findings may not be generalisable to small single-site 
intervention trials or observational studies. IT systems require continuous support 
from experienced staff who operate and maintain the system84. Regardless of the 
study design or context, the majority of articles in this review identified that study 
staff play a vital role in the reporting of data monitoring activities by 
communicating issues, participating in teamwork and providing continuous 
feedback to minimise discrepancies. This indicates the importance of an effective 
support structure within a clinical study. Another study also confirmed that 
successful data quality improvements should include on-the-job staff mentoring to 
engage staff in data collection, cleaning and analysis, and thus provide ongoing 
skill development with on-site monitoring210. Further research needs to consider a 
more holistic approach to data quality monitoring, to be addressed by regulatory 
agencies in the future.  
There are strengths and limitations that need to be highlighted for the current 
 
 




systematic review. A major strength of this review is that it is the first review to 
systematically assess different data monitoring procedures applied in clinical 
research studies. Previous reviews have investigated and compared only one data 
monitoring procedure. With regards to limitations, the majority of the articles 
included for review had low levels of evidence according to the study design108. 
However, the inclusion of cross-sectional and case-series studies were warranted 
to provide a holistic view on the variability of data quality monitoring procedures 
and their relation with a wide range of clinical settings. It is presumed that many 
clinical studies may complete data monitoring, but do not publish their procedures 
which reduces the generalisability of our findings. This review focused only on 
the literature databases CINAHL, Cochrane, MEDLINE and PubMed. It should 
be acknowledged that many organisations are now publishing relevant real-word 
experiences within the “grey literature” (white papers, monographs, web-based 
case studies) which were not included in this review as they were out of the scope. 
The sole focus on clinical research studies may also have excluded relevant 
articles from industry sources and the informatics literature. Additionally, limited 
articles assessed the value and performance of data monitoring procedures and 
whether they were effective in identifying data quality issues. Such limitations 
challenged the conclusions for the clinical significance in relation to acceptable 
data quality. The majority of articles in this review concluded that reduced on-site 
monitoring or SDV can still retain adequate data quality. However, there is a 
scarcity of evidence for small single-site intervention trials and observational 
studies. It should be recognised that publication bias may exist, as researchers 
may be more liable to publish articles that are aligned with the views of their 
associated primary study and have favourable data quality findings. Although 
 
 




monitoring procedures may have had some common basic characteristics, they 
were not homogenous, and each clinical study was set in a unique setting and 
diverse in methods, data sources and outcome variables.  
3.5 Conclusion 
In conclusion, there has been a slow increase in new approaches (i.e. centralised 
monitoring and RBM) to monitor data quality since the 2016 GCP E6(R2) 
guideline. However, a wide variety of monitoring procedures were reported and 
no “one-size-fits-all” approach could be determined. Differences in the 
monitoring procedures occurred despite regulatory agencies promoting a RBM 
approach; these findings imply that the guidelines are broad, fall short of detail 
and are left open to interpretation. Since the majority of articles included in this 
review were associated to large multi-site intervention trials, this may suggest that 
existing guidelines are clearer and more suited towards such studies. The review 
identified that centralised monitoring was conducted more frequently when 
compared to other monitoring procedures. Moreover, clinical studies appeared to 
appreciate resources including IT systems and their staff members which are key 
to minimising and resolving data queries and discrepancies. Taken together, these 
findings suggest that while new approaches may represent an opportunity for 
more effective and efficient data quality monitoring, work is required to modify 
existing guidelines to include a more holistic monitoring approach which is 
flexible and can be tailored to most clinical studies.  
This chapter has identified that there has been a gradual transition in the published 
literature to meet updated recommendations made by regulatory agencies. Thus, 
the next step is to explore the procedures implemented at Australian clinical trial 
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As outlined in Chapter 1, current research has made it clear that international and 
national guidelines specify data monitoring should be undertaken to ensure study 
safety and quality. To optimise the efficacy of monitoring, there has been an 
emphasis to reduce on-site monitoring12,211. However, it is important to recognise 
that the GCP E6(R2) guideline is flexible and does not provide specific details on 
when to conduct monitoring or how much monitoring is required43,44. Despite 
such recommendations to reduce on-site monitoring, the majority of clinical trials 
continue to conduct traditional 100% SDV76. A lack of clear guidance on which 
monitoring method is valid and cost-effective to ensure data integrity has created 
confusion within the clinical research community. 
Evidence of the effect of non-standardised data quality checks within clinical 
studies is demonstrated in the online blog of publication retractions due to 
fraudulent data58. This website lists 562 publications in 2017 alone that had to be 
withdrawn due to incorrect data and/or analyses. As described earlier in this 
thesis, there appears to be a lack of knowledge about systematic procedures for 
data quality assessment and monitoring in clinical studies4.To ensure data 
integrity in clinical research it is imperative to publish a “gold standard 
methodology” to be available for all researchers to reference and utililse.  
To the candidate’s knowledge, no research had been conducted in an Australian 
research setting prior to this study. Thus, the aim of this feasibility study was to 
gather information about current data quality tools and procedures that are used 
within Australian clinical trial sites. It was hypothesised that clinical trials will 
use varying data quality monitoring procedures.  
 
 





4.2.1 Planning  
A feasibility study was considered appropriate to inform the design, planning and 
justification for a national survey (Chapter 5). Feasibility studies are conducted to 
answer the question ‘can this study be done?’212. Given that many organisations 
consider their data quality tools and procedures to be confidential31 a small 
version of the survey was designed to determine if clinical researchers would 
respond to a web-based survey sent via email on a highly confidential topic.  
4.2.2 Setting 
Clinical trial sites listed on the Australian Government National Health and 
Medical Research Council (NHMRC) Australian Clinical Trial site list were 
invited to participate in this survey (n=148)213. Staff members targeted to 
complete the survey included the manager/employee in charge of trial-related data 
quality assurance processes. The NHMRC clinical trial list was considered as a 
representative sample as it is a government listing of all trial sites in Australia 
conducting clinical studies of all phases (I-IV), types (treatment, 
diagnostic/screening, and prevention) and diseases/conditions in Australia.  
Clinical trial sites that were identified to have an affiliation with the University of 
Wollongong (UoW), the organisation where the thesis candidate was enrolled, 
were excluded from the study to avoid the potential risk of bias. Overlapped sites 
which may have caused duplication were also excluded. Several clinical trial 
networks on the list responded that they did not run clinical trials independently. 
In this case, permission was given for these networks to forward the survey to 
their collaborating organisations. Informed tacit consent was obtained by 
 
 




completion and return of the online survey. 
4.2.3 Development of the online survey form 
Eleven survey questions were adapted in short form from published and validated 
survey questions45,55. Information gathered from the survey included data quality 
management methods and procedures, error levels, data monitoring, staff training, 
and development (see Appendix J).  
Construct validation was completed by a convenience sample of ten UoW 
researchers who reviewed the survey questions to ensure that the intended concept 
was assessed. Participants were also asked to comment on any procedural, 
usability and transparency issues faced in completing the survey. Expert advice 
from a data management manager was sought to ensure content validity, question 
clarity and answers fully addressed the research questions. The online survey was 
designed using the Research Electronic Data Capture (REDCap) tool 214,215 hosted 
at the UoW.  
4.2.4 Survey administration 
A cross-sectional study design was applied to get an overview of the current 
quality tools and practices implemented in Australian clinical trials. Invitations 
for participation were sent to the identified contact person for each clinical trial 
site via email. The email contained a brief introduction and a direct link to the 
survey. Each site was provided with an individual identification code and three 
email reminders were sent over a four-month period to non-respondents. Clinical 
trial sites were asked to forward the survey to their collaborating sites using the 








4.2.5 Data analysis 
Survey responses were standardised into categorical options and numerically 
coded for analysis. Statistical analyses were conducted using IBM SPSS software 
(Version 22, IBM Australia, Lane Cove, NSW, Australia). Data was explored via 
descriptive statistical analyses. Free text responses were analysed using the six 
phases of thematic analysis144 and managed using NVivo qualitative data analysis 
software (QRS International Pty Ltd. Version 10, 2012). Ethics approval was 
obtained from the University of Wollongong Human Research Ethics Committee 
(HE16/131).  
4.3 Results 
Of the 148 clinical trial sites identified, 142 initial invitations were sent, see 
Figure 4-1. A total of 34 clinical trial sites consented to participate in the online 
survey, yielding a response rate of 24%. Of the 34 responses, 14 were excluded 
from the analyses due to missing data for >25% of the survey questions. Three 
clinical networks forwarded the survey email to respondents that were more 
appropriate and to their collaborating sites. Finally, 20 clinical trial site employees 
completed the survey in full and were included in the data analysis. Survey 
respondents were all female, a majority had completed a university degree and the 
mean duration of current employment was 5.74  5.15 years (range 0.5 – 22 
years) (see Table 4-1). At each site, more than one type of clinical trial was 


















Table 4-1: Demographics of clinical trial site employees. 
 
 








                                                          
 
dOne clinical trial employee did not enter the current job title. 
Variable n(%) 
Gender  
     Male 0(0) 
     Female 20(100) 
Highest level of education  
     College/TAFE course 1(5) 
     Bachelor degree 12(60) 
     Doctoral degree 7 (35) 
Duration of current employment (years)   
     0 – 4  9(45) 
     5 – 9  7(35) 
     10 – 15  3(15) 
     + 15 1(5) 
Appointment (current job or position)  
     Continuing employment (no specified end date) 9(45) 
     Fixed-term contract (specified time or ascertainable period) (years) 11(55) 
          < 1         
          2 




Current job title (n=19)d  
     Research Fellow 
     Research Governance Officer 
     Manager 
     Clinical Trial/Study Coordinator 
     Chief Operating Officer 







Types of Clinical Trial Number of 
Trial Sites 
Treatment 16 
Phase II 14 
Phase III 14 
Quality of life 12 
Prevention 11 
Epidemiology 11 
Phase 1  10 
Phase IV 10 
Screening 9 
Diagnosis 7 
Genetic screening 6 
 
 




4.3.1 Data management and monitoring 
At the time of the survey, ten sites (50%) reported having a clinical data 
management plan in place and the majority (n=19) had implemented at least one 
or more procedures to ensure data quality (see Table 4-3). Only two sites had set 
an error acceptance level, <5% and 5-10%, respectively, both responding that no 
follow-up or further monitoring was conducted if the error rate was found to be 
higher than the error acceptance level.  
The structure of data monitoring was reported in terms of variables to be selected, 
its coverage and amount, and time of execution. Monitoring 100% of the data 
points was the most common (n=7) response, although the procedures varied 
widely, and the amount of data included in the monitoring ranged from 10-100%. 
Among the 12 sites (60%) that provided a response, the frequency of data 
monitoring varied from monthly to annually (n=6), was specific to the study 
design (n=5) or was completed when data points are identified with issues of poor 
quality (n=1). The variables included in data monitoring were completed on all 
(100%) data points (n=5), only critical data points (n=1), critical and non-critical 
data points defined by each study (n=3) or were dependent on the clinical trial 
(n=3). When asked about how their data was monitored, seven sites (35%) 
reported that they implemented at least one or more sampling techniques to 
extract data points, seven sites (35%) did not know and one site (5%) did not 




















Currently have a clinical data management plan 10(50) 7(35) 3(15) - 
Procedures to ensure high-quality data 19(95) - 1(5) - 
 Centralised monitoring 13(65)    
 Remote monitoring 11(55)    
 Logic, range and consistency checks 11(55)    
 On-site source data verification 10(50)    
 Statistical techniques 7(35)    
 Risk-based targeted monitoring 5(25)    
 Risk-based triggered monitoring 3(15)    
Currently have an error acceptance level 2(10) 11(55) 7(35) - 
Percent of data monitored 14(70) - 5(25) 1(5) 
 10% 2(10)    
 20% 2(10)    
 75% 2(10)    
 100% 7(35)    
 
Amount of data monitored depends on data 
point/outcome measured 
1(5)    
Frequency of internal data monitoring 12(60) - 3(15) 5(25) 
 Every month 2(10)    
 Every 9 months 1(5)    
 Annually 3(15)    
 
Monitoring completed when data points are 
identified with issues of poor quality 
1(5)    
 Varies between projects and study design 5(25)    
Variables included in data monitoring 12(60) - 4(20) 4(20) 
 Critical data points 1(5)    
 Critical and non-critical data points 3(15)    
 All (100%) data points 5(25)    
 Varies between projects and study design 3(15)    
Sampling techniques to select data pointse  7(35) 1(5) 5(25) 7(35) 
 Simple random sampling 4(20)    
 Systematic sampling 2(10)    
 Stratified sampling  2(10)    
 Cluster sampling 1(5)    
 Varies between projects and study design 1(5)    
 
4.3.2 Training and development  
Staff training and development devoted to data quality were conducted at all 
clinical trial sites (100%, see Table 4-4). The average amount of time spent on 
staff training and development per person, per clinical trial was 11.58  9.01 
hours, (range 2 to 30 hours) over a 12-month period.  
                                                          
 









The personnel responsible for reviewing the reports of data quality and 
consistency varied from chief investigators (65%), auditor/monitor (60%), the 
data manager (55%) and sponsor (50%). In total, 75% of respondents answered 
that more than one person reviewed the reports.  
Table 4-4: Type of staff training and development devoted to data quality. 
Type of training/development n(%) 
Education throughout clinical trial (as needed) 13(65) 
ICH-GCP training 12(60) 
Group education and training 11(55) 
SOP training 11(55) 
Education prior to research 10(50) 
Skills training and development 7(35) 
One-on-one education and training 6(30) 
Not applicable 1(5) 
Other 1(5) 
ICH-GCP: International Council for Harmonisation and Good Clinical Practice 
SOP: standard operating procedure 
 
4.4 Discussion  
This feasibility study highlights the heterogeneity of data quality management 
practices within Australian clinical trials. Only 50% of the respondent clinical 
trial sites currently had a clinical data management plan in place, confirming our 
proposition that developing and maintaining a data management system is a 
challenge for clinical trials50. This is also in accordance with a recently published 
survey45. This survey reported considerable variation in data management, with 
over 50% of clinical research centers having a data management system but many 
did not comply with guidelines and legal requirements (GCP and FDA)45. 
Reasons may include individual clinical trials implementing different procedures 
dictated by the sponsor, or monetary constraints in academic versus 
pharmaceutical clinical trials51.  
 
 




Centralised and remote monitoring were found to be the most common data 
monitoring methods utilised, although there appeared to be a lack of credible 
literature to suggest the advantage of these ‘newer’ methods over the more 
traditional approaches26. This study identified that 50% of the sites still used 
traditional data monitoring methods such as 100% on-site SDV, which is an 
expensive, labour-intensive activity60 and does not guarantee error-free results150. 
Andersen et al.70 compared the effect of partial SDV and traditional 100% SDV 
using post hoc analyses of three-phase III RCTs. Since completing traditional 
100% SDV monitoring only reduced error marginally (0.26%) compared to 
partial SDV, the authors challenged the belief that a 0% error rate is an 
unachievable goal. Only two out of the 20 trial sites in our survey reported having 
an error acceptance level, being ≤10%, which is in line with the published 
literature27-29. However, neither of the two sites responded that further follow-up 
(i.e. on-site visits) or data monitoring was conducted if an unacceptably high 
(>10%) error rate was found. One of the two clinical trial sites stated that they 
implemented a 5-10% threshold range, however, no further comment was made 
on why or when a different threshold for data validation was adhered to. As the 
survey was administered to clinical trial sites, the researchers have assumed that it 
might be possible that different clinical trial types have a tighter threshold than 
others; for example, a 5% threshold for a phase IV trials compared to 10% for 
epidemiological trials. Future research is required to explore the rationale for 
different levels of error acceptance within clinical trials.  
The major quality assurance activity reported to ‘prevent’ data errors was regular 
education and training of data collectors throughout the clinical trial. Although the 
majority of survey respondents reported that staff training and development was 
 
 




undertaken, the amount of training time varied greatly. Many researchers receive 
little to no training in regard to best practice for attaining, evaluating and 
controlling the quality of data collected. This is in line with the literature that 
reported limitations of time and resources, such that not all research trials can 
implement all of the necessary data quality management tools and procedures30.  
 
The results of this feasibility study are limited to clinical trials listed on the 
Australian NHMRC clinical trial site list. The survey results are subject to 
potential bias in a positive direction as the staff member who completed the 
survey may be more knowledgeable about their organisation’s data quality 
management procedures. As clinical trial sites were recruited as an organisation it 
was not possible to track if the staff member who completed the survey was best 
positioned to do so. In addition, the tools and procedures differed among clinical 
trials, which were influenced by overarching site policies. All of these cause 
difficulties in interpreting the results. The decision to exclude respondents with 
large amounts of missing data were reviewed by the research team and were 
identified as respondents who only completed the participant demographic 
questions. Due to this it is not possible to make a missing at random assumption 
as may occur for other studies. In addition, due to the small sample size it was 
also deemed inappropriate to impute missing values as this may give misleading 
results216. The reason for the low response rate might be clinical data audits and 
data management procedures are usually considered confidential by many 
research organisations and kept in-house31. As it was not possible to collect data 
about how many forwarding e-mails were sent by the clinical trial sites, this data 
was not accounted for in calculating the survey response rate. The low response 
 
 




rate is a major limitation and meant that the results of this survey should be used 
with caution. They may not be generalisable as a representative sample of clinical 
trial sites. It may be the reality that if non-responding sites had completed the 
survey the response to having a data management plan in place could be even 
better or worse than has been reported. The authors’ highlight that this was not a 
validated survey and formal validation of the instrument is required in future 
studies.  
4.5 Conclusion 
This study was the first survey to gather information about current data quality 
tools and procedures within Australian clinical trial sites. This survey found that 
clinical trial sites were implementing newer approaches such as centralised and 
remote monitoring despite the majority were still completing 100% SDV, a 
labour-intensive and cost-inefficient method. It is clear that data quality 
management procedures vary widely between clinical trials sites, with only 50% 
of the trial sites with a data management plan in place. Further research is 
required to assess differences between data management tools and procedures 
between clinical trials within a clinical trial site. This will allow researchers to 
investigate what is ‘standard practice’ and focus on developing and implementing 
publicly available data quality monitoring procedures to ensure data integrity.  
Data quality is essential for the reliability of scientific findings generated from the 
investment in clinical trials, adequate infrastructure, staff skills, management 
support and resources need to be in place to ensure data is effectively managed. It 
is time that quality assurance and quality control tools and procedures 
implemented in clinical trials are cited in all publications. Outcomes from the 
 
 




feasibility study highlighted that a different sampling approach would be needed 
to administer a survey at a national level to improve coverage and a higher 
response. In the subsequent chapter, an expanded version of the survey will be 
administered as a national survey to explore the detailed procedures that are 









CHAPTER 5 HETEROGENEITY IN CLINICAL RESEARCH 
DATA QUALITY MONITORING:  
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5.1 Introduction  
The evidence presented in the previous chapters, suggests that there are 
inconsistent monitoring definitions and implementation methods. Also 
highlighted previously, is the fact that the methods used to collect, process and 
handle data largely depend on the research question and available resources25. 
This has resulted in individual methods being implemented and consequently 
there is no “gold standard”. In addition, there is limited international guidance and 
training on the procedures to monitor data quality for all but drug intervention 
trials191. Together this creates misunderstandings for clinical researchers.  
The importance of data quality is well established within the clinical research 
community191,217,218 and the need for training has been identified219-221. 
Unfortunately, only a few data management training programs have been 
proposed and are specific to the nursing literature222,223. Recently, Read224 
published a case study to educate clinical researchers on best practice with data 
management, including core competencies in data quality maintenance. However, 
none of these programs explicitly emphasise the importance of monitoring to 
ensure data quality. In an effort to overcome the lack of evidence, further 
empirical research is needed.  
Thus, the current study aimed to explore the procedures that are implemented for 
ensuring data quality nationally in Australian clinical studies with the objective to 
acquire an improved understanding on how data is defined, collected, processed 
and handled, alongside any education and training related to data quality. It was 
hypothesised that clinical studies will implement ad-hoc procedures pragmatically 
to ensure data quality, and not all studies will follow the recommended 
 
 





guidelines. Moreover, the current study presents the initial quantitative findings 
(study 3a) from the explanatory sequential research design98 of this thesis.  
5.2 Methods 
5.2.1 Planning 
A mixed mode multi-contact national survey design was implemented to achieve 
higher responses (in comparison to the feasibility survey) by ensuring broad 
contact with the target population and providing them with the opportunity to 
respond. In order to reduce total survey error, all four sources of error (coverage, 
sampling, non-response and measurement error) were simultaneously controlled 
by applying a tailored holistic approach informed by the principles proposed by 
Dillman et al.125. Social exchange theory was considered to decrease cost, 
establish trust and increase the benefits for survey respondents127-129. Overall, the 
survey design was tailored to the population (clinical researchers), situation 
(Australia) and topic (data quality). The design, development and reporting of the 
survey results followed the CHERRIES statement123,124. 
5.2.2 Setting 
Clinical studies listed on the ANZCTR225 as of 1st March 2018 were invited to 
participate in a cross-sectional survey. The ANZCTR database is an online 
registry of clinical studies being undertaken in Australia, New Zealand and 
elsewhere. An advance search of the ANZCTR database was completed with the 
following inclusion criteria: intervention and observation trials; randomised and 
non-randomised trials; recruitment status either ‘recruiting’ or ‘active, not 
recruiting’; all gender; all age groups; ethics approved; both healthy and non-
healthy volunteers; and recruitment country being Australia. Persons listed on the 
 
 





ANZCTR registry as the contact for scientific queries were asked to complete the 
survey. Sampling error was reduced by inviting all clinical studies that met the 
inclusion criteria. However, as it is not a legal requirement for clinical studies in 
Australia to be listed on the registry, it was inevitable to miss those not on the 
registry. 
Clinical studies with affiliation to the UoW, the organisation where the thesis 
candidate was enrolled, were excluded from the study. Also excluded were 
clinical studies with international contact details. Those who did not wish to 
participate were provided with an option to withdraw and provide an optional 
reason. Informed tacit consent was given by completion of the online survey. 
Ethics approval was obtained from the UoW Human Research Ethics Committee 
(HE16/131). 
5.2.3 Question development and design 
A 46 item self-administered semi-quantitative closed survey design was 
developed and informed by our feasibility survey191. The questions from the 
feasibility survey included broad topic areas and therefore it was necessary to edit 
the questions to include each of the broad topic areas followed up by a narrower 
subset of questions. The national survey included the following seven sections: 
respondent demographics, clinical study demographics, data definition, data 
collection, data processing, data representation and education and training. 
Adaptive questioning was applied to 14 items branching the total number of 
questions depending on individual survey responses. Answers to all items were 
voluntary. Respondents were provided with the option to skip or leave question 
items blank, or choose non-responses, such as “not applicable” or “don’t know”. 
See Appendix K for national survey items.  
 
 





REDCap, a secure, web-based application designed to support data capture for 
research studies214, was used to design the survey, collect and manage data. 
Construct validation, including wording, structure, order and grouping of 
questions were evaluated by a convenience sample of three UoW health and 
information science researchers (PY, AM and YP). Once consensus on the design 
of questions was reached further feedback was sought through think-aloud 
cognitive interviews226 with five UoW clinical researchers and based on two 
theories. Firstly, how individuals respond to survey questions was based on the 
psychological perspective promoted by the Cognitive Aspects of Survey 
Methodology (CASM) viewpoint by Tourangeau’s four-stage cognitive model227. 
Secondly, the cognitive interview as a means to test survey questions 
(methodology) was based on Ericsson and Simon’s think-aloud interview 
theoretical basis228,229. The cognitive interviews used a descriptive approach230 
and aimed to reduce measurement error by gaining a better understanding of how 
respondents understand and interpret the survey items, visual design, presentation 
and navigation problems. Participation in the face-to-face audio recorded 
interview was voluntary and each participant provided written informed consent 
to commencing the interview.  
5.2.4 Survey administration  
In order to reduce coverage error respondents were contacted via postal delivery 
and e-mail to encourage responses231. The initial postal letter was sent on 26th 
March 2018 and followed by three e-mail reminders over an 11-week period. The 
letter contained a link to the REDCap online survey login and included an 
individual access code. The email reminders included a personal Uniform 
Resource Locator (URL) that allowed the respondent to log into the survey. To 
 
 





increase the likelihood of responses and simultaneously reduce nonresponse error 
multiple contact attempts were made which varied in contact timing. Each clinical 
study was provided with a de-identified participant code to ensure anonymity and 
allowing repeated login to review and edit items prior to final submission and 
survey closing. If surveys were incomplete the most recent data entry was saved 
for data analysis. 
5.2.5 Data analysis 
Incomplete surveys were included in the analysis to respect all respondents’ 
contributions and reduce the bias of topic salience. Data was analysed using IBM 
SPSS software (IBM Corp. Released 2017. IBM SPSS Statistics for Windows, 
Version 25.0. Armonk, NY: IBM Corp.). Descriptive statistics summarised the 
characteristics of the respondents, clinical study demographics and the aggregated 
responses to survey items. For ‘select all that apply’ survey items, the multiple 
response set was used in SPSS using a dichotomies scale. Free text responses 
were analysed using deductive content analysis232. 
Univariate analysis was performed to determine the potential association between 
data quality monitoring variables and clinical study type using chi-square 
analysis. Any independent variables (predictors) which achieved significance at 
p<0.2233 were considered for inclusion in the multivariate analysis. The dependent 
variable was an intervention (clinical) trial or not (i.e. an observational study). All 
covariates included in the model are listed in Table 5-8. The cross-sectional 
associations between clinical study demographics, data collection setting and data 
quality monitoring procedures and those classified as an intervention (clinical) 
trial were analysed using three methods - forced entry, forward and backward 
likelihood ratio (LR) stepwise - logistic regression (p<0.05). This decision was 
 
 





made in accordance with the recommendations for data analysis and research 
without precedence, i.e., to base a hypothesis for testing234,235. Forced entry 
method is the preferred method236, forward and backward stepwise logistic 
regression are reported in Appendix R and Appendix S, respectively.  In all three 
methods, the dependent variable and the independent variables met the p<0.2 
criteria (see footnote Table 5-8; Appendix R, Table 1; and Appendix S, Table 1) 
that were considered were identical. The probability for the forwards stepwise 
method was set at 0.5 and the backwards stepwise method set at 0.1 234,235. Survey 
responses ‘not applicable’ and ‘don’t know’ were coded as missing and removed 
from the regression analysis. The survey question, ‘Does the clinical study involve 
staff in developing case report forms (CRF)s?’ was exempt from this; instead, 
‘not applicable’ answers were included considering the possibility of a student, 
volunteer and/or single project lead/person developed the CRFs. 
5.3 Results 
Initial postal invitations were sent to 3835 of the 3999 clinical studies identified in 
the ANZCTR registry (Figure 5-1). 146 respondents could not be contacted as the 
postal letter was returned to the sender (RTS) and all three follow-up e-mails 
bounced back with an error message. Therefore, only 3689 respondents received 
the invitation to complete the survey. A total of 589 viewed the initial survey page 
(16% view rate) and 570 agreed to participate (96.8% participation rate). Only 
547 responses were included in this analysis (14.8% response rate) as 23 empty 
responses were excluded. Finally, 441 responses were complete (77.4% 
completion rate) and 106 were partially complete. Survey respondents were more 
likely to be female, have a doctoral degree, employed for a duration of 0-4 years 
and on a continuing appointment (Table 5-1). The deidentified data set (n=547) 
 
 





and the instructions for access have been made public at 
https://github.com/lah993/DQ_national_survey in accordance with the Creative 











Figure 5-1: National survey invitation flow diagram.  
 
 





Table 5-1: Survey respondents’ demographic characteristics (n=547). 
Characteristics n (%) 
Gender Female 332 (60.7) 
Male 206 (37.7) 
Prefer not to disclose 6 (1.1) 
Prefer to self-describe 1 (0.2) 




Doctoral degree 347 (63.4) 
Masters/Postgraduate degree 115 (21.0) 
Bachelor degree (including Honours) 84 (15.4) 
Did not complete high school 1 (0.2) 






0-4 157 (28.7) 
5-9.9 140 (25.6) 
10-14.9 102 (18.6) 
15-24.9 93 (17.0) 
25+ 35 (6.4) 
Missing  20 (3.7) 
Appointment 
(current job 
or position)  
Student 23 (4.2) 
Casual 13 (2.4) 
Continuing 292 (53.4) 
Visiting / Honorary Fellow 15 (2.7) 
Fixed-term contract, nearest half yeara (years) 198 (36.2) 
 <1  25 (12.6) 
 1-1.9 66 (33.3) 
 2-2.9 17 (8.6) 
 3-3.9 22 (11.1) 
 4-4.9 24 (12.1) 
 ≥5  44 (22.2) 
  Missing  0 (0) 
 Missing 6 (1.1) 
a specified time or ascertainable period 
 
 
Characteristics of the clinical studies described by the survey respondents are 
provided in Table 5-2. The majority of survey respondents were associated with 
clinical studies that were administered from academic (university) organisations, 
were an interventional clinical trial, phase IV and single-site. In addition, clinical 
studies mostly collected data from a hospital setting, targeted 100-499 participants 
for baseline enrolment and did not employ a data monitor or data manager (Table 
5-2).   
 
 












administers the studya,b  
Academic (university) 317 (47.4) 59.7 
Hospital 190 (28.4) 35.8 
Independent research institute 66 (9.9) 12.4 
Cooperative group/consortium 29 (4.3) 5.5 
Non-government organisation 18 (2.7) 3.4 
Government 17 (2.5) 3.2 
Industry  8 (1.2) 1.5 
Not applicable 2 (0.3) 0.4 
Other 6 (0.9) 1.1 
Missing 16 (2.4) 2.9 
Health professionals’ 
part of the clinical study 
team 
0 4 (0.7)  
1 170 (31.1)  
2 162 (29.6)  
3 110 (20.1)  
>4 78 (14.3)  
Missing  23 (4.2)  
Study type Intervention (clinical trial) 451 (82.4)  
Observation  80 (14.6)  
Missing  16 (2.9)  
 Intervention typec Treatment 314 (69.6)  
Prevention 83 (18.4)  
Quality of life 20 (3.7)  
Screening 12 (2.7)  
Epidemiological 8 (1.8)  
Diagnostic  8 (1.8)  
Genetic 1 (0.2)  
Missing  5 (1.1)  
Phase type Phase 0 (Exploratory) 51 (9.3)  
Phase I 67 (12.2)  
Phase II 92 (16.8)  
Phase III 94 (17.2)  
Phase IV  69 (12.6)  
Don’t know  10 (1.8)  
Not applicable  144 (26.3)  
Missing  20 (3.7)  
Number of clinical study 
trial sites  
1 296 (54.1)  
2-4 116 (21.2)  
5-9 46 (8.4)  
10-19 32 (5.9)  
>20 39 (7.1)  
Missing  18 (3.3)  
 Multi-site studies 
being part of an 
international studyd 
Yes  53 (22.7)  
No  179 (76.8)  
Missing 1 (0.4)  
Data collection settinga,e Hospital 321 (48.8) 60.9 
University  83 (12.6) 15.7 
Private practice 49 (7.4) 9.3 
Health centre 48 (7.3) 9.1 
Independent research institute  46 (7.0) 8.7 
In-home care 23 (3.5) 4.4 
 
 





Other  68 (10.3 12.9 
Missing  20 (3.0) 3.7 
Participants targeted for 
baseline enrolment 
<20 49 (9.0)  
20-99 192 (35.1)  
100-499 203 (37.1)  
>500 82 (15.0)  
Missing  21 (3.8)  
Employ a data monitor 
or data manager 
Yes 250 (45.7)  
No 255 (46.6)  
Not applicable 17 (3.1)  
Don’t know 6 (1.1)  
Missing  19 (3.5)  
a Multiple response question (select all that apply) 
b Total n (%) =669 (100.0) 
c Intervention type, n=451. 
d Part of an international study, n=233. 
e Total n (%) =658 (100.0) 
 
Table 5-3 shows survey responses regarding data definition, collection, storage 
and representation, and education and training on data quality. The majority of 
respondents (366, 66.9%) reported that the clinical study followed national and/or 
international regulations, guidelines and/or standards (Table 5-3). Of those who 
responded ‘yes’ and ‘don’t know’f, n=422 (77.1%) to following regulations, 
guidelines and/or standards the National Statement on Ethical Conduct and 
Research (86.0%) was most commonly used. This was followed by the GCP 
guideline (54.5%) and the Australian Clinical Trials Handbook (33.6%) 
(Appendix L). The most common (46.4%) response to the question about the 
recording medium for source data was a single data capture instrument. The major 
recording instrument was paper (77.0%) and least was mobile or tablet application 
(10.4%) (Appendix M). Just under half (46.4%) of the respondents reported not 
using any clinical data management software to store their data. Of those who did 
(35.3%), the majority (93.3%) utilised a single application (93.3%) (Table 5-3); 
                                                          
 
f Survey respondents who selected ‘don’t know’ were also presented with the same list of regulations, 
guidelines and/or standards as those selected ‘Yes’.  
 
 





REDCap data management software was most common (17.6%) (Supplementary 
data 2). At the time of the survey, only 48 (8.8%) respondents reported a set error 
acceptance level; of which 28 (58.3%) reported the level ranging from 0-10% 
(mean 4.6 ± 2.8 SD). Further, only 72 (13.2%) clinical studies reported generating 
data quality and consistency reports. The personnel responsible for reviewing 
these reports varied, ranging from the chief investigator (63.9%), senior staff 
management (50.0%) and data entry staff (43.1%) (Appendix N). In total, two-
thirds (66.7%) of respondents answered that more than one person reviewed these 
reports. Less than half of the respondents answered that training and/or 
development devoted to data quality was provided to the primary person(s) 
responsible for data entry (240, 43.9%) and data monitoring (205, 37.5%) (Table 
5-3). The most common training component for both data entry staff (79.1%) and 
data monitors (80.8%) was in protocol procedures (Appendix O). Similarly, 
respondents answered that training in more than one area was received by data 
entry (205, 85.4%) and data monitoring (176, 85.9%) staff. 
 
 





















Data dictionary   
Does the clinical study…  
 have a data dictionary? 262 (47.9) 190 (34.7) 44 (8.0) 23 (4.2) 28 (5.1) 
 involve staff in developing CRFs? 289 (52.8) 135 (24.7) 76 (13.9) 18 (3.3) 29 (5.3) 
 have a definition for protocol deviation 
and/or violation? 
349 (63.8) 117 (21.4) 42 (7.7) 9 (1.6) 30 (5.5) 
 have a data quality monitoring plan or 
SOP for quality assurance and quality 
control? 
343 (62.7) 136 (24.9) 22 (4.0) 13 (2.4) 33 (6.0) 
 outsource data monitoring to another 
company?  
27 (4.9) 454 (83.0) 27 (4.9) 5 (0.9) 34 (6.2) 
 follow national and international 
regulations, guidelines and/or standards 
for data monitoring?  
366 (66.9) 59 (10.8) 34 (6.2) 56 (10.2) 32 (5.9) 
Data collection and storage 
Does the clinical study… 
 have a standard operating procedure 
specifically for data collection? 
399 (72.9) 85 (15.5) 10 (18.) 10 (1.8) 43 (7.9) 
 implement procedures to overcome 
missing values in the process of data 
collection? 
242 (44.2) 153 (28.0) 60 (11.0) 49 (9.0) 43 (7.9) 
Number of data capture instruments used to record source data? 
 1  254 (46.4)     
 2 149 (27.2)     
 3 68 (12.4)     
 4+ 37 (6.8)     
 Missing  39 (7.1)     
Does the clinical study use a clinical data 
management tool to store data? 
193 (35.3) 254 (46.4) 26 (4.8) 22 (4.0) 52 (9.5) 
 Number of tools used to store data?a 
  1 180 (93.3)     
  2 13 (2.4)     
  Missing  0 (0)     
Data representation  
Does the clinical study… 
 have an error acceptance level?  48 (8.8) 222 (40.6) 92 (16.8) 94 (17.2) 91 (16.6) 
  If yes, and the error rate is found to be 
higher than the approved acceptance 
level, does your organisation 
implement further follow-up 
monitoring?b 
25 (52.1) 7 (14.6) 11 (22.9) 2 (4.2) 3 (6.3) 
 have a standard equation and/or method 
used to calculate error? 
50 (9.1) 219 (40.0) 88 (16.1) 89 (16.3) 101 (18.5) 
 have data quality and consistency reports 
generated?  
72 (13.2) 229 (41.9) 78 (14.3) 67 (12.2) 101 (18.5) 
 have a feedback mechanism in place to 
ensure continuous quality improvement?  
99 (18.1) 209 (38.2) 73 (13.3) 61 (11.2) 105 (19.2) 
Education and training 
Is it required that the primary person(s) responsible for data entry have… 
 achieved a minimum level of education 269 (49.2) 113 (20.7) 49 (9.0) 18 (3.3) 98 (17.9) 
 a minimum level of experience 207 (37.8) 164 (30.0) 54 (9.9) 21 (3.8) 101 (18.5) 
 training/development devoted to data 
quality 
240 (43.9) 135 (24.7) 57 (10.4) 15 (2.7) 100 (18.3) 
Is it required that the primary person(s) responsible for monitoring the data have… 
 achieved a minimum level of education 268 (49.0) 68 (12.4) 66 (12.1) 34 (6.2) 111 (20.3) 
 
 





 a minimum level of experience 209 (38.2) 114 (20.8) 74 (13.5) 37 (6.8) 113 (20.7) 
 training/development devoted to data 
quality 
205 (37.5) 122 (22.3) 72 (13.2) 33 (6.0) 115 (21.0) 
Are the skills and performance of the 
person(s) in charge of data monitoring 
assessed via periodic on-site evaluations by 
a third party (e.g. manager) during 
monitoring visits? 
72 (13.2) 243 (44.4) 76 (13.9) 40 (7.3) 116 (21.2) 
a Number of applications used to store data, n=193 
b The total number of answers for this question is n=48.  
Abbreviations: CRF, case report form; SOP, standard operating procedure. 
 
 
5.3.1 Monitoring methods  
Table 5-4, shows survey responses regarding data processing. At the time of the 
survey, 418 (76.4%) respondents answered that more than one monitoring method 
was applied to the clinical study. With statistical techniques (64.5%), logic, range 
and consistency checks (63.6%) and SDV (55.0%) most commonly applied to 
audit and monitor data. 















Data processing  
Does the research team of the clinical study complete any of the following data monitoring procedures?  
 Statistical techniques  353 (64.5) 69 (12.6) 29 (5.3) 20 (3.7) 76 (13.9) 
 Logic, range and consistency 
checks 
348 (63.6) 77 (14.1) 37 (6.8) 18 (3.3) 67 (12.2) 
 Source data verification 301 (55.0) 105 (19.2) 48 (8.8) 23 (4.2) 70 (12.8) 
 On-site monitoring 259 (47.3) 148 (27.1) 46 (8.4) 20 (3.7) 74 (13.5) 
 Double data entry 190 (34.7) 224 (41.0) 43 (7.9) 17 (3.1) 73 (13.3) 
 Centralised monitoring 150 (27.4) 200 (36.6) 87 (15.9) 24 (4.4) 86 (15.7) 
 Remote monitoring 86 (15.7) 258 (47.2) 98 (17.9) 17 (3.1) 88 (16.1) 
 Risked-based targeted 
monitoring 
58 (10.6) 247 (45.2) 102 (18.6) 50 (9.1) 90 (16.5) 
 Risked-based triggered 
monitoring 
56 (10.2) 244 (44.6) 106 (19.4) 50 (9.1) 91 (16.6) 










Table 5-5 summarises the survey responses regarding the use of monitoring 
procedures. Over three-quarters (78%) of the clinical studies applied SDV to 
verify source data in an electronic database. We found that clinical studies that 
apply SDV were more likely to verify a subset (46%) instead of all (42%) data 
points. Conversely, clinical studies that applied on-site monitoring were more 
likely to verify all data points (54%) than a subset or proportion of data points 
(34%). Three-quarters (75.6%) of the respondents who applied a remote 
monitoring method performed data review and site performance evaluations using 
centrally available data. The majority of clinical studies who utilised a centralised 
(57%), risk targeted (59%) or risk triggered (64%) monitoring method applied 

























Does the clinical study use a source data verification procedure to (n=301)  
 verify source data to 
electronic database 
236 (78.4) 33 (11.0) 14 (4.9) 5 (1.7) 13 (4.3) 
 verify source data to 
electronic case report form 
(eCRF)  
104 (34.6) 88 (29.2) 67 (22.3) 6 (2.0) 36 (12) 
 verify all (100%) data 
points  
127 (42.2) 138 (45.8) 11 (3.7) 11 (3.7) 14 (4.7) 
Does the clinical study use an on-site monitoring procedure to (n=259) 
 verify all (100%) data 
pointsa 
141(54.4) 89 (34.4) 11 (4.2) 10 (3.9) 8 (3.1) 
Does the clinical study use a centralised monitoring procedure to (n=150) 
 guide on-site visits? 86 (57.3) 41 (27.3) 16 (10.7) 2 (1.3) 5 (3.3) 
 completely replace on-site 
visits?  
16 (10.7) 101 (67.3) 14 (9.3) 1 (0.7) 18 (12.0) 
 other  5 (3.3) 41 (27.3) 32 (21.3) 5 (3.3) 67 (44.7) 
Does the clinical study use a remote monitoring procedure to (n=86) 
 perform periodic site audits 
via tele/video conference? 
38 (44.2) 41 (47.7) 2 (2.3) 0 (0) 5 (5.8) 
 perform data review and 
site performance 
evaluations using central 
available data?  
65 (75.6) 11 (12.8) 1 (1.2) 2 (2.3) 7 (8.1) 
 other  10 (11.6) 22 (25.6) 14 (16.3) 4 (4.7) 36 (41.9) 
Does the clinical study use a risk-based targeted monitoring procedure to (n=58)  
 guide centralised 
monitoring visits? 
29 (50.0) 16 (27.6) 5 (8.6) 3 (5.2) 5 (8.6) 
 guide on-site visits? 34 (58.6) 15 (25.9) 4 (6.9) 5 (8.6) 2 (3.4) 
 completely replace on-site 
visits? 
7 (12.1) 38 65.5) 4 (6.9) 3 (5.2) 6 (10.3) 
 other 4 (6.9) 8 (13.8) 16 (27.6) 6 (10.3) 24 (41.4) 
Does the clinical study use a risk-based triggered monitoring procedure to (n=56) 
 guide centralised 
monitoring visits?  
28 (50.0) 13 (23.2) 8 (14.3) 4 (7.1) 3 (5.4) 
 guide on-site visits? 36 (64.3) 10 (17.9) 5 (8.9) 3 (5.4) 2 (3.6) 
 completely replace on-site 
visits? 
5 (8.9) 36 (64.3) 9 (16.1) 2 (3.6) 4 (7.1) 
 other 0 (0) 12 (21.4) 13 (23.2) 5 (8.9) 26 (46.4) 










5.3.1.1 Periodic audit sampling and minimum frequency of monitoring procedures  
Half of the respondents who conducted centralised monitoring reported that a 
periodic sampling method was applied, while only one third did periodic sampling 
for on-site monitoring (33.3) and partial SDV (31.3%) (Table 5-6). Sampling 
‘data’ were most commonly reported for all three monitoring methods (Figure 
5-2) and a sample of 1-25% of data, centres, sites or participants (Figure 5-3). 
Although, respondents who completed partial SDV reported verifying all (100%) 
data associated with consent forms (68%), eligibility criteria (64%), critical data 
(56%) and serious adverse event (SAE) reports (71%) (Figure 5-4). While, 
verifying non-critical data points and non-SAE reports responses varied greatly, 
with no clear proportion favoured.  
The minimum frequency of data monitoring varied between on-site monitoring, 
100% SDV and partial SDV (Figure 5-5). Respondents reporting on-site 
monitoring favoured visits once per month (30%), while 100% SDV respondents 
answered once per week (22%), once per month (22%) and two to three times 
annually (22%) were the preferred monitoring frequencies. In comparison, 
conducting partial SDV the minimum frequency of monitoring visits most 
commonly reported was annually (48%). We were also interested in factors that 
determine the frequency of on-site monitoring, in which study design (37%), 
budget (33%) and monitoring plan specified in protocol (31%) were the top three 
factors reported by respondents as seen in Appendix Q.  
 
 





Table 5-6: Sampling and minimum frequency of monitoring visits included in 















Does the clinical study conduct periodic audits of a subset of data, sites, centres or participants? 
 Centralise monitoringa 75 (50.0) 45 (30.0) 6 (3.1) 4 (2.7) 20 (13.3) 
 On-site monitoring (excluding 
100%)b 
33 (33.3) 56 (56.6) 6 (6.1) 2 (2.0) 2 (2.0) 
 Partial SDVc 50 (31.3) 73 (45.6) 8 (11.3) 8 (5.0) 11 (6.9) 
Is there a minimum frequency of monitoring visits for the clinical study?  
 On-site monitoringd 71 (27.4) 126 (48.6) 47 (18.1) 4 (1.5) 11 (4.2) 
 100% SDVe 18 (14.2) 72 (56.7) 24 (18.9) 13 (10.2) 0 (0) 
 Partial SDVc 23 (14.4) 03 (58.1) 24 (15.0) 10 (6.3) 10 (6.3) 
Abbreviations: SDV, source data verification.  
a Centralised monitoring, n=150 
b On-site monitoring (exclude 100%) all critical non-critical, don’t know and other, n= 99 
c Partial SDV, n=160 
d On-site monitoring, n=259 






Figure 5-2: Clinical studies that ‘yes’ perform monitoring for a subset of data, 
sites, centres or participants (centralised monitoring, n=75; on-site monitoring 
(excluding 100%), n=33; partial SDV, n=50).  
*No missing data. 
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Figure 5-3: Clinical studies that ‘yes’ perform monitoring on a proportion of the 
subset of data, sites, centres or participants (centralised monitoring, n=62 
(excluding 100%); on-site monitoring (excluding 100%), n=33; partial SDV, 
n=50).  
* For example, 10% data monitored from outcome A and 50% data monitored from outcome B.  
Abbreviations: SDV, source data verification. 
 
 
Figure 5-4: Proportion of data verified from subset of source data verification 
monitoring (partial SDV) (n=160).  
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Figure 5-5: Clinical studies that ‘yes’ have a set minimum frequency of 
monitoring visits (on-site monitoring n=71, 100% SDV n=18, partial SDV, n=23).  
*No missing data. 





5.3.1.2 Factors likely to trigger non-scheduled monitoring visit 
Table 5-7 summarises the factors, kinds of data and type of data analysis likely to 
trigger a non-scheduled site monitoring visit for risk-based triggered and 
centralised monitoring. From the 11 listed factors, incidence of adverse events 
(63% and 44%) and the number of protocol deviations (48% and 44%) were the 
two leading factors likely to trigger a site monitoring visit for risk-based triggered 
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Table 5-7: Risk-based triggered monitoring (n=56) and centralised monitoring 
(n=150) factors, kind and type of data likely to trigger a non-schedule site 
monitoring visit.  











Which of the following factors are likely to trigger a non-scheduled site monitoring visit?a,b,c 
 Incidence of adverse events 34 (16.5) 63.0 63 (13.3) 44.1 
 Number of protocol deviations 26 (12.6) 48.1 63 (13.3) 44.1 
 Missing case report forms (CRFs) 24 (11.7) 44.4 43 (9.1) 30.1 
 Subject dropout/withdrawal 20 (9.7) 37.0 46 (9.7) 32.2 
 Number of data queries 19 (9.2) 35.2 45 (9.5) 31.5 
 Rate of enrolment  17 (8.3) 31.5 36 (7.6) 25.2 
 Suspected fraud 16 (7.8) 29.6 41 (8.6) 28.7 
 Screen failure rate 12 (5.8) 22.2 28 (5.9) 19.6 
 Lack of experience with the site 11 (5.3) 20.4 32 (6.7) 22.4 
 Geographical location of site 9 (4.4) 16.7 11 (2.3) 7.7 
 Laboratory data signals 8 (3.9) 14.8 12 (2.5) 8.4 
 None 1 (0.5) 1.8 12 (2.5) 8.4 
 Not applicable 7 (3.4) 13.0 33 (6.9) 23.1 
 Other 0 (0.0)  0 3 (0.6) 2.1 
 Missing  2 (1.0) 3.6 7 (1.5) 4.7 
What kinds of data are used to trigger a non-scheduled site monitoring visit?a,d,e 
 Case report form (CRF) data 37 (44.6) 69.8 64 (31.8) 44.8 
 Laboratory data 15 (18.1) 28.3 25 (12.4) 17.5 
 Data related to performance, e.g. time of day, 
duration, sequencing of study activities 
13 (15.7) 24.5 38 (18.9) 26.6  
 External data sets, e.g. national death 
registry, prescribing data, episode or claims 
data 
2 (2.4) 3.8 6 (3.0) 4.2 
 Not applicable 11 (13.3) 20.8 52 (25.9) 36.4 
 Don’t know 1 (1.2) 1.9 7 (3.5) 4.9 
 Other 1 (1.2) 1.9 2 (1.0) 1.4 
 Missing  3 (3.6) 5.4 7 (3.5) 4.7 
Which type of data analyses are likely to trigger a non-scheduled site monitoring visit?a,f,g 
 Missing data 30 (32.6) 57.7 65 (30.4) 46.1 
 Plausibility checks 22 (23.9) 42.3 43 (20.1) 30.5 
 Simple descriptive statistics 11 (12.0) 21.2 19 (8.9) 13.5 
 More complex statistics 2 (2.2) 3.8 6 (2.8) 4.3 
 Multivariate risk assessment 2 (2.2) 3.8 3 (1.4) 2.1 
 None 1 (1.1) 1.9 0 (0) 0 
 Not applicable  13 (14.1) 25.0 53 (24.8) 37.6 
 Don’t know 7 (7.6) 13.5 13 (6.1) 9.2 
 Other 0 (0) 0 3 (1.4) 2.1 
 Missing  4 (4.3) 7.1 9 (4.2) 6.0 
a Multiple response question (select all that apply) 
b Risk-based triggered monitoring total n (%)=206 (100.0)  
c Centralised monitoring total n (%)=475 (100.0) 
d Risk-based triggered monitoring total n (%)=83 (100.0) 
e Centralised monitoring total n (%)=201 (100.0) 
f Risk-based triggered monitoring total n (%)=92 (100.0) 










5.3.2 Regression model 
After deletion of 368 cases with missing values, data from 179 clinical studies 
were available for regression analysis. A total of 155 clinical studies (86.6%) 
were classified as an intervention trial. A test of the full regression model using 
the forced entry with all 13 predictors against a constant-only model was not 
significant, χ2 (13, 179) = 15.827, p=0.259 (Table 5-8). Multivariate analysis 
demonstrated that having a definition for a protocol deviation and/or violation 
(odds 3.065, p=0.096) was borderline significant and positively associated with 
intervention (clinical) trials. None of the other covariates had a significant 
association with clinical study classification. The forced entry model correctly 
classified the outcome for 87.2% of the cases. Both the forwards χ2 (1, 179) = 
3.797, p=0.051 (Appendix R) and backwards stepwise χ2 (5, 179) = 9.997, 
p=0.075 (Appendix S) models bordered on significance. However, both models 
demonstrated that having a definition for a protocol deviation and/or violation 
(forward stepwise odds 2.433, p<0.05) (backward stepwise odds 2.640, p<0.05) 
had significant, positive association with intervention trial. The forwards and 
backwards stepwise models both correctly classified the outcome for 86.6% of the 
cases. A higher Nagelkerke R square indicates that the forced entry model (0.155) 
was a better model fit, in comparison to the forwards stepwise (0.038) and the 
backwards stepwise (0.100) models.  
 
 





Table 5-8: Forced entry method, coefficients of the model predicting whether a clinical study was observational or interventional 
(dependent variable) based on n=179 (32.7%). 
Category Variable  Univariable analysis Multivariate analysis 
      95% CI  
  




Lower  Upper  P 
Clinical study 
demographics 
Phase of study (4, 373) = 52.930 0.000 a       
Trial sitesb  (2, 529) = 1.760 0.415       
Participants targeted for baseline enrolmentc (3, 526) = 5.028 0.170       
 Participants at baseline P1#    -0.405 0.216 0.667 0.121 3.687 0.642 
 Participants at baseline P2#    0.508 0.322 1.663 0.287 9.633 0.571 
 Participants at baseline P3#   0.120 0.000 1.012 0.125 8.193 0.991 
Data monitor  (1, 505) = 0.027 0.870       
Data collection 
setting  
Health centre (1, 527) = 0.222 0.638       
hospital (1, 527) = 9.859 0.002 0.185 0.099 1.204 0.379 3.821 0.753 
Independent institute (1, 527) = 0.618 0.432       
In home care (1, 527) = 0.711 0.399a       
Private practice (1, 527) = 0.905 0.341       
University  (1, 527) = 9.776 0.002 1.719 2.352 5.581 0.620 50.248 0.125 
Other (1, 527) = 8.708 0.003 1.426 1.515 4.161 0.430 40.276 0.218 
Study set up  
Data dictionary  (1, 452) = 0.002 0.968       
Develop CRFs (2, 500) = 0.906 0.636       
Definition protocol deviation and/or violation  (1, 466) = 3.950 0.047 1.120 2.773 3.065 0.820 11.458 0.096 
Data quality monitoring plan/SOP QA and QC  (1, 479) = 2.437 0.119 0.452 0.438 1.571 0.412 5.987 0.508 
Outsource data monitoring (1, 481) = 5.118 0.024a       
Follow guidelines/regulations  (1, 467) = 3.031 0.082 -0.293 0.198 0.746 0.206 2.706 0.656 
SOP for data collection  (1, 484) = 0.625 0.429       
Overcome missing values  (1, 395) = 0.960 0.327       
Data collection and 
storage 
Data capture instruments to record source datad  (3, 508) = 3.751 0.290       
Data management storage tool used (1, 447) = 0.423 0.515       
Data monitoring 
method(s) 
Logic, range and consistency checks  (1, 425) = 0.029 0.865       
Double data entry  (1, 414) = 0.040 0.841       
Statistical techniques  (1, 422) = 0.394 0.530       
Risk-based targeted monitoring  (1, 305) = 0.144 0.705       
Risk-based triggered monitoring  (1, 300) = 3.114  0.078 0.209 0.066 1.233 0.251 6.063 0.797 
Remote monitoring  (1, 344) = 2.372 0.123 -0.239 0.121 0.788 0.205 3.027 0.728 
 
 





Centralised monitoring  (1, 350) = 1.535 0.215       
On-site monitoring  (1, 407) = 1.358 0.244       
Source data verification   (1, 406) = 2.294 0.130 -0.426 0.542 0.653 0.210 2.030 0.462 
Data representation  
Error acceptance level  (1, 270) = 0.876 0.349       
Standard equation/method to calculate error  (1, 269) = 0.023 0.880       
Generate data quality and consistency reports  (1, 301) = 0.718 0.397       
A feedback mechanism CQI  (1, 308) = 2.365 0.124 -0.567 0.901 0.567 0.176 1.829 0.342 
R2 = .911 (Hosmer & Lemeshow) .085 (Cox & Snell) .155 (Nagelkerke). Model χ2 (13, 179) = 15.827, p=0.259. Correctly classified 87.2% of the cases.  
Abbreviations: CI, confidence interval; CQI, continuous quality improvement; SOP, standard operating procedure; QA, quality assurance; QC, quality control. 
* χ2 (df, n)  
a 1 cell has an expected count less than 5, therefore excluded. 
b Category of trial sites: 1 site, n=296; 2-4 sites, n=116; >5 sites, n=117. 
c Category by number of participants enrolled in baseline study: <20 participants, n=49; 20-99 participants, n=192; 100-499 participants, n=203; >500 participants, 
n=82. 
d Number of data capture instruments to record source data category: 1 instrument, n=254; 2 instruments, n=149; 3 instruments, n=68 4+ instruments, n=37.  
Participants at baseline uses <20 participants as the referent category. #Participants at baseline P1 (20-99), P2 (100-499), P3 (>500). All other variables are compared 
with ‘no’ as the referent category.  
Independent variables included in multivariate analysis: clinical study demographics (Participants targeted for baseline enrolment); data collection setting (hospital, 
university and other); study set-up (definition for a protocol deviation and/or violation, data quality monitoring plan/SOP QA and QC and follow 
guidelines/regulations); Data monitoring methods (risk-based triggered monitoring, remote monitoring and source data verification); and data representation (a 










In this Australian national survey, we found that clinical studies are implementing 
various procedures to ensure data quality; however, not all clinical studies 
followed International or National guidelines to ensure data integrity. A 
borderline association was found between the data quality monitoring variable, a 
definition for protocol deviation/violation and intervention trials, which may 
suggest that clinical studies were more likely to implement the required 
procedures when they were provided with additional guidance and resources. 
Additionally, we saw that technology has modified study processes in data 
collection and storage, and assisted with implementing ‘new’ monitoring 
methods. Smaller, single-site clinical studies are yet to adopt technology and are 
applying traditional approaches, including SDV and on-site monitoring to 
monitoring data quality. This is despite international guidelines and current 
evidence promoting ‘new’ methods such as RBM. This reflects a lack of guidance 
for clinical researchers conducting small single-site studies to apply ‘new’ 
methods. We also found variations in the proportion, sampling and frequency 
among monitoring methods and survey respondents. In addition, the incidence of 
adverse events and the number of protocol deviations were the most likely factors 
to trigger a non-scheduled site monitoring visit for both risk-based triggered and 
centralised monitoring. These observations suggest that further education and 
training are required to implement standardised practices to guide data quality in 
smaller-scale clinical studies. Additionally, evidence suggests that guidance 
which is accessible to all clinical researchers is warranted to assist them to 
undertake ‘newer’ data quality monitoring methods.  
Approximately 50% of the survey respondents were not following GCP 
 
 





guidelines for monitoring data quality. This may suggest that GCP may not be 
explicit enough to ensure data integrity is followed in all clinical research settings. 
As the GCP guidelines were written predominantly for drug intervention 
trials13,238, there might be limitation for their applicability to all clinical studies. 
Another reason might be that the majority of survey respondents were from 
smaller, single-site research studies with limited resources. This suggests that 
GCP needs to provide more accessible information that are tailored for the needs 
of all clinical research studies including non-drug intervention trials, cohort and 
observational studies.  
Further, this study identified that GCP training was only provided to 45% of data 
entry staff and 51% of the primary person(s) responsible for monitoring data 
quality. This number is far below the recommendation of a recent working group 
who concluded GCP training should be provided to all study personnel engaged in 
the design, conduct, performance, monitoring, auditing, recording, analysis or 
reporting of a clinical trialg 239. Despite this recommendation, there was a strong 
consensus that GCP training lacks relevance to behavioural intervention studies, 
which may also explain the observed low GCP training rate for those single site, 
non-drug intervention trials in this study. Another explanation may be that in 
Australia it is recommended if there is inconsistency between GCP and the 
National Statement, the National statement takes precedence86.  
With additional guidance and resources, it appears that clinical studies are more 
                                                          
 
g Clinical trial as defined by the National institute of Health (NIH): A research study in which one or 
more human subject are prospectively assigned to one or more interventions (which may include 
placebo or other control) to evaluate the effects of those interventions on health-related biomedical or 
behavioural outcomes.   
 
 





likely to implement the required procedures. This observation is supported by the 
borderline association (forced entry) between a definition for protocol deviation 
and/or violation and intervention trials. This was further supported by both of the 
stepwise models demonstrating that having a definition for a protocol deviation 
and/or violation had a significant, positive association with the intervention trial. 
This association was found in all three models and may result from a level of 
compliance with the Consolidated Standards of Reporting Trials (CONSORT) 
statement that recommends reporting protocol violations240,241 and the National 
Statement which recognises that sponsors, investigators/researchers, institutions 
and Human Research Ethics Committees (HRECs) all have responsibilities to 
monitor clinical trials16. Further, supplementary guidance is provided in a 
reporting framework for protocol deviationsh, ‘Reporting of Serious Breaches of 
Good Clinical Practice (GCP) or the Protocol for Trials Involving Therapeutic 
Goods’ which provides definitions, reporting procedures and timeframe, deviation 
examples, form templates and general question and answers242. Supplementary 
guidance has been provided for protocol deviations, which may explain the reason 
for the association, albeit the limited compliance with other areas related to 
monitoring the quality of clinical studies. For example, a review of 80 clinical 
trials found that protocol deviations are underreported and larger clinical trials 
(larger number of patients, sites, longer duration, complex management structure) 
were more likely to report protocol deviations than smaller clinical trials243. These 
findings may suggest that larger trials may have better management and improved 
facilities, thus are more likely to report protocol deviations and/or violations. It is 
                                                          
 
h The term deviation (recommended by ICH E3 – Structure and Content of the Clinical Study Report 
2012) has been used to describe any breach, divergence or departure from the requirement of Good 
Clinical Practice or the clinical trial protocol, whether minor or major.  
 
 





an equally plausible alternative hypothesis to suggest that smaller sites perform 
smaller studies with simpler designs, hence are easier to execute without protocol 
deviations and/or violations. The findings of the review and the current study both 
suggest that when greater guidance and resources are provided, clinical studies are 
more likely to implement necessary procedures to ensure accurate, reliable and 
credible data. Therefore, we advocate for eliminating disparity in resources and 
providing clinical studies of all sizes and study type with equal access to freely 
available standard procedures and clear frameworks. 
Although technology plays a key role in improving processes and efficiency in 
clinical studies, smaller, single-site clinical studies are yet to adopt technology, as 
46% of the respondents in this survey reported they did not report using data 
management software. A possible explanation for this is that small, single-site 
studies find it difficult to afford expensive and sophisticated technology despite 
the potential benefit of facilitating critical-decision making procedures51. This is 
in line with the literature that reported due to the limitation of time and resources, 
not all research trials implement the necessary data quality management tools and 
procedures30. Further, evidence suggests that the adoption of e-technology (digital 
and electronic technology that utilizes mobile devices or the Internet) into the 
design of clinical research studies has been relatively slow due to limited 
empirical evidence to support the benefits of such technology in improving study 
design and results244. Instead, this study revealed clinical studies implemented 
‘traditional methods’ which included paper data capture and SDV. In accordance 
with this finding, a previous Canadian survey also reported that 59% of the 
clinical trials used paper CRFs and reported advantages such as quick to 
implement, simple and convenient245. It is clear that traditional methods 
 
 





implemented to collect and monitor data are still being used despite updated 
published evidence that promotes ‘new’ methods which compliment trial 
procedures by improving the resources available26,32,68. The results of this survey 
need to be interpreted with caution as we did not specifically ask respondents to 
point out the difference between automatic and manual data capture to record 
study events. With automatic capture a machine reads the paper which may 
reduce the amount of overall error in clinical studies. Currently, there is lack of 
coherent guidance and standard “good practices” in clinical research. Paper data 
collection and transcription of data into an electronic system are more likely to 
introduce avenues for error, is a costly and an onerous procedure246. Similarly, 
two reviews on monitoring methods, found SDV to be time consuming, expensive 
and does not guarantee error free results26,74. To overcome this issue standard 
procedures and education are needed on the benefits of incorporating technology 
into clinical studies to improve research outcomes.  
We found that 55% of survey respondents conducted SDV in comparison with 
less than 11% who implemented RBM approaches. This may suggest that RBM 
may be overlooked or unknown to many researchers conducting smaller scale 
clinical trials like the respondents in this survey. However, there appears to be a 
slow adoption of RBM, which may be explained by the GCP Integrated 
Addendum only coming into effect in November 2016. Therefore, we are likely to 
see a rise in its implementation in the future. Similar to the results of this survey 
where the majority (60%) of respondents identified their organisations as 
academic organisations, a study in Ireland identified that only 21% of academic 
clinical researchers implemented RBM103. Other core findings from this Irish 
study stated that IT demand increased costs, a greater staff workload was required 
 
 





and a lack of training/knowledge were all barriers to RBM being an effective 
approach. These findings are contrary to previous research which suggests 
that RBM can reduce cost while improving quality83. Yet, we consider it too early 
to judge as cost savings and the effectiveness of RBM approaches are still under 
evaluation104. At the current stage and without a ‘gold standard’ approach to 
RBM, there remains a wide variation in methodologies; therefore, it is unclear 
how clinical researchers should implement a RBM method on site. There is a need 
for training and education to support and promote RBM in all clinical studies and 
its wide adoption across the clinical research community.  
This study also found variations in the proportion, sampling and the frequency of 
data included in monitoring approaches. A possible explanation for this variation 
could be the push to reduce 100% monitoring as it is time and cost inefficient in 
determining discrepancies70,189,209. Eisenstein et al. 150 found that without 
compromising scientific objectives, the most efficient way to reduce trial costs 
was to reduce the number of on-site monitoring visits. However, Tantsyura et 
al.208 also pointed out that there was no experimental or statistical evidence to 
support the idea that the greater percent of data monitored the higher the data 
quality. Despite this recommendation, our study found that conducting 100% on-
site monitoring was the most common method utilised. We found that the 
respondents who did not conduct 100% monitoring would be most likely to 
include a sample of 1-25% of data points for partial SDV, centralised or on-site 
monitoring. However, including only a subset of data to monitor data quality has 
been flagged as a concern by clinical researchers who stress that any 
discrepancies will lead to an inquiry into the consistency and validity of the whole 
dataset 247. Previous research has suggested that errors on primary or critical data 
 
 





points in clinical research have a more serious impact than secondary or non-
critical data 74,248. Indeed, our respondents who completed partial SDV and 
reported that non-critical data and non-SAE reports have the lowest proportion of 
100% data verified.  
Another important finding was the large variation in the frequency of monitoring. 
Interviews conducted by von Niederhäusern 104 also highlighted that the monitors 
feared missing systematic errors, patient violations and critical issues due to a low 
frequency of monitoring visits 104. Additionally, monitors believed that increasing 
the frequency of monitoring visits would improve data quality and the main 
restriction for the amount and frequency of monitoring was funding constraints. 
These align with our findings that study design and budget were the top two 
factors that determined the frequency of monitoring visits. We also identified the 
essential need for complementary and easy-to-use frameworks to guide clinical 
researchers to improve research quality rather than just meeting GCP-
conformance.  
We found that the incidence of adverse events and the number of protocol 
deviations were the two most likely factors to trigger a site monitoring visits for 
risk-based triggered and centralised monitoring methods. This finding may seem 
rationale as adverse events and protocol deviations are serious risks for clinical 
studies and areas of ethical concern. However, utilising monitoring tools to focus 
on the areas of concern to detect irregular patterns has gradually becoming a 
popular approach 248. Previous research has also estimated conducting a triggered 
site monitoring visit can reduce approximately 25% of total site visits by 
comparison to the traditional approaches249. However, to date only one study has 
compared triggered visits and un-triggered site monitoring75 which concluded that 
 
 





these methods warrant further investigation.  
Clinical studies require triggers to be predefined in the monitoring plan and 
include threshold values with descriptions specific to the study. For example, a 
few studies have identified ‘acceptable thresholds’ of 1% 250  and 5% 251 to guide 
decision making and the frequency of conducting on-site monitoring. In this study 
instead of asking respondents their acceptable threshold, we asked them what 
triggers a site monitoring visit. Therefore, our results could be used to guide 
clinical researchers in identifying the most common factors likely to trigger a site 
visit. Yet, given the increasing use of technology, which may utilise automatic 
triggers, it seems possible that an increase in remote monitoring in combination 
with triggers to guide on-site monitoring will be the optimal method in the future. 
However, before a standardised method is determined, we encourage clinical 
researchers to share their approaches to, and experiences with triggered 
monitoring via literature.  
There are several limitations to this study. First, the majority of responders were 
from small, single-site academic studies, causing limitation on representativeness 
of the results to the broader research community including a substantial number of 
multi-site international clinical trials. An additional restriction is that our survey 
respondents were clinical studies listed on the ANZCTR database as ‘recruiting' 
or ‘active, not recruiting’, in which the ANZCTR accounts for approximately 
60% of registered clinical studies in Australia53. Another limitation is that the 
respondents were identified from a Clinical Trials Registry by Australian postal 
address. The same contact person could have been contacted repeatedly due to 
being listed more than once via multiple associations with the Registry. This 
could have a negative or positive impact on response rates. Survey results are 
 
 





subject to potential bias in a positive direction as the respondents who completed 
the survey may be more knowledgeable about data quality monitoring measures 
and procedures than those who were non-respondents. Furthermore, the number 
of non-respondents might be due to confidentiality considerations31. Although we 
attempted to calculate the total number of ‘return to sender’ letters and bounced 
emails, these numbers should be considered with caution. Although we include a 
response rate (14.8%), the denominator (n = 3689) used in this calculation should 
be considered with caution252. The denominator may differ as the number of 
studies who received the invitation to participate cannot be confirmed due to the 
multi-modal approach and there could be the possibility that ‘return to sender’ 
letters and rejected emails may have been missed or lost. 
It should be highlighted that throughout this research we have referred to clinical 
research as it is mostly concerned with prospective clinical studies, though we 
note that clinical studies may also include retrospective observational studies. 
While we did ask respondents about the study type, we did not explicitly ask them 
about their study designs. We did not attempt to sample evenly by clinical study 
type and, therefore, our results do sway towards 83% of respondents reporting for 
an intervention trial. However, this figure is similar with the national figure of 
86% of registered clinical studies were intervention trials between 2006 – 15 53. 
Thus, the results of our study may be considered generally representative of 
Australian clinical studies. Respondents who answered ‘Yes’ within the survey to 
implementing more than one monitoring procedure may have negatively impacted 
response rates as adaptive questioning increased the total number of survey 
questionnaire items and time to complete the survey. The logistic regression 
output should be interpreted with caution as it was derived from a limited 24 
 
 





observational studies that were included in the analysis. This was due to only 15% 
of respondents reporting for an observational study and SPSS logistic regression 
using listwise deletion which meant if there were any missing values in the model 
the entire case was excluded from analysis. Finally, as with any survey, the results 
are subject to recall bias. 
5.5 Conclusion 
In summary, this study found that not all Australian clinical studies follow GCP 
guidelines and the majority of study personnel do not receive GCP training. 
Instead, small, single-site academic clinical studies implement various non-
standardised ad hoc measures and procedures to ensure data quality. When 
provided with additional guidance, resources and frameworks, clinical studies are 
more likely to implement the necessary procedures. Small, single-site academic 
studies are yet to adopt technology to replace their use of traditional methods to 
collect and monitoring data, which are costly and burdensome. Additionally, 
formal guidance and training need to be continuously improved to enable all 
clinical researchers to perform ‘new’ and efficient data quality monitoring 
procedures that are compliant with GCP guidelines, such as RBM. This is vital for 
improving the efficiency of quality monitoring procedures and the quality of data 
captured from clinical studies. The current study presented the initial quantitative 
results which suggest that a standardised monitoring approach needs to be 
adopted for small clinical trial studies, which are not interventional drug trials. 
Therefore, the following chapter will describe qualitatively the experiences of 
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6.1 Introduction  
Data monitoring is recommended to ensure that studies comply with the E6(R2) 
GCP guideline. However, some studies have suggested that the GCP guideline is 
too broad, is written to follow the strict industry standards, predominantly for 
drug-registration trials and grounded on informal consensus rather than scientific 
evidence13,238. In line with these claims, Chapters 4 and 5 have identified that the 
GCP guideline is not suitable for certain types and contexts of clinical studies, 
such as small non-drug intervention trials and observational studies.  
With increasing study size, complexity and regulatory scrutiny, it is increasingly 
difficult for clinical studies to ensure data quality. Prerequisite for efficient and 
high quality clinical research is knowledgeable and experienced researchers 
regardless of the study setting253. A joint task force has identified the core 
competency domains of clinical research including study and site management, 
leadership and professionalism, and communication and teamwork254. This is in 
line with a RBM approach which requires efficient teamwork, staff engagement 
and workflow to identify and resolve issues. However, within clinical study teams 
there is often miscommunication and a duplication of effort due to the tendency to 
work in silos255. What is not yet clear is the impact of the clinical research 
environment on data quality and study findings. This indicates a need to 
understand clinical researchers’ experience with the working environment, the 
working procedures and their impact on data quality. 
Given the previous chapters (Chapter 4 and 5) have identified substantial 
heterogeneity in Australian clinical research data management and monitoring 
approaches, further investigation in the area was warranted. This study aimed to 
 
 





describe Australian researchers’ experiences with data quality monitoring in 
clinical studies. A hypothesis generating approach will report both motivating 
factors and barriers to meeting the recommended regulatory requirements for data 
quality monitoring from clinical researchers’ perspective. Furthermore, the 
current study presents the qualitative findings (study 3b) from the explanatory 
sequential research design98 study.  
6.2 Methods  
6.2.1 Study design  
The semi-structured interviews described in this chapter followed a guided-
phenomenological approach which was deemed appropriate to explore clinical 
researchers’ commonalities as well as the structure and essence of the 
participants’ ‘lived experiences’ associated with data quality monitoring256,257. 
Participants were considered experts and any new topics raised were explored in 
depth within the corresponding interview. The study was carried out and reported 
using the COREQ guidelines and checklist (Appendix T)138.  
A semi-structured interview guide was developed with reference to the initial 
survey, study 3a (Chapter 5). To collect open-ended data the interview guide was 
tailored to be informed by the quantitative results reported by each survey 
respondent. The interview guide began with general questions asking the 
participants to describe their work experiences with clinical research. This was 
followed by their experiences with data quality monitoring (a) before the 
commencement of a clinical study, (b) during the data collection phase, (c) the 
methods applied, (d) during the data analysis phase and translation of data into 
information and (e) training and education received (Appendix U). Probing 
 
 





questions were used to seek clarification. The interview guide was assessed for 
face-validity by a senior researcher (YP) prior to use. The interview guide was 
pilot tested with two colleagues (AM and SD) who worked within clinical studies 
and had experience with monitoring data quality. 
6.2.2 Participant recruitment  
An opportunity sample of Australian clinical researchers who had recently 
completed a quantitative survey for our research team (as described in Chapter 5) 
were invited to participate in the interviews. In brief, Australian clinical 
researchers listed on the ANZCTR as the contact person for a clinical study’s 
scientific queries225 were contacted. After completing the quantitative survey, 
respondents were invited to participate in the interview. No previous relationship 
was established with participants prior to recruitment. It is recommended that 
phenomenological studies should interview five to 25 individuals who have 
experienced a phenomenon258. Therefore, all clinical researchers who expressed 
an interest were sent an invitation to participate and an outline of the interview 
questions (Appendix V). Non-respondents were sent one single email reminder. 
6.2.3 Data collection  
Telephone interviews were conducted between September 5, 2018 and October 
22, 2018. Each interview was scheduled for a period of 30 to 60 minutes and no 
repeated interviews were conducted. Researcher (LH) had training in research 
theory and prior experience in observing qualitative research, thus she conducted 
the interviews. As LH was familiar with the previous survey results, she 
employed the strategy of “bracketing”257,259 to set aside her own presumptions 
whilst remaining open to the reality experienced by the participants. In order to 
minimise bias she wrote down her own views about data quality monitoring prior 
 
 





to proceeding with the interviews. Ethics approval was obtained from the 
University of Wollongong Human Research Ethics Committee (HE16/131) and 
written informed consent was gained. Despite an offer made to interview 
participants to quality check their own transcripts, no participants elected for this 
option.   
6.2.4 Data analysis  
All interviews were audio recorded and iteratively transcribed verbatim, removed 
of identifiers and checked for quality by an independent reviewer (CMi, EM or 
DB) (see Appendix W). All transcripts were uploaded, managed and reviewed 
using the qualitative analysis software QRS NVivo, version 11.0 (QSR 
International Pty Ltd, Doncaster, VIC, Australia). Inductive thematic analysis was 
employed to make sense of and build a narrative for the collected data144. Each 
transcript was analysed individually before the full transcripts underwent thematic 
categorisation. This was to preserve the richness of each interviewee’s experience 
and to ensure that the analysis was grounded in the language of the participants. 
Themes were categorised as they became apparent. Thematic saturation was 
reached after seven participants were interviewed145,260. The primary data theme 
categorisation was coded by LH who discussed emergent themes with a second 
researcher YP. Further, to check the robustness of the themes AM and PY 
independently reviewed and audited the themes for plausibility.  
6.3 Results 
From the initial survey, 26 of the 441 (6%) survey respondents expressed an 
interest to participate in an interview. When contacted, four participants declined 
to participate, three due to time constraints and one did not give reason. A total of 
 
 





15 participants did not respond to the email communication. Seven participants 
were interviewed, and all were associated with intervention treatment clinical 
trials in an Australian setting (Table 6-1).  
Five primary themes emerged from the interview: (i) education and training, (ii) 
ways of working, (iii) working with IT, (iv) working with data and, (v) working 
within regulatory requirements. A thematic map (Figure 6-1) was created to 
describe the relationships between the primary themes. Each primary theme is 
presented in an oval and broken lines reflect the relationship between the primary 
themes. The direction of the relationship is indicated by the arrow heads. The map 
illustrates the influence of ‘education and training’ on the other four primary 
themes. While ‘working with IT’ was seen to influence the ‘way of working’ 
theme, all other themes had reciprocal relationships. There was no relationship 
between ‘working within regulatory requirements’ and ‘working with IT’. The 
hierarchical structure of the primary themes (n=5), secondary themes (n=8) and 
subthemes (n=39) are presented in Appendix X. The primary themes are shown in 
bold, secondary themes are bold and italicised, and the subthemes are italicised in 
the following text. A detailed list of the secondary themes, sub-themes and 









Table 6-1: Characteristics of participants and the associated clinical study demographics. 
Participant Clinical study 





















P1 Male  Doctoral 15 Continuing H I-T 4  Single H - 20-99 
P2 Male Doctoral 1 Fixed-term contract  A I-T 4 Multi H, PP Yes >500 
P3 Female Postgraduate 8 Continuing  A I-T 4 Multi MS No 100-499 
P4 Female Doctoral 6 Fixed-term contract  H I-T 2 Multi H, A Yes >500 
P5 Female Doctoral 8 Fixed-term contract  A I-T 3 Single II - 100-499 
P6 Male Doctoral 1.5 Fixed-term contract  A I-T NA Multi CS No >500 
P7 Female Doctoral 2.5 Fixed-term contract  A I-T 3 Single H - 100-499 
Abbreviations: A, academic (university); CS, correction service; H, hospital; II, independent institute; I-T, intervention (clinical) trial – treatment; MS, medical service; PP, 
private practice; NA, not applicable.  
a Study phase: Clinical trials of biomedical interventions typically proceed through four phases - 1, Phase I; 2, Phase II; 3, Phase III; 4, Phase IIII.  










Figure 6-1: A thematic map of the relationships of the five primary themes. 
 
6.3.1 Education and training  
Importance. The importance of training and education arose from participant 
experiences of receiving training to meet regulatory standards, where 
“everybody…should have basic [GCP] training” (P4). A few participants 
reflected a lack of understanding of the importance of training and education, and 
suggested more needs to be done.  
Staff training. There was consensus about the importance of staff training from 
organisation to organisation. Participants described that their training experience 
reflected the study context and the SOPs of their organisation in guiding them on 
completing tasks. One participant described, “if you went from one organisation 
I’ve worked in, to another…the training would have been more or less the same” 
(P3). Training was delivered through pre-implementation formal training or on-
job informal training.    
 
 





6.3.2 Ways of working 
Responsibility. Participants stated the importance of providing staff ownership 
over their collected data as it was an opportunity for them to contribute to the 
study. This ownership would foster trust and create relationships between 
collaborating staff, sites or centres. Participants recognised that it was up to them 
and solely their responsibility: “you're…never gonna get another chance to do this 
[clinical study] again. So, why not make sure that you do it right” (P2). 
Participants mentioned difficulties of working with clinicians whose research 
activities were an additional responsibility on top of their usual duties, which was 
seen to increase the clinicians’ workload. 
Staff engagement. Pilot testing was suggested as an approach to engage staff in 
the design and to allow them to familiarise with the study, which was described as 
useful and would positively impact study outcomes. However, one participant saw 
the effect of engaging with staff differently. It was a way to get to know and 
identify staff members: “You know I was checking so I knew who was fudging 
stuff and who was actually doing it properly…you’d soon get them out of the 
way” (P4). Workplace communication resulted in staff participating in teamwork 
through open conversations and feedback. The majority of participants would 
seek advice from senior staff members, their boss and experts in the research 
field.  
Organisational environment. Many participants felt that there was an 
organisational hierarchy in clinical research, which could create a disconnection 
between the levels of staff at the top and bottom. A participant experienced that 
senior staff members could lose touch with reality: “I'm sort of in the middle you 
know of the tree…in reality only people who are doing the data capturing in the 
 
 





field are who know whether…the CRF [case report form] or the questionnaire 
there are actually feasible or not for the participants to fill in” (P6).  
Skills and expertise. Involving skilled and expert staff members was ideal to 
interpret results of different tests. Participants described working in 
multidisciplinary studies which relied on the specialised staff members with the 
relevant training and education. 
6.3.3 Working with IT 
Technology induced changes. There was widespread acknowledgement that the 
introduction of technology had changed the landscape of clinical studies. 
Participants advised that by adopting technology they had moved away from 
paper-based studies. This was described to be a positive experience as it upskilled 
staff, improved quality and reduced the number of checks: “I really believe 
this…new system is going to help a lot… it’s reducing the checks, I think that are 
needed” (P5).  
Quicker and easier. There was recognition that technology had encouraging 
effects as software could enable quicker and easier identification of data 
discrepancies and/or errors. There was also a benefit to having all data stored in a 
centralised system. One participant described, “it's much easier to have quick look 
and know if there is much more [to be] checked on.” (P5).  
Investment. Investing in technology allowed researchers to utilise functions 
including database locking, audit trails, preformatted fields and automatic range 
flags. Participants described functions as inevitably improving the efficiency of 
timely procedures including hand searching paper documents.  
 
 





Unintended consequences. In some instances, instead of making improvement or 
bringing benefits technology actually caused data loss. There was an 
understanding that different software systems were not compatible which 
adversely increased workloads. Feelings of frustration were raised related to how 
a software interface was designed. A participant described the hindrance caused 
by an unstable offline system, “there's a chance that you might move the…data on 
the server and replace it with the empty data record on the iPad…that might lead 
to data loss on the server…which is a lot of trouble” (P6).  
6.3.4 Working with data  
Monitoring 
Method and frequency. All participants had experience with ‘simple’ data 
checking. The frequency of data monitoring varied although the use of technology 
could lead to more frequent checking. Furthermore, the amount of monitoring was 
dictated by study funding, with one participant expressing they had taken salary 
and staff cuts due to limited funding, “we have run this study on the smell of an 
oily rag” (P4). 
Approach. There was little consensus in data monitoring approaches among the 
participants. Numerous participants described their approach was the same for 
different studies, “Oh, no, there was no difference. It was exactly the same” (P1). 
While, others experienced varying approaches, suggesting that the approach 
depended on the clinical situation and context. 
Detailed plan or framework. Participants described the importance of 
implementing a detailed plan or framework for data monitoring prior to 
commencing a study. This was a standard procedure for some participants, while 
 
 





others were unaware that a monitoring plan was a requirement.  
No data checking or monitoring. Participants expressed concerns that they had 
worked in organisations where no monitoring was undertaken. This was due to 
the monitoring not being seen as an important activity and a lack of knowledge on 
how to conduct data monitoring. 
Assumptions or opinions. A few participants believed drug trials were more 
complicated. Additionally, commercial entities were suggested to be more 
stringent to the point the amount of monitoring required was excessive. These 
participants had opinions that there was enough evidence to suggest that the 
amount of money, time and resources spent on certain monitoring methods was 
wasteful.   
Errors 
Error avoidance. Participants’ implemented different strategies to minimise error, 
which included measurement guidance, pictures on data collection forms, data 
ranges, real-time checking and sending all tests to a central place for analysis.  
Error acceptance. The expectations for clinical studies can factor into how 
researchers interpret the amount of error that is tolerable. One participant 
suggested it was not possible to standardise an error acceptance level, while 
another participant suggested that they selected an error acceptance level based on 
their individual opinion.  
Human error. Accepting that humans make mistakes and that errors exist arose 
from participants describing their experience with the process for data collection 
and transcribing data from paper into an electronic system. Technology was 
 
 





suggested to reduce human error although this relied on software configuration. In 
particular, a participant who utilised Excel spreadsheets for data storage 
expressed, “You just need to accept there’s like a human mistake” (P7). 
Audits 
Being audited. Participants who had been audited described this experience as 
unpleasant. Auditors were not liked, and the mandatory auditing process was 
considered to be scary. Although, one participant reflected on being audited as a 
positive learning experience and would recommend the procedure to other 
studies, “it was a very good process, I enjoy it. It was frightening like a bit scary, 
but I…learn a lot” (P7).  
Missing 
Identifying missing data. There was a general consensus that technology would 
aid in quicker identification of missing data in comparison with paper forms. 
However, no participants discussed calculating the amount of missing data before 
and after technology implementation.   
Strategies to overcome missing data. Ensuring researchers had strategies in place 
to overcome missing data was commonly considered among the participants. One 
strategy referred to by the participants was “retrospectively ask patients for that 
data” (P3).  
No missing data. Although it was vital to minimise missing data, it was also 
important to acknowledge that missing data does exist. A few participants 
described that they had no missing data points and everything was always 
completed.   
 
 







Elements of quality data. Participants felt a motivation and obligation to ensure 
that the data collected, stored and reported was legible and transparent. One 
participant described that they had witnessed staff ignorance about the data 
limitations and the criteria to judge a meaningful result. Participants highlighted 
the need for improvement in the quality of clinical data. 
Factors influencing data quality. A few participants acknowledged that the goal 
of certain studies was not just about achieving good quality data but forming a 
long-lasting relationship between services and participants. For example, “not just 
about data quality ours [study] are about creating a relationship with the 
services… and gaining trust in a community” (P3). Additionally, the timeliness of 
data with the increased use of technology meant real time data collection allowed 
for improvements in quality and less missing data. 
Reporting data queries. Data queries were often noted on forms and kept separate 
to where data was stored. All of the participants who had experienced reporting 
queries explained that this was to ensure that the queries never showed up in the 
database.  
6.3.5 Working within regulatory requirements 
Good clinical practice 
GCP downfalls. Many participants described the GCP guideline as inflexible and 
the scope needed to be broadened as it mostly applied to drug trials. The 
participants felt completing GCP training was a dreary exercise. Despite this, they 
recognised that the guidelines served a purpose and provided staff context to the 
 
 





overall structure of clinical studies. A participant voiced, “There’s a general 
consensus and feeling that, the [GCP] guidelines are too strict. They have a 
purpose, but they are very much open to interpretation” (P3). 
GCP benefits. Participants reflected on the importance of the GCP guideline in 
that it provides substantial trust to all procedures completed within a study. 
Responses illustrated the depth and stability of having a common set of 
guidelines: “we often referred back to it [GCP]…to make sure we're doing this 
and people actually understood how that fitted in” (P4). 
Protocol 
Creation. Being able to create protocols to address study procedures was 
described as an easy process by one participant as they created the protocol from a 
template provided by the ethics committee. Over time this participant explained 
with experience that they had begun to incorporate other information specific to 
their area of research. 
Implementation and adherence. It was vital that studies implement protocols to 
ensure the study procedures are safe for the study subjects and data is of high 
quality. The majority of participants spoke about implementing and adhering to 
protocol defined approaches which were revised on a regular basis.  
Publishing. The significance of publishing the protocol was mentioned by the 
participants who had experienced this process and felt that the process ensured 
that the study design was clear and was followed.  
Standard Operating procedures 
Creation. SOPs were written in large organisations by senior and specialised staff 
 
 





members. One participant described that staff members who created SOPs often 
felt fatigue with the repetitive procedure. While another mentioned the irony that 
all SOPs and monitoring plans were similar. It was strongly argued that the SOP 
outlining the data monitoring plan was always a standalone document, providing 
clear instructions on how to carry out monitoring procedures. 
Introduction. Participants reported that occasionally new staff members were 
resistant to introducing SOPs as they were naïve about their importance. The 
resistance was often reduced with training and education, resulting in participants 
calling for standardising documents and clearer guidance: “I think if you can 
highlight that we need to have you know SOPs” (P4). 
Setting. SOPs were described as needing to be tailored to the study context, where 
the activities of the organisations were based on the resources available. When 
clinical studies were required to meet the same SOPs, staff felt resentment around 
meeting stricter requirements and demanding extra requirements. Not 
implementing context specific SOPs was reported as being problematic, “you 
have to create SOPs that people can actually work within and towards 
comfortably” (P2).  
6.4 Discussion 
From the interviews, we found that Australian organisations conducting 
intervention clinical trials which are testing new treatment options are 
implementing a variety of data quality monitoring procedures tailored to their 
clinical situation and study context. Participants experienced challenges in 
meeting regulatory requirements, utilising IT and fostering working relationships. 
Additionally, it was a common phenomenon for all clinical studies to lack 
 
 





guidance, education and training in relation to data quality monitoring procedures. 
Taken together, clinical researchers are calling for further education and training 
on data quality monitoring procedures. 
Due to the unique and different needs of clinical studies, the participants 
described that data quality monitoring procedures were tailored to their clinical 
situation and study context. A “one-size-fits-all” approach to data quality 
monitoring was not applicable for all clinical studies. Moreover, participants 
expressed the need to meet regulations, particularly for large drug-intervention 
trials where a strict requirement is necessary to uphold and to meet the procedures 
outlined by the funding body and sponsorship agreements. Conversely, 
participants in smaller clinical studies described a more flexible setting where 
their studies were run subject to individual interpretation and allowed for 
incremental changes throughout study procedures. The present study, therefore, 
raises the possibility that there is an individual ‘enthusiasm factor’ related to the 
study researchers and coordinators that could positively impact on the quality of 
the data. In support of this notion a study in a primary care setting261 identified 
that a chosen person who has the essential skills and eagerness to maintain data 
quality can lead and engage others to do so. This strategy has the potential to be 
used by small clinical studies where there is no designated data manager.   
Participants voiced their challenges with meeting regulatory requirements and 
utilising technology to improve data quality. Our participants experienced the 
similar barriers that have been reported by previous researchers including meeting 
the demand for excessive monitoring, a lack of funding and inadequate 
infrastructure262. A lack of IT infrastructure has made it difficult for clinical 
studies to meet the required data monitoring procedures. This difficulty was 
 
 





keenly felt by the independent, non-commercial and academic small-scale 
researchers who work with limited budgets263. Such challenges may explain why 
no relationship was found in this study between the primary themes ‘working 
within regulatory requirements’ and ‘working with IT’ despite the GCP guidelines 
recommending a RBM approach underpinned by an IT platform. Regardless of 
these challenges, participants expressed positive experiences with IT to improve 
data quality and to reduce error by improving transparency and building a level of 
trust between research communities and participants. Furthermore, the 
significance of having internationally recognised guidelines and procedures has 
meant that clinical staff understood the importance of project governance.  
This study provides evidence on the positive impact a good working relationship 
can have on data quality. Open communication between staff is crucial to the 
success of data monitoring. Additionally, the principal investigators working 
alongside other staff members was identified as a critical activity to promote 
successful study conduct and to maintain staff engagement. This result echoes 
findings that appropriate communication and advice promotes staff morale and 
enables collection of quality data264,265. These lessons are useful for the 
contemporary clinical research study that is demanding increased need for 
collaboration.  
Unfortunately, the participants experienced a lack of guidance, education and 
training. This result was not surprising as previous research has also reported a 
lack of understanding amongst clinical study researchers regarding the benefits of 
training on overall study performance266. Participants reported GCP training as 
tedious and not relevant. Additionally, some participants with experience of 
working within multidisciplinary environments reported that clinical staff may 
 
 





lack knowledge about research methods due to taking on research as additional 
work267. Little was found in the scientific literature reporting about training and 
education for clinical study data quality monitoring. However, many companies 
do conduct GCP training course both online and in-person (e.g. PRAXIS268, 
Quintiles269, NIDA Clinical Trials Network270 and ARCS Australia271). It is clear 
that an emphasis needs to be placed on available training courses which cater to 
clinical researcher’s different levels of expertise and roles in data collection and 
monitoring. 
Our study had several limitations. Firstly, we had limited representation of 
clinical study types with all seven participants currently working on intervention 
treatment clinical trials. Therefore, the experiences of the participants may not be 
representative of the broader clinical research community. Secondly, this research 
is limited by responder bias as interviewees may have been hesitant to report 
negative experiences associated with their current or prior employer. The 
interviews were telephone-based, body language may have provided useful data 
which could not be assessed. As with any qualitative data the interviews and 
themes that emerged are subjective experiences of the interviewees and 
interviewer. Finally, the linking of the primary themes shown in the thematic map 
was designed to run structural equation modelling, however due to the small 
sample size there was an insufficient number of cases to run the multivariate 
statistical analysis technique272. 
6.5 Conclusion  
This study identified a variety of data quality monitoring procedures implemented 
by clinical researchers tailored to their clinical context. It also unveiled challenges 
 
 





experienced by clinical researchers in meeting regulatory requirements, utilising 
technology and fostering working relationships. At present, there is a lack of 
guidance for observational studies and non-drug intervention trials for data quality 
monitoring procedures. The interviews disclosed that standardised frameworks 
which are accessible to all clinical studies are warranted. Therefore, this led to the 
development of an open-source data monitoring framework to improve quality 
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7.1 Introduction  
Regardless of the study design or clinical area, high quality data collection and 
standardised data processing and representation are paramount to reliable clinical 
study findings8,9,25. From the broad definition of a clinical study, several 
challenges arise to ensure high data quality due to different objectives and data 
requirements. Many strategies and interventions have been developed to reduce 
these challenges, including careful design of CRFs, SOPs, personnel training and 
data monitoring or assessment. However, a lack of consistent guidelines creates 
confusion for researchers who are searching for standardised procedures.  
Clinical research now relies heavily on the evaluation of electronically 
communicated data for critical decision-making through which data quality is 
increasingly important. As highlighted in the previous chapters little attention has 
been given to clear guidelines and definitions relating to monitoring data quality 
which are accessible to all clinical study types. Thus, the aim of this study was to 
develop a “fit-for-use” DQMF for clinical research. A hypothesis generating 
approach, in which inductive reasoning from studies 1 to 3 generated ideas to 
guide the development of the framework. This framework will aid clinical studies 
to maintain high data quality by providing guidance on critical areas of study 
operations.  
7.2 Methods  
7.2.1 Planning  
For the purpose of this research, a holistic design-oriented approach was applied 
to design and develop the DQMF. The approach provided guidance to the 
researchers in creating the framework (artefact) and further understanding the 
 
 





reality of different stakeholders (clinical research studies) of the framework147. 
This gave further guidance to the researchers by helping to recognise data failures 
by developing the framework against a real-world state148. Design science is 
considered a problem-solving paradigm and seeks to extend the boundaries of the 
human and organisational capabilities by creating new and innovative artefacts149. 
Human knowledge and understanding of the problem and the solution are 
acquired in the ‘building’ and the ‘application’ of the artefact. Therefore, this 
research follows the conceptual framework and seven guidelines proposed by 
Hevner et al.149 for understanding, executing and evaluating design-oriented 
research. This process utilised a build-and-evaluate loop iteration and evolving 
design of the artefact. This preliminary methodological research focuses on the 
‘build’ process of the artefact, keeping in mind that further evaluation and testing 
was outside of the scope. The proposed framework aims to help those designing, 
implementing and working in clinical research to understand the complex inter- 
and intra-relationships between the concepts that need to be planned both 
methodically and structurally, in order to improve the data quality of clinical 
research. 
7.2.2 Framework development 
The design of the DQMF was guided by data quality concepts outlined in the 
previous chapters: the perspective of information sciences with clinical research 
grounding. The prior studies determined that clinical studies are implementing ad 
hoc procedures pragmatically to ensure data quality. Thus, there is a necessity for 
further research into “standard practice”. The ontology of key terms, concepts, 
methods, and standards were extracted and recorded from the literature review, 
survey questions and interviews. A consensus approach and mind mapping 
 
 





techniques were used to present associations in a non-linear diagram/network 273. 
The dependent variable, ‘data quality monitoring’ was placed at the centre of the 
network to create the mind map where associations were added and ‘branched’. 
This process was undertaken collaboratively by the researchers (LH, PY, AM and 
YP) to foster a natural thinking process, allowing the addition of new concepts, 
relationships and annotations274. Furthermore, branches and nodes were grouped 
together under comparable topic areas via researcher agreement to construct a 
hierarchical tree-like diagram.  
7.2.3 Face validity testing  
Once the researchers (LH, PY, AM and YP) came to a consensus, the DQMF was 
presented to a convenient sample (n=8) of working health professionals 
(dietitians, nutritionists, educators, public health practitioners) for face validity 
testing. Participants had clinical research experience (1 – 15+ years) in the 
university academic, private institute and hospital settings. The primary 
researcher (LH) moderated an interactive one-hour workshop to gain feedback on 
the design and useability of the proposed DQMF within different settings. Each 
participant was provided with an individual copy of the DQMF and encouraged to 
note any questions or issues. The workshop communicated the process by which 
the artefact was created and defined as the mechanism to finding an effective and 
efficient solution. Once the information was presented, participants were asked to 
refine the DQMF based on their own knowledge and expertise. The primary 
researcher (LH) opened up the discussion to explore reasons why amendments 
were suggested. The workshop identified that standardised terminologies, 
definitions and dialogue are crucial. According to participants’ responses, 
amendments were discussed and agreed upon and a supporting list of key terms 
 
 





and definitions were devised. Each stage of development was aligned with the 
international guidelines (GCP12, European Clinical Research Infrastructure 
Network (ECRIN)275, Good Automated Manufacturing Practice (GAMP)276, and 
ISO 211) to ensure the taxonomy and terminology complied with global 
procedures.  
7.3 Results  
Refinement and evaluation of the key concepts led to the development of the 
DQMF which contains the components of data quality, data quality monitoring, 
and data quality management; presented as a nested concentric network to 
illustrate the relationships and hierarchy (Figure 7-1). Each layer contains 
specific procedures and concepts undertaken within each layer. The importance of 
training and education is highlighted across all layers. It was determined in the 
stakeholder workshop that dialogue, definitions and terminology should be 
implemented consistently. Due to the need to clarify terminology and ensure 
effective communication we have included Table 7-1, which highlights key terms 
and their definitions related specifically to the DQMF.  
 
 






Figure 7-1: Data quality monitoring framework 
 
 





7.3.1 Inner tier 
Four key independent variables were identified and adapted from Nahm 25, see 
Figure 1-1 who illustrated the way data definition, collection, processing and 
representation each impact on data use which also impacts on data and 
information quality. On the contrary, data and information quality also impact 
use. The data evolution life cycle (DELC) was deliberated for inclusion within the 
inner tier throughout the development phase as it reflects a sequence of stages 
known as data collection, organisation, presentation, and application 277. The 
researchers chose not to integrate this cycle as the stages of collection, 
organisation and presentation relate closely to the terminology and stages of 
Nahm’s 25 framework, respectively. Additionally, the main focus of the DQMF is 
‘data quality monitoring’ in which Nahm’s framework highlighted the factors that 
affect data quality while the DELC represents data evolution. The addition of 
‘application’ was discussed; however, the framework illustrates how data is 
utilised and applied in clinical research by linking ‘data’ to ‘information’.  
7.3.2 Middle tiers 
Data quality monitoring was separated into two main concepts: quality assurance 
and quality control. The terms quality assurance and quality control are often used 
inaccurately or interchangeably10 as previously described in Chapter 1.7.1. In 
brief, quality assurance is the process to “prevent” data errors while quality 
control is the process to “alleviate” or “remove” the impact of errors that have 
occurred during data collection and/or analysis49.  
7.3.3 Outer tiers 
Data quality management and data governance include developing and 
implementing national and international standards and regulations in the full data 
 
 





life cycle, including planning before and execution of protocols and policies for 
data capture and analysis. The design of the DQMF has drawn upon an illustration 
by Ohmann et al.50 as shown in Figure 1-3, by extracting key concepts within 
each of the regulatory requirements and documents. In this light, a simpler and 
broader approach was required to guide clinical researchers by providing 
overarching concepts of infrastructure, protocol and regulations/standards. This 
approach was chosen as it allowed clinical researchers to make an informed 
decision regarding the most suitable management strategy for their study while 
incorporating legal requirements. Further, it acknowledged the broad range of 
clinical research studies and the fact that healthcare requires person-to-person 
interactions for collaboration and integration between strategy, process 
(automated/non-automated) and the supporting information systems. By providing 
a consolidated framework, the researchers aimed to provide a clear guidance to 













Audit A systematic and independent examination of trial-related activities and 
documents to determine whether these activities were conducted, and the data 
were recorded, analysed and accurately reported according to the protocol, the 
sponsor, SOP, GCP and applicable regulatory requirements 12.  
Compliance Adherence to all the trial-related requirements, GCP requirements and 
applicable regulatory requirements 12.  
Continuous 
improvement 
Systematically planning, collecting and assessing data to distinguish a chance to 
ameliorate the process of clinical trial data management 63,278.   
CRF/eCRF Case report form/electronic case report form: A printed, optical or electronic 
document designed to record all of the protocol-required information 12. 
Data An individual fact or pieces of information.  
Data collection The process by which data elements are accumulated25. 
Data definition Occurs as the protocol or research plan is developed. Procedures include 
identifying data to be collected, defining data elements and designing CRFs 25.  
Data governance Encompasses people, processes and information technology required to formally 
manage and exercise control over methods used by data stewards and data 
custodians in order to improve data quality 34.  
Data processing The processes and systems applied to audit and monitor data 25. 
Data representation Relates to data analysis and the process of translating data into meaningful 
information 25. 
Data quality Data quality can be defined as the degree to which a set of characteristics of data 
fulfils requirements 279. 
Data quality 
management 
The development, execution, and supervision of plans, policies, programs and 
practices that control, protect, deliver and enhance the value of data and 
information assets 280.  
Data quality 
monitoring 
The oversight and review of research processes, procedures, records, data 
reporting, appropriate conduct and ongoing evaluation.  
Education and 
training  
The knowledge or skills obtained or developed by a learning process and the 
further instruction and education to an agreed standard of proficiency.  
Information A collection of data or facts. 
Infrastructure Buildings, supplies, policies, procedures, information technology and other 
assets that support the human resources of an organisation.  
Methods and 
techniques  
Risk-based monitoring: A mixed method approach focused on the critical data 
points and processes that are identified to have the most risk via a targeted or 
triggered assessment191.  
Remote monitoring: Data monitored off-site, includes delivering documents via 
email, fax or snail mail to monitoring personnel to conduct source data 
verification191. 
Centralised monitoring: Data collected through an electronic data capture and 
queries identified by a monitor that may need further attention to alleviate 
problems191. 
Source data verification: Comparing source data (original or certified copy) 
documents to data recorded or entered into a case report form or electronic 
record or database191. 




A handbook of instructions designed to guide the research team to successfully 
carry out aspects of a research project according to the research protocol 281.  
Monitoring The act of overseeing the progress of a clinical trial, and of ensuring that it is 
conducted, recorded, and reported in accordance with the protocol, SOPs, GCP 
and the applicable regulatory requirement(s) 12. 
Policy  Communicates and documents an organisations overall intentions and direction 
with respect to quality. A written quality policy, and top-level management 
should demonstrate commitment to the quality policy by supporting the 
organisation's infrastructure with adequate resources. Off-line quality control 
 
 





activities, such as quality engineering, quality planning, and procedures 
applicable to each study, will be enhanced by this infrastructure and facilitate 
error prevention 34.  
Protocol A document that describes the objective(s), design, methodology, statistical 
considerations and organisation of a trial. The protocol usually gives the 
background and rationale for the trial, but these could be provided in other 
protocol referenced documents12. 
Quality assurance  All those planned and systematic actions that are established to ensure that the 
trial is performed, and the data are generated, documented (recorded), and 
reported I compliance with GCP and applicable regulatory requirements 12. 
Quality control The operational techniques and activities undertaken within the quality 
assurance system to verify that the requirements for quality of the trial-related 
activities have been fulfilled 12. 
Regulations/ 
standards  
International Organizations for Standardization (ISO): ISO 14155:2020282 – 
Clinical investigation of medical devices for human subjects – Good Clinical 
Practice: This International Standard specifies general requirements intended to; 
protect the rights, safety and well-being of human subjects, ensure the scientific 
conduct of the clinical investigation and the credibility of the clinical 
investigation results, define the responsibilities of the sponsor and principal 
investigator, and assist sponsors, investigators, ethics committees, regulatory 
authorities and other bodies involved in the conformity assessment of medical 
devices. 
International Conference of Harmonisation (ICH) - Good Clinical Practice 
(GCP) E6(R2) guideline12: An international ethical and scientific quality 
standard for designing, conducting, recording and reporting trials that involved 
the participation of human subjects.  
Regulatory authorities: Bodies having the power to regulate. Individual 
countries have different regulatory requirements and enforcement abilities, for 
example, the US FDA Guidelines for Monitoring of Clinical Investigations67,283, 
the EU Clinical Trial Directive154 and the EMA66,284 and the Australian 
Government’s National Statement on Ethical Conduct in Human Research16.  
Standard operating 
procedure (SOP) 
Detailed written instructions to achieve uniformity of a specific function. A 
written process of instructions necessary to carry out a policy or a way a task 
can be performed the same way each time12.  
 
7.4 Discussion  
The DQMF provides a single consolidated framework for monitoring data quality 
of clinical research studies with reference to key international documents. A 
systematic approach is essential to ensure high data quality and for confidence in 
data reuse and technological improvements for clinical research. Within the 
pharmaceutical/private industries278 and information sciences literature, data 
quality tools and procedures appear to be well developed with many frameworks 
acknowledging the multiple dimensions of data quality285-290. However, only a 
small body of clinical research has described data quality frameworks146,278,291-293, 
and even less has identified the appropriate methods to quantify the quality of 
 
 





data28 leading to different tools and procedures being implemented. In addition, 
although many data quality dimensions and attributes have been determined 
within the clinical and health literature, the majority provide no usable definitions. 
Public sharing of such knowledge is crucial in developing a standardised 
approach that can be implemented across the clinical and broader research 
community to improve the rigor of clinical research studies. 
The interest in standardisation within the clinical research community has grown 
in recent years and therefore, the DQMF considers data quality monitoring from a 
broad perspective. This generic framework brings together concepts from the 
scientific literature, government documents, and policies to illustrate links 
between concepts and their effect within and amongst the layers. This differs from 
previously published frameworks, which have focused on specific concepts in 
isolation, not considering the inter- and intra-relationships. This singular approach 
has caused confusion within clinical research. The utility of the DQMF is that it 
provides a single consolidated framework, which is adaptable according to study 
context and data availability. This research will benefit a long-term strategy and 
focus to fill the knowledge gap and reduce confusion around data quality 
monitoring in individual clinical research studies.  
In recent years there has been a movement away from paper-based to a digital and 
adaptive learning environment. It is, therefore, necessary to improve the methods 
and approach to collection, storage and sharing of clinical research data. 
Electronic solutions are relatively new to clinical research and require substantial 
change to existing procedures and professional training. Challenges arise in 
incorporating electronic data standards (Clinical Data Interchange Standards 
Consortium (CDISC) and Health Level Seven (HL7)) and the role they play in 
 
 





ensuring efficient and economic data sharing294. The DQMF provides guidance to 
clinical researchers on areas of study operations and ensuring high data quality 
throughout the research process. By utilising this generic framework, it is 
anticipated to minimise obstacles related to primary data quality and for its reuse. 
As the DQMF continues to evolve, our knowledge and understanding of the 
challenges from adapting to an electronic world will be addressed. This is vital to 
ensure the framework has future applicability.  
Many organisations do collect and analyse data for their own benefit to meet 
SOPs and ensure quality assurance and control. In terms of quality assurance and 
quality control, the SOP is one of the most generic, reusable and important 
documents within clinical research49. However, within academic research settings, 
published on-site audits that include quality assurance are less often reported. This 
may be due to unclear audit methods, a lack of time and funding, audits perceived 
as unnecessary and publishing SOPs not being seen as a ‘value added’ activity60-
62. Furthermore, there is general agreement among clinical study management 
groups that establishing reliable guidelines as a monitoring strategy (i.e. quality 
control) would need to be determined on a risk-adapted basis43. It is recognised 
that strategies need to be tailored for different types of studies to determine 
adequate and appropriate monitoring63,64. However, published methodology 
papers are warranted to promote routine auditing and monitoring within both 
academic and commercial research settings. Research grants seldom include 
funding for such programs65. Identifying all possible data discrepancies before 
they occur, with all best intentions, may not happen; therefore, a standardised 
framework will provide useful guidance. 
The DQMF has gathered current published information on the conduct of clinical 
 
 





study data management, albeit limited. The application of the framework is a vital 
implementation strategy to the overall improvement of the quality of clinical 
study data and the follow-on-effect of results, conclusions and 
recommendations61. The framework aims to guide clinical research study practice, 
which consist of complex, isolated and independent tools, procedures and 
frameworks. Of note, the DQMF places ‘policy’ above ‘regulations/standards’ 
which is reverse to the clinical research study quality system illustrated in Figure 
1-2 and is the focus of Figure 1-3. The DQMF has been developed for individual 
clinical research studies rather than an entire organisation and refers only to data 
quality monitoring295. As such, this framework does not include an extensive list 
of all regulatory requirements associated to data management and governance that 
clinical studies may be required to meet. However, the DQMF is a value-added 
function by providing oversight, guidance and management on the complex area 
of data quality monitoring. The holistic designed-orientated approach used in this 
research provides an easily integrated knowledge development tool for clinical 
research practice.  
 It should be highlighted that the proposed DQMF was developed from the 
published literature and draws on the personal experiences of the research team 
and participants. This may be considered a bias. A major limitation of the DQMF 
is that it is yet to be applied in practice. The researchers stress the importance of 
testing the framework within a broad spectrum of research studies to identify 
facilitators and barriers, thereby ensuring best practice for data quality. According 
to the design-science research guidelines, further evaluation, contribution, rigor, 
and communication are needed to develop a convincing argument for the utility of 
this framework. Before the DQMF can be recommended to be applied to practice, 
 
 





it is suggested that empirical research be conducted through a reactive Delphi 
study296 to validate and allow experts to reach a consensus of opinion on the 
illustration, terms, instructions for implementation and its use in practice, and 
overall, what constitutes data quality monitoring in clinical research.  
7.5 Conclusion  
A DQMF has been developed for clinical research studies. The utility of this 
framework is to reduce the confusion around data quality monitoring whilst 
allowing for adaptations according to study context and data availability. The 
framework will guide new studies or identify procedures in existing studies to 
improve data quality monitoring. The framework demonstrates how data quality 
monitoring develops over the life cycle of a clinical study and how knowledge 
management may guide new approaches to research. Overall, the DQMF will aid 
in the development of a long-term strategy to increase efficacy for clinical 



















8.1 Thesis summary  
Clinical research studies are important for extending medical knowledge and 
patient care. Thus, high quality evidence-based medicine is dependent on 
identifying and preventing data errors in clinical research via implementing data 
monitoring procedures. There has been very limited research investigating which 
data quality monitoring procedures are suitable within all clinical study contexts, 
particularly in observational studies and non-drug intervention trials. Furthermore, 
there is a need for standardised monitoring frameworks and guidance which are 
accessible and relevant to all clinical studies whilst highlighting the ongoing 
importance of education and training.  
The central aim of the thesis was to explore and understand the varying data 
quality monitoring procedures used in Australian clinical research studies and to 
develop a DQMF. Currently, researchers pragmatically implement ad-hoc 
monitoring procedures. This thesis has provided a novel “fit-for-use” framework 
which includes clear definitions and concepts to reduce the challenges 
surrounding data quality monitoring. The findings of this thesis are focused 
towards observational studies, non-drug and/or small single-site intervention trials 
that have limited resources and are often using Open Source software solutions to 
monitor data quality. As a result of this thesis, researchers will be more informed 
about how other studies monitor data quality and the facilitators and barriers 
associated with such procedures. Clinical researchers identified numerous 
challenges and complexities associated with implementing data monitoring 
procedures. The most notable was a lack of guidance, education and training, 
which is particularly relevant given the rapid advancements in technology and 
complexity of clinical studies.  
 
 





The results of this thesis contribute to the literature the importance of minimising 
error throughout a study and providing a data quality framework to work towards. 
The findings reveal that it is necessary to provide guidance to all research 
contexts to guarantee similar data quality within Australia and internationally. 
However, this thesis has shown a lack of understanding by some Australian 
researchers on how to implement monitoring procedures to meet regulatory 
requirements. Despite regulatory agencies endorsing approaches, which represent 
an opportunity to be more effective and efficient, challenges exist with respect to 
suitable local processes. Although, it is acknowledged that a “one-size-fits-all” 
approach to monitoring is not appropriate. This thesis has implications for not 
only clinical researchers, but also regulatory agencies which provide guidance and 
oversight on responsible research practices and promote research integrity.   
8.2 Core thesis findings  
This thesis suggests that data quality monitoring procedures implemented by 
clinical research studies are multifaceted. Using the DIKW framework to guide 
the research, this thesis has ensured the existing knowledge base relating to data 
quality monitoring in an Australian clinical research setting has been thoroughly 
examined.  
To explore the variability of data quality monitoring procedures in clinical 
research studies, this thesis began with a systematic review and meta-analysis of 
primary research studies (Chapter 3, Study 1). The review found that a wide 
variety of data quality monitoring procedures exist and no “one-size-fits-all” 
approach could be determined. This was the first SR and meta-analysis to 
summarise the findings of different data quality monitoring procedures. There has 
 
 





been a slow increase in the use of RBM and centralised monitoring since their 
endorsement in the 2016 GCP E6(R2) guideline. The majority of included articles 
were associated with large multi-site intervention trials, suggesting the GCP 
E6(R2) guideline may be clearer and more suited towards such trials. Analysis 
from this thesis found that centralised monitoring was conducted more frequently 
over a 365 person-day period when compared to other monitoring methods.  
To gather information about the current data quality tools and procedures that are 
used within Australian clinical trial sites, a feasibility study of clinical trial staff 
members was completed using an online survey (Chapter 4, Study 2). This 
research was novel as no studies had looked at data quality monitoring or 
management in an Australian setting. The results highlighted the heterogeneity of 
data quality monitoring and management procedures and confirmed that there are 
challenges in developing and maintaining a data management system as reported 
by European clinical research centres45, American clinical research sponsors55 and 
now from this survey of Australian clinical trial sites. Among the survey 
respondents, only 50% of the trial sites had a data management plan in place. The 
feasibility study revealed that clinical trial sites were implementing ad-hoc data 
quality procedures pragmatically.   
Due to individual and specialised monitoring procedures being implemented at 
Australian clinical trial sites, it was necessary to further explore the procedures 
for ensuring data quality nationally (Chapter 5, Study 3a). The national survey 
presented a unique opportunity to provide details of monitoring procedures in 
both intervention trials and observational studies. The findings revealed that 
clinical studies implemented various procedures and not all studies followed 
guidelines for data monitoring. In particular, small single-site academic studies 
 
 





were applying SDV which is no longer recommended by regulatory agencies. 
These findings suggest that there is a lack of regulatory guidance and accessible 
information for clinical researchers conducting small single-site studies. 
Additionally, implementing new monitoring procedures relies heavily on 
technologies that small single-site studies were yet to adopt. Regression analysis 
showed that there was a borderline association between a definition for protocol 
deviation/violation and intervention trials suggesting that clinical studies were 
more likely to implement the required procedures when they were provided with 
additional guidance and resources. 
It is important to understand the Australian clinical researcher experience with 
data quality monitoring. To do so, clinical researchers who had completed the 
national survey were invited to participate in a semi-structured interview (Chapter 
6, Study 3b). The results suggest that Australian trials testing new treatment 
options are implementing a variety of monitoring procedures tailored to their 
study context. Participants experienced challenges in meeting regulatory 
requirements, utilising IT and fostering working relationships. Barriers to 
implementation included meeting the demands for excessive monitoring, a lack of 
funding and inadequate infrastructure; felt by independent, non-commercial and 
academic small scale researchers. Similar barriers have been reported in a 
systematic review and internal communication of European clinical 
researchers262. In comparison, good working relationships between staff had a 
positive impact on data quality yet it was common for staff working on clinical 
studies to lack guidance, education and training, in relation to relevant data 
quality monitoring procedures.  
Strategies and interventions have been developed to reduce the many challenges 
 
 





faced by clinical research studies, including careful design of CRFs, SOPs, 
personnel training and education, and data monitoring. Thus, the final study in 
this thesis utilised the findings of the previous studies to generate a “fit-for-use” 
DQMF for clinical research (Chapter 7, Study 4). This study provided a single 
consolidated framework for monitoring data quality of individual clinical research 
studies with reference to key documents. Each layer of the framework contains 
important procedures, terms and concepts to be considered when designing and 
conducting a clinical research study. The importance of training and education 
spans all layers of the DQMF. This study revealed that standardised 
terminologies, definitions and dialogue are crucial to the success of the DQMF. 
Importantly, application of the DQMF to various clinical research studies for real 
world use is crucial to refining and evaluating the generic framework. The utility 
of this DQMF aims to reduce the confusion around data quality monitoring whilst 
allowing for adaptations according to study context and data availability. 
Although education and training in data quality monitoring has the potential to 
provide immense benefit to researchers conducting clinical studies, little research 
has been conducted in this area. Together the respondents and participants of 
Chapters 4, 5 and 6 had a common understanding that there are a lack of 
guidance, formal education and training courses (e.g. GCP training) relevant to 
non-drug intervention trials and observational studies. Even though the current 
GCP training is limited in its applicability the importance of education and 
training was exigent. As a result, the findings presented in the thematic map of 
Chapter 6 and the DQMF in Chapter 7 suggest that education and training are 
pivotal to data quality and research integrity, with a knock-on effect of ensuring 
the participant safety and well-being.  
 
 





As mentioned previously, the theoretical framework underpinning this thesis is 
the DIKW model which has guided the overall structure of this thesis. Chapters 3, 
4 and 5 have contributed to the quantitative data and Chapter 6 has provided a 
unique rich view of the qualitative data. Together these chapters have expanded 
on the information available about the current practices, barriers, and potential 
solutions to data monitoring in Australian clinical research settings. Although 
Chapters 3 to 6 represent unique and significant contributions, they are a snapshot 
in time during a period of rapid advancement in national and international 
regulatory requirements, research urgency (in the age of COVID-19) and 
expanding use of mobile and cloud-based IT technologies. Therefore, over time 
the studies in Chapters 3 to 6 will no longer reflect current practice. The DQMF 
(Chapter 7) was drawn from the learnings of Chapters 3 to 6 which should have a 
long-lasting and impactful contribution to the literature. The framework is an 
entirely new contribution of knowledge as currently there is no comparable 
framework in the clinical monitoring and management literature.  
8.3 Limitations of this thesis. 
The limitations of each study have been reported in their respective chapters. The 
overall limitations of the thesis will be discussed here. The first is that the studies 
were conducted during the release of the updated ICH GCP guideline which came 
into effect on the 10th November 2016. As such the international guidelines now 
recommend a new risk-based approach to monitoring that were not mentioned in 
the previous 1996 guideline. The present thesis may not have explored the full 
impact of the updated GCP E6(R2) guideline on clinical studies, as time is needed 
to allow for the changes to be implemented. Moreover, Australia to date is not 
listed as a country to have entirely implemented the GCP E6(R2) guideline. In 
 
 





Australia, if requirements specified in the National Statement differ from those 
specified in the guideline for GCP, the National Statement takes precedence. The 
NHMRC published the first guidance document on risk-based management and 
monitoring in 2018. It is unclear what the time period for the adoption of new 
monitoring approaches will be in Australian clinical studies.  
The generalisation of findings from this thesis may be limited due to the context 
which it was implemented. The participants were Australian clinical researchers 
listed on an Australian government website or registry. Therefore, the present 
results about monitoring procedures may not be representative to the broader 
research community. In addition, the monitoring procedures of clinical studies led 
by industry or contract research organisations may differ. The results lacked detail 
from researchers working on large multi-national, multi-site and/or multi-centre 
studies, likely due to that these studies are being undertaken in multiple countries, 
and registered with another registry, for example ClinicalTrials.gov in the US.  
The results of studies 2, 3a and 3b are subject to potential bias in a positive 
direction as the study participants who took part in these studies may be more 
knowledgeable about data quality monitoring procedures and the recommended 
regulatory requirements. In addition, large organisations that conduct clinical 
studies may consider their data quality procedures confidential, and thus they may 
have chosen not to participate. This led to the uncertainty about whether the full 
picture about data quality monitoring in clinical studies in Australian was 
captured.  
The importance of industry wide definitions and methods are essential to enable 
strategic management and evaluate quality information. Without standardisation, 
 
 





Principal Investigators of clinical research are left with inefficient data quality 
management procedures. As this thesis was not designed to assess which data 
management or monitoring tool or procedure is most effective, but rather to 
gather information about tools and procedures used in Australian clinical trials. 
Further research is required to fully examine the optimal procedures and available 
resources for monitoring data quality to assure and control data integrity in all 
clinical research studies.  
8.4 Future research and recommendations 
Whilst this thesis has developed a novel “fit-for-use” DQMF for clinical research 
studies, several recommendations have been developed. The present thesis has 
shed light on the problematic nature of a “one-size-fits-all” approach to data 
quality monitoring in clinical research studies. Future research should examine 
the most feasible, time and resource efficient data quality monitoring procedures 
and associated training for clinical researchers conducting observational studies, 
non-drug and/or small single-site intervention trials. Importantly, this guidance 
needs to be published in an open-source environment and endorsed by the 
regulatory agencies to ensure it is taken up by all Australian researchers. 
Additionally, longitudinal studies are required to investigate if after implementing 
more guidance on quality management systems that the error rates and 
researchers’ education are improved.  
The evidence of this thesis enables us to hypothesise the reasons and challenges 
as to why observational studies, non-drug and/or small single-site intervention 
trials are not using current guidance and technology for data monitoring. We 
speculate that the major challenges are limited resources, facilities, management 
 
 





and funding. As suggested by Eisenstein et al.150 the financial cost of monitoring 
site data is estimated to represent 25-30% of the total study costs. This evaluation 
is based on two randomised phase III multinational drug trials which called for 
>14000 patients. A different evaluation for observational studies, non-drug and/or 
small single-site intervention trials is required and may result in different 
percentage costs. One consideration is for clinical studies to use freely available 
software or web-based applications for data capture and management. The two 
primary data management tools used by the national survey respondents were 
REDCap214  and OpenClinica (www.OpenClinica.com). Both of these tools 
provide easy to use electronic data capture (EDC) systems with built-in data 
validation (logic, range and consistency checks), data tracking (audit trails), 
automated export procedures for statistical analysis and the availability to import 
data from external sources. There are multiple alternative EDC systems that are 
not named here. However, clinical researchers need to consider the additional 
costs that the freely available open-source software may incur for staff training, 
maintenance, support, hardware and security to operate the system. It is 
recommended that researchers evaluate the available software options and 
compare them with their intended goals and requirements to make an informed 
decision. Research into the use of technology to improve study procedures needs 
more empirical evidence to guide clinical researcher choice in overcoming 
challenges related to data collection, monitoring and upholding quality. 
From the findings of this thesis clinical studies need to develop a data 
management plan, a risk and safety management plan and a monitoring plan as 
previous research suggests that data management plans are not developed in all 
cases45,51,191. The monitoring plan should explicitly define the approach for data 
 
 





definition, collection, processing and handling, and clearly describe the education 
and training related to data quality that staff undertake. Sharing these plans 
between observational studies, non-drug and/or small single-site intervention 
trials will enable knowledge sharing between clinical study sites and provide 
additional guidance on any challenges or reasons why procedures worked or did 
not work. This could be supported by an online platform which provides generic 
and baseline templates which are available for download by clinical researchers, 
to share and integrate procedures efficiently between organisations and groups. 
To provide greater motivation to developing data management plans as core to 
clinical research, future research should consider the use of incentives (e.g. career 
development and training) as a strategy to improve staff self-awareness and 
engagement in their commitment to maintaining data quality261.  
Clinical researchers interviewed in this thesis highlighted the importance of 
education and training. The results of the SR and meta-analysis also confirmed 
the need for further education, training, development and reflection to understand 
and implement the necessary data quality monitoring procedures. Recent evidence 
suggested that GCP training provided only a small amount of knowledge and was 
primarily for new employees or as necessary due to regulatory compliance297. 
Furthermore, a multisite evaluation study piloted a new online training course for 
social and behavioural clinical research professionals to overcome the idea that 
the GCP training is only geared towards studies that test drugs, devices and 
biologics298. The findings suggest that the course provided a good overview of 
GCP related to social and behavioural clinical trials. Future research should 
extend the findings of this pilot study to include observational studies and explore 
the facilitators and barriers of clinical research professionals to guide the 
 
 





development of practical GCP training modules for such studies. Until more 
suitable education and training course are developed it is recommended that 
clinical research professionals of all clinical studies complete the GCP education 
and training as it remains the international “gold standard”.  
In particular, a research question that arises from this thesis is: ‘In clinical 
research studies does implementing a data management, monitoring and quality 
checklist improve the reporting and quality of clinical research studies?’ The 
checklist would offer an evidence-based, minimum set of recommendations to 
overall improve the quality of research involving human participants used in 
healthcare decision-making. This research program would aim to translate some 
of the findings from this thesis into practice, to identify potential barriers that may 
make knowledge translational problematic and to design the solution to address 
the challenges.  
8.5 Conclusion 
In conclusion, this thesis has provided a novel DQMF to aid in the development 
of a long-term strategy to increase efficacy for clinical research data quality 
monitoring. This thesis acknowledges that a “one-size-fits-all” approach to 
monitoring is not appropriate. The evidence provided suggests that not all 
Australian clinical research studies follow the GCP guideline or National 
Statement. This research is valuable as it supports a growing body of evidence 
emphasising the challenges faced by clinical researchers to meet international and 
national regulatory requirements. Despite regulatory agencies endorsing new 
monitoring approaches, which represent an opportunity for effective and efficient 
monitoring, the application of the current guidelines is challenging for some 
 
 





researchers due to the requirements of technology. This was apparent as clinical 
research studies implemented a variety of data quality monitoring procedures. 
Guidance should not be limited to suit multi-site drug intervention trials only. An 
emphasis needs to be placed on including observational studies, non-drug and 
small single-site intervention trials. Furthermore, data monitoring training and 
education needs to be accessible and applicable to all clinical study types, large 
and small. The result of this thesis reinforces the need for researchers to consider 
data quality monitoring at the early stage of study design and data definition right 
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Appendix A: Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist  
Table 1: PRISMA checklist 
Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  72 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study 
eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; 
limitations; conclusions and implications of key findings; systematic review registration number.  
n/a 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  73-74 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
74 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, 
provide registration information including registration number.  
n/a 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as criteria for eligibility, giving rationale.  
74-75 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to 
identify additional studies) in the search and date last searched.  
74 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it 
could be repeated.  
74-75 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if 
applicable, included in the meta-analysis).  
75-76 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and 












Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made.  
76 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether 
this was done at the study or outcome level), and how this information is to be used in any data 
synthesis.  
78 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  n/a 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (e.g., I2) for each meta-analysis.  
77-78 
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, 
selective reporting within studies).  
n/a 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if 
done, indicating which were pre-specified.  
77-78 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram.  
81 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up 
period) and provide the citations.  
82-89 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  107 and 
Appendix I 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for 
each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
102-105 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  104-105 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  n/a 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see 
Item 16]).  




DISCUSSION   
 
 








Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their 
relevance to key groups (e.g., healthcare providers, users, and policy makers).  
107-110 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete 
retrieval of identified research, reporting bias).  
111 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future 
research.  
112 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of 
funders for the systematic review.  
n/a 














Appendix B: Source data verification auditing methods  
Table 1: Summary of excluded articles assessing the effects of SDV auditing methods on data quality in clinical research studies in 
alphabetical order (n=13) 
Author, year 





























    
Ayoub et al. 
2007 
   F 
437 
(67) 
12    
A two-day training 
program, continuous on-
site supervision, email 
support and periodic online 
training provided adequate 
data management.  
Datta et al. 
2007 
   F 
100 
(13) 
14    
Accuracy and 
completeness calculated for 
registry. Inaccuracies due 
to changes in data 
recording. 
Favalli et al. 
2000 
   S 11 (28) 
All key 
data of the 
protocol 
   
Mean incorrect data was 
7%, though varied between 
centres. This was largely 
due to incorrect 
transcription.  
Gaies et al 
2016 
   
ICU 
encounters 
434** ~140    
Data submitted to the 
registry appeared to be 
complete, accurate and 
timely.   
Giganti et al. 
2019 
   F 250 (1) 21    
Discrepancy rate was 
17.1%. Recommendations 
by audit team led to re-
 
 








entry of some variables at 
sites. SDV process can 
improve data quality.  
Guan et al. 
2016 
   F 38 (10) All items    
A systematic approach is 
proposed to evaluate and 
improve dietary data 
quality. 
Johnson et al. 
2010 
   P 42 (6) NR    
100 errors/10,000 fields. 
Discrepancies listed, 
discussed at meetings, 
reviewed by managers and 
assigned a root cause. Data 




   F 
108,599 
(100) 
All items    
Data queries calculate per 
CRF page. Average 1 data 
query every 3 CRF pages 
Lim et al. 2018    F 
12,569 
(10) 
16    
SDV conducted through 
visual verification and 





Rahbar et al. 
2013 
   F 115 (2) 
30 F:11 
 
85 F: All 
   
Error rates calculated for 
four years. Between 2008-
2010 error decreased from 
4.8% to 2.2%.  
Steigler et al. 
2000 
   P 57** 3    
Missing values and non-
compliance were under 
5%. 
Thoburn et al. 
2007 
   F 
10010 
(24) 
13    
Data accuracy and case 
completeness for four years 
1998-2001 was 95% and 
97% respectively. Audit 












CRF: Case report form; F: Files; ICU: Intensive Care Unit; NR: Not recorded; P: participants; Site: sites; SDV: Source data verification.  
Data, n(%): Refers to the number (n) of sites, files, participants or ICU encounters monitored compared to the total sites, files, participants or ICU encounters 
available to monitor. For example, 5(25) is five files included in data monitoring from a total of 20 files, therefore 25%.  
a 250 records were reviewed from 316 patient records (79%) selected using stratified random sampling. A total of 19331 records were available in the pre-audit 
dataset.  
* Monitored number (n) of sites, files or participants not available in publication. Only a percentage provided. 





   S 10 (10)  
4 
indicators 
   
Completeness of forms was 
generally high and 
verification ratios indicated 
high reporting consistency 
at the first reporting level. 
Missing data was minimal.  
 
 







Appendix C: Study design(s) of associated primary studies  
Table 1: Overview of the articles reporting quantitative data and the study design 
of their associated primary studies. (n=45)* 
Author, year 
Study design(s) of associated primary study(s) 
 
Aceituno et al. 2017 1 observational prospective cohort study 
Andersen et al. 2015 3 randomised double-blind placebo-controlled trials 
Andrianopoulos et al. 2011 2 observational prospective cohort studies 
Bagniewska et al. 1986 1 Randomised double-blind placebo-controlled trial  
Bakobaki et al. 2012 1 randomised double-blind placebo-controlled trial  
Barrier et al. 1992 NRa 
Brosteanu et al. 2017 11 clinical trials 
6 randomised, open-label, two-arm parallel-group, superiority 
trials 
3 randomised, double-blind, placebo-controlled, two-arm parallel-
group, superiority trials 
2 randomised, open-label, two-arm parallel-group, non-inferiority 
trial 
Caloto et al. 2001 1 epidemiological study 
Castelnuovo et al. 2012 1 observational retrospective cohort studyb 
Dennis et al. 2019 1 epidemiological study 
Diani et al. 2017 NRc 
Duda et al. 2012 1 observational prospective cohort study 
Edwards et al. 2014 1 Pragmatic randomised, placebo-controlled trial 
Embleton-Thirsk et al. 2019 1 randomised double-blind, placebo-controlled trial  
Engen et al. 2020 1 open-label, randomised trial  
Fougerou-Leurent et al. 2019 6 clinical trials  
3 randomised double-blind placebo-controlled trials 
1 randomised single-blind controlled trial 
1 RCT 
1 non comparative pilot study 
Fox et al. 2017 1 ongoing non-intervention registry 
Guthrie et al. 2012  1 cluster RCT 
Higa et al. 2020 1 pilot study: a double-blind, placebo-controlled, parallel-group, 
comparative study and a longitudinal study 
Hossman et al. 2017 2 clinical trials 
1 RCT  
1 single arm trial 
Houston et al. 2015 1 randomised single blinded controlled trial 
Kirkwood et al. 2013 3 clinical trials: 
2 randomised double-blind controlled trials 
1 unblinded trial 
Krzych et al. 2011 1 two-arm randomised trial 
Liddy et al. 2011 1 cluster-randomised controlled trial using a step-wedged design  
Lindblad et al. 2014  NRd 
Mealer et al. 2013  NRe 
Mitchel at al. 2014 NRf 
Mphatswe et al. 2012 NRg 
Nahm et al. 2008 4 RCTs 
Pogue et al. 2013 1 RCT 
Pradhan et al. 1994 1 RCT 
Rahbar et al. 2018 1 longitudinal prospective cohort study 
Rao et al. 2016 1 observational prospective cohort study 
Reisch et al. 2003 1 case-control study 
Ruiz et al. 2016 1 observational prospective cohort study 
Soran et al. 2006  4 RCTs 
Stenning et al. 2018 3 RCTs 
 
 








Study design(s) of associated primary study(s) 
 
Timmermans et al. 2016 1 factorial RCT 
Tolmie et al. 2011 1 randomised double-blind placebo-controlled trials 
Tuder Smith et al. 2012 1 parallel, open-label, multicentre, phase III, superiority RCT 
Van den Broeck et al. 2007 1 randomized, double blind controlled trial 
Verhulst et al. 2012 1 observational prospective cohort study 
Verweij et al. 1997 1 RCT 
Von Niederhausern et al. 2017 43 studies 
34 intervention trials 
9 observational studies 
Weiss et al. 1993 NRh 
NR: Not recorded; RCT: Randomised controlled trial.   
a Monitoring procedure(s) applied to one hospital database.  
b Monitoring procedure(s) applied to the study for routine care and not part of another study. 
However, due to the completeness and richness of the data the client population was 
retrospectively registered as a cohort study.  
c Monitoring procedure(s) applied to two cardiac lead studies.  
d Monitoring procedure(s) applied to four new drug application studies. 
e Monitoring procedure(s) applied to one clinical trial from two clinical trial networks.  
f Monitoring procedure(s) applied to one clinical trial.  
g Monitoring procedure(s) applied to one district health information system.  
h Monitoring procedure(s) applied to large clinical trials from a research cooperative group.  
* Excluded 11 articles describing 11 studies which are from eight cross-sectional surveys, two 
qualitative studies and one mixed-method study which included a quantitative survey. Such 
studies were excluded due to not prospectively or retrospectively implementing a monitoring 












Appendix D: Monitoring procedures assessed for performance/value  
Table 1: Overview of the monitoring procedures assessed for performance and/or 
value in order of publication date (n=16).  
Author, year Monitoring procedure(s) assessed  
Nahm et al. 2008 SDV 
Bakobaki et al. 2012 OSM and CM  
Tuder Smith et al. 2012 SDV and CM 
Kirkwood et al. 2013 CSM  
Mealer et al. 2013  On-site SDV only and remote SDV + on-site SDV  
Pogue et al. 2013 CSM led to OSM  
Lindblad et al. 2014  OSM and CM 
Andersen et al. 2015 Complete 100% SDV and Partial SDVa 
Brosteanu et al. 2017 Extensive OSM and RBM 
Diani et al. 2017 RBM 
Fox et al. 2017 Complete 100% SDV, partial SDVa and risk-based 
site selected SDV 
Stenning et al. 2018 Triggered and targeted RBM 
Embleton-Thirsk et al. 
2019 
SDV and CM 
Fougerou-Leurent et al. 
2019 
Full 100% SDV and targeted SDVb  
Engen et al. 2020 OSM, local + CM and local + CM 
Higa et al. 2020 RBM 
CM: Centralised monitoring; CSM: Centralised statistical monitoring; OSM: On-site monitoring; 
RBM: Risk-based monitoring; SDV: Source data verification.  
a Partial SDV: only critical variables. 














Appendix E: Data quality monitoring procedures and additional checks 
Table 1: Summary of included articles assessing the impact of on-site monitoring (specifying source data verification) as a 
monitoring procedure on data quality in clinical research studies in alphabetical order (n=21). 





















to CRF or 
eCRF 
        
Andersen et al. 
(2015) 










100% cSDV on 25% 
subjects in addition to the 
first 10 subjects/site and 





criteria, informed consent 
form(s), drug 
accountability, SAEs and 
first AE.  
 
To investigate the impact 
of SDV, 100% SDV was 
completed independent of 
previous monitoring.  
Discrepancies 
recorded and 
registered. Does not 
support 100% SDV to 
provide meaningful 
improvement in data 
accuracy. 
Andrianopoulos 
et al. (2011) 
















validated and amended 




patient or procedural 





Audit 2:  
Annually 




 Y  P Random  25 (5) NR NR 19150 Baseline and early-
treatment visit data was 
re-entered. All data 
compared fields from 
coordinating centre and 
clinic data entry. 
Miskeys defined as 
any difference 
between clinical entry 
and data form. 
Miskey rates/1000 
data fields by form 
 
 








generated and compared 
with data entry forms  
and by clinic.  
Barrier et al. 
1992 





Twice NR NR Audit 1 (database): 
Actual record (Clinical 
notes) compared to ideal 
record (derived from 
clinical notes). 
 
Audit 2 (Hospital 
activity): Ideal record 
compared to hospital 
admission. 
Data quality = 
completeness x accuracy. 
Monthly meetings  
Castelnuovo et 
al. 2012 
Y   P Pre: randomly  Pre: 100** Twice  4 NR Pre: Retrospective 
comparison of paper-
based notes and 
standardised forms to 
database. 
Errors classified as 
missing and incorrect 
information. 
Calculated total error 
rate. 







comparison of clinical 
notes in EMR to database. 
Duda et al. 
2012 
Y   F Random  Audit 1: 
184 (86) 
 





Audit 1: As 
many forms, 
a site could 
locate 
 






Completed audit forms 
and audit results were 
categorised using 
standardised audit codes 
from the EORTC. 
Classification performed 
by two reviewers. 
Disagreement resolved by 
joint review.  
Reports to data 
coordinating centre. 
Findings allowed for 
recommendations for 
each site.  
Embleton-
Thirsk et al. 
2019 











Phase 1:  
11 key data  
 
Phase 2:  












Phase 1: paper CRFs to 
patient notes.  
Phase 2: Scanned copy of 
paper form to database 
 
SDV and quality control 
immaterial changes to the 
key outcome measures of 
the trial and its 
interpretation. A 0.5% 
error threshold was set. 
Once all queries were 
resolved and closed 
from phase 1, phase 2 
was completed All 












Leurent et al. 
2019 
 Y  P Selected 
patients 






















implement full SDV 
(100%) and targeted SDV 
(only key data) from 6 out 
18 (33%) randomly 






SOPs. Queries were 
sent to study 
coordinators.  
Fox et al. 2017   Y S Phase 1: NA 
 









Phase 3: 80% 
sites targeted 












Phase 3:  














Phase 1: All 
 
 




Phase 3:  








Phase 3:  
92507 
 
Several phases of 
monitoring.  
 
Phase 1: Complete SDV 
(100%)  
Participants n=15** 
Result: labour intensive 
and time consuming.  
 
Phase 2: Complete SDV 
and partial SDV 
Participants (total) n= 
1012** 
Participants cSDV: 110 
(10)  
Participants pSDV: 902 
(90) 
Result: Support pSDV of 
critical variables.  
 




Data quality score (13-
item) assigned to each site 
depending on ‘out of 
control’ critical variables. 
Sites ranked and worst 
performing selected for 
OSM.  
 
Result: Data quality score 
was most effective to 
identify sites with poor 
data quality (based on 
pSDV).  
Data quality issues 
identified and 
reported to all sites. 
At regular intervals, 
results reported to the 
steering and audit 












Hossman et al. 
2017 
 Y  F NA 14 620 
(100) 
NR NR NR An independent 
monitoring team 
conducted SDV. ~3855 
queries from 171 784 
CRF pages  
Queries were created 
and resolved. Many 
queries were not 
formally documented. 
Houston et al. 
2015 
Y   F Random Audit 1: 21 
(10) 
 
Audit 2: 21 
(10) 





NR  1505 QA rule developed: if 
>5% data variables were 
incorrect a second 10% 
random sample 
(excluding files already 
sampled) would be 




Data points categorised 
using standard audit 
codes from EORTC. 
Error increased by 19% 
from audit 1 to 2.  
Recommendation for 
CQI were made to 
ensure future data 
integrity during the 
trial.  
Mealer et al. 
2013 














NR  5954** Arm A: Remote SDV 2-4 
weeks prior to a 
scheduled on-site SDV 
Arm B: traditional on-site 
SDV only 
 
Remote SDV validated 
data elements captured on 
CRFs submitted to the 
coordinating centre. Same 
verification protocols 
used for remote and on-
site SDV.  
 
99% of data values were 
successfully monitoring 
remotely.  
Remote monitors had 
telephone access to 
all local coordinators 
that were available 
during on-site visits. 
When data could not 
be verified remotely 
on-site SDV was 
performed. 
Mphatswe et al. 
2012 




6 NR The degree of agreement 
between the data elements 
for a clinic that appeared 
in the database were 
compared to data 
obtained from individual 
facility registries. 
Completeness and 
accuracy of data 
Study team provided 
individual facilities 
with feedback on the 
quality of the data  
 
 







improved from 1st to 3rd 
audit.  
Nahm et al. 
2008 













Audit plan incorporated 
both statistically 
calculated sample size 
used in industry CRF-to-
database audits and 
National Cancer 
Institute’s method of 
auditing cases source-to-
database at each site. Data 
files were audited when 
expected enrolment 
reached 20-30% and 70-
80%.  
Corrective action 
process and uses 
reports to 
communicate and 
monitor audit results. 
Rahbar et al. 
2018 
Y   F Random *(5-10) NR Various 
types of 
data 
190127 Calculated error rate on 
17 CRFs  
PI of the study 
accepted 
responsibility for data 
entry and QA.  
Ruiz et al. 2016 Y   F Random  NR Monthly NR 30 million Study monitor checks the 
consistency  
Study monitor 
identifies the origin 
of the discrepancy, 
i.e. data entry or data 
transfer (systematic 
error).  
Tuder Smith et 
al. 2012 




NR Retrospective monitoring 
plan to perform 100% 
SDV to verify that data 
items were consistent, 
complete and correct. 
NR 
Van den Broeck 
et al. 2007 





NR Error rate <1% set as 
criterion of successful 
data handling.  
Error calculated and 
reported.  
Verhulst et al. 
2012 










Two sites were included 
in both SDV phases. SDV 





Outcomes from SDV 
activities will support 
decisions related to 
future training and 
data entry support.  
 
 







Abbreviations: AE, Adverse events; cSDV: complete source data verification; CRF: Case report form; CQI: Continuous quality improvement; eCRF: Electronic case report form; EMR: Electronic 
medical record; EORTC: European Organization for Research and Treatment of Cancer; F: files; NR: Not recorded; OSM: On-site monitoring; P: participants; pSDV: partial source data verification; 
PI: Principal investigator; QA: Quality assurance; Site: sites; SAE: Series adverse events; SDV: Source data verification; SOP: Standard operating procedure; Y: Yes.  
Data, n(%): Refers to the number (n) of sites, files or participants monitored compared to the total sites, files or participants available to monitor. For example, 5(25) is five files included in data 
monitoring from a total of 20 files, therefore 25%.  
* Monitored number (n) of sites, files or participants not available in publication. Only a percentage provided. 
** Total number of sites, files or participants not available in publication, therefore unable to calculate percentage. 
a Of the 2256 subjects included in the post-database lock SDV, n=666 (26.1%) had also complete 100% SDV while on study. The level of complete 100% SDV was comparable among the three RCTs.  
b Of the 121 hospital admissions in Audit 2, n=71 had been included in Audit 1. 
  
Verweij et al. 
1997 




to only one 
patient entered 
in trial.  












SDV 1: Records of 78 
patients checked 
 
SDV 2: Records of 51 
patients checked  
 
Results improved from 
SDV 1 to 2.  
 
Data coded: correct, 
incorrect, missing on CRF 
NR 
Weiss et al. 
1993 







3787** Every 3 
years 
NR NR Four audit cycles of 25-40 
patient records/site. On-
site records were 
compared to the central 
data centre for accuracy 
and completeness.  
 
Deviations are evaluated 
on scales: trivial, minor 
and major.  
A written report is 
prepared by the team 
leader that counts 
deviations. If 
‘unsatisfactory’ a 
reaudit in 6-12 
months. If still 
unsatisfactory action 












Table 2: Summary of included articles assessing the impact of on-site monitoring (not mentioning or providing details on SDV) as a 







Frequency Variables, n Monitoring activities/tasks performed Reporting structure 
Aceituno et 
al. (2017) 
Ia NA *(100) 2-3 times per year NR All study components monitored in person by PI or project managers. Monthly reports 
Bakobaki et 
al. 2012 
F Purposively 104** Before, during and 
after trial   
NR 324 OSM visits checking consent forms, management and 
accountability systems were functioning and performed SDVb. 
Monitoring findings categorised as critical, major or other/minor into 
site reports. Monitoring reports selected for review from two (50%) 
sites for retrospective review. 
Review of site reports made 
quarterly to a Programme 
Management Board 




P Stratified  755(100) As necessary (or at 
least annually) 
NR OSM comprised checking trial subjects, informed consent documents 
and complete SDVb of all patients 
Monitoring reports.  
Caloto et al. 
2001 




Audit A: Before and 
after trial, and at 3 
month intervals. 
Total of 10 visits. 
124 Audit A: Head researchers visited all facilities Audit results recorded in 
logbooks and ad hoc results 
reported to project 
management team. Reports 






Audit B: 3-month 
intervals 
Audit B: Coordinating centre used the same QC questionnaire for all 
visits, with detailed attention to all aspects to be monitored 












Tape: Site nutritionist evaluated at least one tape/week providing a 
score. When a low score was given two tapes/week were reviewed by 
site nutritionist until corrected. Additionally, country nutritionist 
randomly selected 10% of tapes to evaluate site nutritionist. When the 
volume of tapes was not feasible to review, on-the-spot feedback was 
provided by site or country nutritionist.  







CodingC: NR  CodingC: 
NR 
 
CodingC: Site nutritionist check 100% recalls CodingC and CodingR: 
Immediate feedback to 
interviewer and forwarded 
updated coded recalls to 





CodingR: Weekly CodingR: 
NA  






Data: NR Data: 
*(~10) Data and sites: NR. 
Triggered by CM 
and CSM results 
NR 
Data: Planned to carry out OSM.  Reporting to trial 






Sites: Highest recruiting sites were subject to OSM, irrespective of any 
CM findings. OSM included verifying source data.  
Engen et al. 
2020 
S All sites 
randomised 
to OSM 
99 (51%) Annually NR Each OSM visit focused on participant safety, regulatory and protocol 
requirements, data accuracy, and concluding with an on-site review 
with site staff. 16,599 person hours were spent conducting OSM. 
Travel budget for OSM and the time spent conducting OSM, estimated 
OSM to cost US$2 million. Clinical events were reported >6 months 
form occurrence when conducting OSM.  
Standardised reports 
describing findings and any 
corrective actions required 
of the site.  
 
 







CM: Centralised monitoring; CSM: Centralised statistical monitoring; CodingC: Coding checked; CodingR: Coding reviewed; D: Data; DSMB: Data and Safety Monitoring Board; F: Files; FDA: 
Food and Drug Administration; I: Indicators NA: Not applicable; MR: monitoring reports; NR: Not recorded; OSM: On-site monitoring; P: Participants; PI: Principal investigator; QC: Quality control; 
S: Sites; SDV: Source data verification.  
Data, n(%): Refers to the number (n) of sites, files, data, participants or indicators monitored compared to the total sites, files, data, participants or indicators available to monitor. For example, 5(25) is 
five files included in data monitoring from a total of 20 files, therefore 25%.  
* Monitored number (n) of sites, files, data, participants or indicators not available in publication. Only a percentage provided. 
** Total number of sites, files, data, participants or indicators not available in publication, therefore unable to calculate percentage. 
a I: indicators, monitoring indicators include participant retention, reasons for withdrawal, safety, biological samples and anthropometric measures 
b No further details provided on SDV method.  
c All (n=78) sites to undergo on-site, but only 55 completed at time of publication. 
Liddy et al. 
2011 
F  Random 132 (5) 3 time points  38 Re-audit of a sample of charts and reliability was measured in 16 
(60%) out of 27 primary care practices. 1st time point: Week 1 after 
abstraction. 2nd and 3rd time points: Dispersed within the data collection 
to ensure new abstraction errors or patterns were not introduced.  
Additional quality checks 
occurred if major errors 
were detected or if staffing 
changes occurred.  
Lindblad et 
al. 2014 
S NR 21** NR NR After site inspections, FDA make one of three determinations for each 
site. No action indicated (no problems), voluntary action indicated 
(minor problems) and official action indicated (serious problems).  
NR 
Pogue et al. 
2013 
P Purposively *(85) Twice NR OSM occurred at all hospitals which recruited >40 participants or had 
outliers identified through CSM.  
NR 
Rao et al. 
2016 
S NA 55 (63)c Annually  NR Monitoring to optimise routine work and ensure completeness of the 
data.  
Feedback to site directors.  
Request coordinators to 
correct data and further 
review all submitted data.  
Reisch et al. 
2003 
NR NR NR After double-review  NR Lead investigator/lead study coordinator visited sites to review initial 
chart audits and answered any questions from site abstractors.  
NR 
Soran et al. 
2006 









Initial review (manual review) by data manager of certain source 
documents to identify missing and inconsistency information in a 
timely manner. 
Initial: Data manager 
determines if medical 
review of the form is 
required and if so, submits 











Second review (medical review) by data manager who follows 
guidelines.  
Second: Protocol data 
manager contacts site for 
any missing information. 
Files are returned and 
entered by data manager.  
Van den 




DSMB: NR DSMB: 
NR 
DSMB: ~6 months DSMB: 
Ethical and 
data issues. 
DSMB: Visits evaluated study progress and participant safety. DSMB: From visits 
recommendations led to 
data collection and handling 
SOPs, paper and electronic 









Error rates: Pre, 
during and post entry 
Error rates: 4 
key variables 
Error rates: To determine the frequency of errors made and corrections 
made. Error corrections recorded in audit log which allowed for a triple 
error detection and correction method. 
Error rates: NR 
 
 







Table 3: Summary of included articles assessing the impact of remote monitoring as a monitoring procedure on data quality in 

























et al. (1986) 
Y Y Weekly F  NA *(100) NR NR At the coordinating centre, 
an audit program checked 
data. Alternate or duplicate 
records were stored in the 
temporary audit file for 
review by data manager. 
Audit file contained brief 
message regarding 
problem 
Fox et al. 
2017 
Y NR NR S Sites with 
suboptimal 
data quality 
NR Site specific 
issues 







NR Monitored to check for 
consistency identify 
implausible and outlying 
data, evaluate data quality 
and analyse patterns.  
Monitoring and tracking 
of site-specific issues 
occurs regularly, 
depending on the 
performance of each site. 
Krzych et al. 
2011 
N Y 17 days F NA *(100) Continuous 
(each 
participant 




42 Participating centres 
completed CRFs, tore off 
the top copy and sent pages 
to the coordinating centre.  
Inconsistent, missing or 
illegible data were found 
when the coordinating 
centre reviewed and 
logged all data. Each 
query would be raised 
and sent by fax to the 
centre for clarification 
and resolution. A 3 week 
deadline to return the 
correct data was given.  
Pradhan et 
al. 1994 
Y NR NR D NR *(10) 7 pre-set 
intervals  
NR Errors found during data 
entry or batch checking 
were flagged with a special 
code in database and triaged 
into those that could be 
correct and those that could 
not. Photocopied forms 
returned to the field and 
corrected by data collector 
at next scheduled visit. 
Updated photocopied 
forms were checked, 
edited and sent to central 
data entry location. Use 
of different coloured pens 
for team leaders (blue), 
form editors (pencil), 
supervisors (black) and 
data centre (red). Reports 
were produced by 
 
 







AE: Adverse event; CRF: Case report form; D: Data; F: Files; NR: Not recorded; S: Sites; Y: Yes.  
Data, n(%): Refers to the number (n) of sites, files, data or endpoint packages monitored compared to the total sites, files, data or endpoint packages available to monitor. For example, 5(25) is five 
files included in data monitoring from a total of 20 files, therefore 25%.  
* Monitored number (n) of sites, files, data or endpoint packages not available in publication. Only a percentage provided. 
** Total number of sites, files, data or endpoint packages not available in publication, therefore unable to calculate percentage. 
a Annual follow-up results not included in article.  
  
coordinating centre.  
Rao et al. 
2016 
Y NR 14 - 30 days F Random 667 (5-
10) 
Annually NR Sent medical records using 
encrypted flash drives. Two 
physicians abstracted data 
independently. Compared 
data abstraction to original 
database. 
Generated accuracy 
report and used the 
accuracy of the 
comparison as quality 
indicators of submitted 
data. 
Soran et al. 
2006 



































Ongoing review: Copies of 
all source documents at 
biostatistical centre are 
compared to medical 
review. 
 
Chart review: 1st stage 
compared CRFs with source 
documents. 2nd stage 
includes a scheduled 





Returned to data manager 
for entry into database.  
 
 
Chart review: Findings 
documented by medical 
reviewer and returned to 
data manager. A 
summary of findings is 
provided to protocol 
officer, statistician and 
officer. 
Tolmie et al. 
2011 
Y Y NR Endpoint 
packages 




NR All documents received 
were reviewed to ensure 
they were complete, 
adequate, de-identified, 
legible and consistent.  
Queries generated during 
review were submitted to 
sponsor as soon as 
identified. Unanswered 
queries by next working 
day were logged in 
database. Outstanding 
queries were re-submitted 
to the sponsor at monthly 











Table 4: Summary of included articles assessing the impact of centralised monitoring (including centralised statistical monitoring) as 
a monitoring procedure on data quality in clinical research studies in alphabetical order (n=13). 
















        
Bakobaki et 
al. 2012 
 Y F Purposively  104** 2 weeks  NR Data entry from 
CRF directly to 
database 
A query module on the study database was 
designed to detect missing data, missing CRFs 
and define inconsistencies. Retrospective 
review to determine whether if OSM findings 
could be managed centrally. 
The module tracked 
queries from initiation 
through to resolution 
on the site and 
combined databases.  
Dennis et al. 
2003 
Y  F Random 3(10)a NR NR 3 countries: 
Diskette of 
complete recalls 




Recoding by country nutritionist and 
calculates error rate. Error rate calculated, if 
>6% error batch return to site for recoding 
until passed. Modifications to QC procedures 
for each county where necessary.  





















6  Electronically 
(by encrypted 
electronic data 
forms that could 
be sent by e-
mail or uploaded 
to a secure 
server) or by fax 
CM: to check procedures were in order. 
 
CSM: to check the appropriate patients were 
included and outcome data were accurate. 
CSM drew upon methods for observations 
with lower than expected variation. 
Quantitative variables monitoring using the 
CV to identify if sites had little or too much 
variability in the measurements.  
Sites with a CV 
outside the range were 
flagged for on-site 
monitoring.  Re-
education on trial 
protocol resolved 
issues identified 
during monitoring.  
Embleton-
Thirsk et al. 
2019 
NAb NAb P Patients 










To assess study imaging was performed as a 
sensitivity analysis. Concordance rate between 
local evaluation and central review was 19%.  
Six independent 
reviewers were 
assigned to the 
evaluation. Each 
patient’s data was 
reviewed blinded and 
if two reviewers 
disagreed, a third 
adjudicated.  
Engen et al. 
2020 
 Y S All sites 
randomised 
to no-OSM 





CM was done by central database which posts 
daily reports to the website. Semi-annual 
performance reports were generated for each 
site. CM focused on the accuracy, timing and 
completeness of CRF data and protocol and 
regulatory requirements.  
Reports provided to 
sites were updated 
regularly. Reports 
focused on tracking 











timely data reporting 
and query resolution. 
Guthrie et al. 
2012 
 



























CM: Identified implausible values and extreme 
outliers.  
 
CSM: ICC was used as a component of 
periodic monitoring during data collection. 
ICC was used to detect variation due to cluster 
measurements between centres.  
CM: Outliers reported 
to data entry 
technicians who 








of ambiguity.  
Kirkwood et 
al. 2013 
 Y S NA *(100) NR 148c R-programs 
were created 
Participant level: 7 tests within 3 programs. 
Methods aimed to find data errors such as 
outliers, incorrect dates and irregular data 
patterns. 
 
Site level: 9 tests within 8 programs. Methods 
aimed to find digit preference, values too 
close/far from the means, unusual correlation 
structures, extreme variances which indicate 
fraud or procedural error and under-reporting 
AEs.  
Study 1 and 2: 
retrospective, thus 
queries not sent to 
sites. 
 
Study 3: prospective, 
thus monitoring 
findings checked in 
real time and queries 
sent to centres.  
Lindblad et 
al. 2014 
Y  S Purposively 413** NR NR Data transferred 
from FDA to 
AC. Transfer 
included raw 
data tables in 
SAS transfer 
format.  
8 quality indicators were reviewed for selected 
variables. Site data patterns were examined by 
statisticians. Unusual data patterns were 
referred to as discrepancies. The AC also 
evaluated sites using the first 33% and 50% 
participant data enrolled at each site. 
Comparing discrepancies from the analysis 
from 33%, 50% and 100% of site data.  
Discrepancies were 
assigned one of four 
levels of concern 
(high, moderate, mild 
and no concern). 
Written report to the 
FDA team members 
including results and 
reasons sites were 
flagged.  
Pogue et al. 
2013 
Y  C Purposively 109(56) NR 3 Data accessed 
from database 
Followed a 6-step strategy for model building. 
Built and developed five risk models using 
SAS statistical software. Risk models were 
then converted into risk score cut offs built to 











AC: Analysis centre; AE: Adverse events; CM: Centralised monitoring; CRF: Case report form; CSM: Centralised statistical monitoring; CV: Coefficient of variation; D: Data; DDE: Double data 
entry; DMSC: Data Management and Statistical Core; F: files; FDA: Food and Drug Administration; ICC: Intraclass correlation; NA: Not applicable; NR: Not recorded; OSM: On-site monitoring; 
Participants; QC: quality control; S: Sites; SDV: Source data verification; SAS: Statistical Analysis System; Y: Yes.   
Data, n(%): Refers to the number (n) of sites, files, data or participants monitored compared to the total sites, files, data or participants available to monitor. For example, 5(25) is five files included in 
data monitoring from a total of 20 files, therefore 25%.  
* Monitored number (n) of sites, files, data or participants not available in publication. Only a percentage provided. 
** Total number of sites, files, data or participants not available in publication, therefore unable to calculate percentage. 
a Logged batch of 30 (15 pairs) 
b CM was run independently from OSM.  
c 148 variables reported for two out of the three included trials. 
Rahbar et al. 
2018 
 Y D NA *(100) NR NR Data accessed 
from database 
SAS software used for data querying, 
reporting and cleaning based on univariable 
and multivariable rules that detect potential 
data inconsistencies, missing, out of range 
values and impossible data. All study teams 
DMSC, administration core and sites worked 
closely to seek resolutions to data 
discrepancies identified.  
DMSC held weekly 
conference calls and 
regular e-mail 
communications with 
project staff and 
investigators.  
Reisch et al. 
2003 





Access and sent 
to leading 
coordinating site 
Site coordinators looked for possible errors 
flagged during data cleaning.  
Site coordinators and 
abstractors either 
corrected errors or 
sent back information 




et al. 2016 
 Y D NA *(100) Tests applied 
to centres 
with at least 2 
participants  
NR Transferred 




A series of statistical tests were applied to all 
variables in the clinical database. Tests detect 
irregular patters. Multiple tests applied to 
variables which are selected automatically 
according to statistical properties of the 
variable. Each statistical test returns a P-value 
which is associated with a triplet (centre x 
variable x test).  
Two options:  
1. Extreme P-values 
are individually 
examined by an 
individual familiar 
with the trial.  
2. Data inconsistency 
score is computerised 
to provide a summary 
of inconsistencies 
observed in the centres 
across all tests and 
variables.  
Tuder Smith 
et al. 2012 
 Y P NA 533 (100) NR 4 Access to 
independently 
collected birth 
and death data 
National statistics were used to confirm 
participant existence, date and cause of death. 
Participant details from sites were used for 
matching by independent data. Paper copies of 
the independent data were verified and entered 
onto a database using DDE then compared to 











Table 5: Summary of included articles assessing the impact of risk-based monitoring as a monitoring procedure on data quality in 







Use of risk-based monitoring Strategy informed by risk assessment 








































Risk category assigned 
based on risk assessment 
results: 
K3: low/comparable – 
risk of therapeutic 
intervention is 
comparable to the 
standard care. 
 
K2: intermediate – higher 
than standard care 
 
K1: high – markedly 
higher than standard care 
K3 – 1 visit at each site; 
verification of 100% 
consent form and 20% key 
data 
 
K2 – pre-visits 
(recommended); initiation 
visits; first visit after 1–2 
patients recruited; 1-3 
visits/year depending on 
problems; verification of 
100% consent form and 
20-50% key data; 100% 
SDV for 1 randomly 
selected patient    
 
K1 – pre-visits; initiation 
visits; 1st visit after 1st 
patient; at least 6 
visits/year; verification of 
100% consent form and 
50% key data; 100% SDV 
for 10% of sites patients 
K3 – High level of 
inconsistencies or 
implausible data 
documented; lack of 
response to data 
management queries 
 
K2 and K1 – close 
central monitoring 
For cause 
monitoring – If 
problems or 
irregularities 








visits are made. 
E.g. incidence 













Diani et al. 
2017 
NA Targeted  Y Y  20 key risk 
factors in the 
following 
categories:  









visit results  
Risk factors flagged 
Grade A – green – no 
problems 
 
Grade B or C, yellow = 
minor problems 
 
Grade D or F – red = 
serious problems 
 
Heat map produced as a 
visual overview of all 
sites in a study and 
identifying problems 
needing attention.  
NR NR NR 
Higa et al. 
2020 
RACT Targeted Y Y  Assessed risk 
points: 
1. safety of the 
compound 
2. complexity 
of the study 
3. operational 
experience 
Risk indicators were 
classified into 3 
categories based on the 







Institutions were classified 
into 3 levels: 
1 (low risk): Adaptive 
OSM once in 3 months and 
off-site monitoring once or 
twice a month. SDV on 
critical data only. 
 
2 (medium risk):Adaptive 
OSM once a month and 
off-site monitoring once or 
twice a month 
 
3 (high risk): Based on 
subject visit. Conventional 
OSM, including 100% 




shown in the CM 
dashboard. The 
latest data was used 
by employing 
weekly and monthly 
cut-off data.   
 
3 categories 
according to the 
magnitude of the 








meetings by the 
study team. 










Risks assigned a low to 
high probability score (1-
3) and severity score (1-
3).  
 
Each risk is then assigned 
a score which is a 
multiple of the two 
scores, as well as a risk 
mitigating strategy. 
 
Weekly meetings (~1 
Key metrics displayed 
from the EDC system 
within the monitoring 
reports. Lists of 
observations requiring 
follow-up were maintained 
within the EDC portal.  
 
Initial visit performed at 
all sites. No other on-site 
visits deemed necessary 
based on initial visit. 
Key metrics 
displayed from the 
EDC system within 
the monitoring 




within the EDC 
portal. 
 
CM reports issued 
Email alerts 
occurred at the 
time of data 
entry for any 
SAE and if any 











ADAMON: ADApted MONitoring; AE: Adverse event; CM: Centralised monitoring; EDC: Electronic data capture; GCP: Good Clinical Practice; IC: Informed consent; NA: Not applicable; NR: Not 
recorded; OSM: On-site monitoring; RACT: Risk Assessment Categorization Tool; SAE: Serious adverse event; SDV: Source data verification; Y: Yes.  
hour) with key team 
members to review all 
monitoring activities. 
Meeting frequency 
increased to 2 weeks.  
Second monitoring visit 
was combined with 
closeout visit which were 
performed over the phone.  
 
SDV – electronic and 
paper source documents 
compared to trial database 
completed for 20% of trial 
pages.  
every 2 weeks to 
sites and monitors. 
Frequency increased 
to every 4 weeks.  
























critical, major or other  
 
Critical and major 
findings further 
categorised as ‘new’ or 
‘already known prior to 
monitoring visit’ 
(identified through central 
monitoring or by site).  
Paired triggered and 
untriggered monitoring 
visits: SDV on a sample of 
patients and review of 
consent form, pharmacy 
documents and facilitates 



























Risk of study:  
Low – risk of therapeutic 
intervention is 
comparable to the 
standard care. 
 
Intermediate – higher than 
standard care 
 
High – markedly higher 
than standard care 
 
The assessment of 3 
modulators may lower or 
raise risk within a certain 
risk category influencing 
the duration of site visits 
but not frequency.  
Low risk: 
Initiation – optional  
Interim visits – Endpoints 




Initiation – mandatory 
Interim visits – Endpoints 
defined, IC and safety 
usually 100%) 
 
high risk:  
Initiation – mandatory  
Interim visits – Endpoints 
defined, IC and safety 
usually 100%) 
NA An additional 
risk assessment 














Table 6: Summary of included studies assessing the impact of double data entry as a monitoring procedure and additional check on 
data quality in clinical research studies in alphabetical order (n=8) 
CRF: Case report form; D: Data; DMSC: Data Management and Statistical Core; EMR: Electronic medical record; F: Files; NA: Not applicable; NR: Not recorded; P: 
Participants. PI: Principal investigator; SDV: Source Data Verification.  
Data, n(%): Refers to the number (n) of participants, files or data monitored compared to the total participants, files or data available to monitor. For example, 5(25) is five files 
included in data monitoring from a total of 20 files, therefore 25%.  
* Monitored number (n) of participants, files or data not available in publication. Only a percentage provided. 
** Total number of participants, files or data not available in publication, therefore unable to calculate percentage.  
Author, year Source Data, 
n(%) 
Data selection  Monitoring activities/tasks performed Reporting structure 
Aceituno et al. 
(2017) 
D *(100) NA Entry discrepancies resolved within 1 week and any 
biological implausible data points recorded as 
missing values. 
Monthly reports shared with study staff and 
strategies to improve data quality were set 
for the next month.  
Caloto et al. 
2001 
D 926(10) Random selection  Duplicate data entries typed by the co-coordinating 
centre before fed into a central database.  
Calculated error rate 
Fougerou-
Leurent et al. 
2019 
D 126(100) NA Data manually entered by two different operators 
who entered the data independently. Two resulting 
databases were compared to identify discrepancies, 
which were corrected.  
Data management staff issued corrections 
and strategies in accordance with SOPs 
Hossman et al. 
2017 
D *(100) NA Comparison of two double data entries were reviewed 
by PI or a delegate. Data entry between 1-2 weeks.  
Quantified the rate of incorrect data entry 
Pradhan et al. 
1994 
F NR Identifiers and 
the most 
important data 
DDE was not done for all data items because it was 
not considered cost-efficient given the intelligent data 
entry system.  
NR 
Rahbar et al. 
2018 
F *(5-10) Random Selected CRFs per visit per site to identify 
discrepancies between two entries 
Reviewed by the data manager at DMSC 
and project coordinators at site. 


















Initial: Charts double reviewed by another site 
abstracter. Discrepancies were logged onto an audit 
form. 
 
Second: Abstractor met with site coordinators to 
discuss discrepancies. An audit form was completed 
on all discrepancies.  
Initial: Audit forms sent to the lead study 
coordinator. 
 
Second: Audit form sent to lead study 
coordinator and twice monthly conference 
calls to discuss difficulties noted from the 
monthly double-reviews.  
Soran et al. 
2006 
F 1 batch** NR Forms double entered and verified, and a computer 
screening program is run on the batch to check the 











Table 7: Summary of included studies assessing the impact of logic, range and consistency checks as a monitoring procedure and 
additional check on data quality in clinical research studies in alphabetical order (n=11).  
Author, year Source Data, 
n(%) 
Frequency Monitoring activities/tasks performed Reporting structure 
Bagniewska et 
al. (1986) 
F *(100) Daily  During data entry an audible “beep’ was performed 
for any out-of-range or inconsistent values. Data 
enters could override and “force” entre values.  
Batch reports summarising data entry, editing activity, 
listing out-of-range and inconsistency values. 
Caloto et al. 
2001 
NR NR Monthly 1st computer software program designed to allow for: 
data validation, data consistency, detect duplication 
and check data-entry errors. 2nd program detect data 
inconsistencies. 
Identified at monthly reviews through reports.  
Dennis et al. 
2003 
F *(100) NR Japan: software system flagged out-of-range amounts 
and values. Range values for key nutrients were 
posted in the coding room. USA: out-of-range values 
flagged. Fully automated system.  
Fixed on-the-spot or identified during OSM or CM.  
Edwards et al. 
2014 
D *(100) NR Queries were followed-up using a standard process. 
Re-training was undertaken where necessary and 
monitoring continues. 
Direct discussion with the PI.  
Hossman et al. 
2017 
F *(100) Daily  Real-time validation, plausibility checks (branching 
logic), range checks, regular expressions (dates) 
within software system. 
Regular reporting to check consistency, maintain an 
overview and provide assistance in conducting study.  
Liddy et al. 
2011 
NR NR NR Program has logic models embedded in the enter 
fields, illogical responses are not accepted.  
Warnings prompt chart abstractors of fields left 
incomplete. 
Nahm et al. 
2008 
F *(100) NR Extensive error checking for missing, out-of-range 
and logically inconsistent values across the CRF in 
real time.  
Corrective action process and uses reports to 
communicate and monitor audit results. 
Pradhan et al. 
1994 
F *(100) Daily Within the field, editors scanned forms for illegible, 
incomplete or inconsistent data. Central data entry 
location, range and consistency checks among data 
items within and between forms.  
Within the field, detected problems were reviewed by 
supervisors/team leaders and returned data collectors to 
the village to resolve problems. Central data entry 
location, records updated every 4 months and the data 
entry was designed to check linkages between visits.  
Ruiz et al. 2016 F *(100) NR Cross-checks between identical data collected in 
other sources. Database tracks missing data, 
discrepancies between questionnaires, out of range 
values and consistency checks predefined by 
Data flagged by validation plans generate queries process 
directly to the data manager or forwarded onto data 
monitors to be followed-up at next OSM visit.  
 
 







CM: Centralised monitoring; CRF: Case report form; D: Data; F: Files; NR: Not recorded; OSM: On-site monitoring; PI: Principal investigator; USA: United 
States of America.  
Data, n(%): Refers to the number (n) of files or data monitored compared to the total files or data available to monitor. For example, 5(25) is five files included 
in data monitoring from a total of 20 files, therefore 25%.  
* Monitored number (n) of files or data not available in publication. Only a percentage provided. 




Soran et al. 
2006 
F *(100) NR Form-edit flags identify missing, out-of-range and 
inconsistent values with other information on the 
form.  
Computerised flags. Forms are not merged into the 
system until all flags are resolved.  
Van den 
Broeck et al. 
2007 
F *(100) NR  Software used predefined rules to check for 
completeness, consistency and ranges of allowable 
values.  Discrepancies highlighted onscreen so data 
entry clerk can check against form. Obvious errors 
corrected instantly, other errors sent back to field 
staff or programmer. 
Data manager checked answers and resubmitted the 
corrected data.  
 
 







Appendix F: Forest plots illustrating the sensitivity analysis 
 
Figure 1: Forest plot illustrating the number of times monitoring were applied over the 
duration of a clinical research study using source data verification removing the Ruiz et 
al. 2016 study (n=11). Rate (times monitoring was applied/365 person days).  













Figure 2: Forest plots illustrating the number of times monitoring were applied over the 
duration of a clinical research study using on-site monitoring removing the Dennis et al. 
2003 study (A) and removing both the Dennis et al. 2003 and Caloto et al. 2001 studies 
(B). Rate (times monitoring was applied/365 person days).  













Figure 3: Forest plot illustrating the number of times monitoring were applied over the 
duration of a clinical research study using remote monitoring removing simultaneously 
the Tolmie et al. 2011 and the Fox et al. 2017 studies (n=4). Rate (times monitoring was 
applied/365 person days).  














Figure 4: Forest plots illustrating the number of times monitoring were applied over the 
duration of a clinical research study using centralized monitoring removing the Engen 
et al 2020 study (A) and removing both Engen et al 2020 and Bakobaki et al. 2012 
studies  
Rate (times monitoring was applied/365 person days).  
Abbreviations: CI, confidence interval; CM, centralised monitoring.   
 
 







Appendix G: Cross-sectional surveys  
Table 1: Summary of included cross-sectional surveys assessing the impact of monitoring procedure(s) on data quality in clinical 








Study findings  
Beever et al. 
2019  
To determine current 
risk assessment and 
RBM practices and 
compare with the 





23 CTUs 52% of CTUs decided how much monitoring was required, in terms of 
proportion of RM and OSM. Conducting RM with some OSM was the most 
common type of monitoring approach. All CTIMPs and 91% non-CTIMPs 
undertook some risk assessment in their trial to indicate monitoring approach. 
There was a lack of reflection to making changes during the course of the trial 
and to inform future trials.   
Houston et 
al. 2018 
To gather information 
about current data 
quality tools and 
procedures used within 
Australian clinical trial 
sites.  
Clinical trial sites 
listed on the 
Australian 
Government 
NHMRC website.  
20 clinical trial 
site employees  
CM (65%) was the most common monitoring procedure to ensure high-quality 
data. Clinical trial sites are implementing ad-hoc procedures pragmatically to 
ensure data quality.  
Hurley et al. 
2017 
To explore the 
experience of, attitudes 
to, and perceived 
barriers and facilitators 




CTUs in Ireland.  
132 clinical 
trial staff  
14% of respondents were not familiar with RBM. Barriers to implementing 
RBM included lack of expertise and education, increased costs caused by 
greater IT demands, increased trial staff workload and lack of evidence to 
support if RBM is an effective monitoring approach. Facilitators to RBM 
included legal obligation under updated GCP guidelines, additional regulatory 
guidance and perceived cost saving benefits from performing RBM.  
Jeong et al. 
2019 
To examine the attitudes 
of CRCs working at 
study sites towards the 
implementation of RBM  
CRCs working at 
184 clinical trial 
centres registered 
with the Korean 
Ministry of Food 
and Drug safety.  
607 CRCs 42% of respondents hadn’t heard of RBM and 45% were opposed to 
implementing a RBM procedure. Those opposed believed implementing RBM 
would increase workload of CRCs. Negative attitudes to RBM were worse in 
CRCs with >5 years’ experience. Education is needed to help CRCs develop 
related skills and understand RBM.  
Knepper et 
al. 2016 
To assess the current 
landscape of methods 
used to detect data 
anomalies suggestive of 
 TransCeleratea 
member companies  
18 companies Site monitoring (n=17) was the most common strategy used to detect fraud and 
misconduct in clinical trials. Among the 14 companies that used CM, only 8 
used it on RBM. Over the last five years 75% of companies had modified their 
strategy, suggesting more companies were beginning to rely on more statistical 
 
 







CM: Centralised Monitoring; CRC: Clinical research coordinator; CRO: Contact research organisation; CTIMP: Clinical Trial of an Investigational Medicinal 
Product; CTU: Clinical Trial Unit; GCP: Good Clinical Practice; NHMRC: National Health and Medical Research Council; OSM: On-site monitoring; PI: 
principal investigator; RCT: randomised controlled trial; RM: remote monitoring; RBM: risk-based monitoring.  
a TransCelerate BioParma Inc is a not-for profit organisation which conducts biopharmaceutical research.    





analysis and advanced strategies.  
Kim et al. 
2020 
To understand the 









CROs in South 
Korea 
61 companies 44% of companies underwent some sort of risk assessment before beginning a 
clinical trial. 49% of companies had adopted RBM and 30% were in the 
progress of adopting RBM. Investment in training employees in GCP and 
building quality management between employees and the PI is needed for 
quality improvement.  
Kumar et al. 
2016 
To assess the 
perceptions among 
clinical research staff 
globally (developed and 
emerging) on the 
applicability and 
adaptability of RBM  
Randomly selected 
DrugDevb 





49% of respondents were not aware of RBM and were excluded from the 
analysis. Researchers from emerging countries compared to developing 
countries were more confident that RBM would be more effective in addressing 
data quality, patient safety and findings fraud/fabrication. Globally investigators 
believe that RBM has the potential to reduce drug development down while 
ensuring patient safety and data quality.  
Love et al. 
2020 
To determine the policy 
on monitoring phase III 






38 CTUs 97% of CTUs use a CM process to guide, target or supplement site visits. 91% 
used triggers to decide whether to conduct OSM. A wide variety of CM and 




To describe current 
methods of monitoring 
clinical trials and to 
explore the rationale for 
the use of those 
methods.    
Public and private 












11 CRO and 36 
industry)  
CRO, pharmaceutical and device industry organisations are always conducting 
OSM (80-89%) compared to academic coordinating centres/cooperative 
group/government organisations (31%). The majority (83%) of organisations 
use centrally available data to evaluate site performance, 12% of respondents 
always or frequency used CM to replace OSM. A wide variety of monitoring 
practices are currently being employed.  
 
 







Appendix H: Qualitative studies  
Table 1: Summary of included qualitative studies assessing the impact of monitoring procedure(s) on data quality in clinical research 
studies in alphabetical order (n=4).  






Main themes identified Study findings 
Chantler et al. 
2014 
 
To observe the 
approach of two 
innovative 
monitoring models, 
consider how this 




experiences of and 
views about the 
nature, purpose and 
practice of 
monitoring.   
Monitor and 
investigators of a 
Thai research unit 
and an African 




















 Ensuring protocol, ethics and 
regulatory compliance and 
increasing transparency 
 Protecting study participants rights 
and safety 
 Evaluating the science and 
increasing data accuracy 
 Supporting and training staff 
Monitoring can be a 
scientific and constructive 
expertise rather than a 
threatening process. 
Monitoring activities need 
to emphasise the 
importance of cooperative 
relation needs between 
sponsors, investigators and 
monitors.  
Hurley et al. 
2017 
To explore the 
experience of, 
attitudes to, and 
perceived barriers 
and facilitators 




clinical trial units in 
Ireland. 
22 interviews: 












 Barriers associated with the 
implementation of RBM (lack of 
knowledge/training, increased costs 
caused by greater IT demands, 
increased workload, lack of 
verification) 
 Facilitators associated with the 
implementation of RBM (necessary 
requirement/mandate, availability 
of, and need for, guidance and 
economic benefits).  
There is a need for training 
and regulatory-endorsed 
guidelines to support the 
implementation of a RBM 
approach in academic-led 
clinical trials.  
 
 












et al. 2017 




they face during 
monitoring, their 
perspectives on risk-






monitored by the 
CTU at the 
University of Basel, 
Switzerland.  
3 Monitors  Semi-
structured 
interviews 
 Factors influencing risk-based 
monitoring findings 
 Monitoring process and challenges 
faced 
 Role of monitors and future 
perspectives  
Monitors reported 
understanding the aspects 
of a risk-based approach 
but fear missing 
systematic errors due to 
the low frequency of 
visits. Monitors stressed 
the importance of well 
trained, motivated and 
experienced trial personnel 
for overall trial quality and 
success. 
Zhang et al. 
2017 
To evaluate the 
feasibility, 
advantages, and 
challenges of mEDC 
in data collection, 
project management 
and telemonitoring 




controlled trial which 
compared two 
different medications 
in patients with 
hypertension in 
China.  
80 interviews:  




manager and 1 




 Doctors mentioned mEDC was 
convenient and simple 
 CRAs and project managers 
believed that mEDC offered 
functions that were not available in 
traditional computer-based trials 
(e.g. remote monitoring and 
validation in real time) 
 DMs believed mEDC was safe and 
could help reduce workload during 
data cleaning processes.  
In the clinical trial the 
mEDC was well accepted 
in supporting data 
collection and project 











Appendix I: Quality assessment and rating for articles 
Table 1: Quality assessment and rating for articles in alphabetical order (n=56).  















































































































































































Reference number  170 70 171 172 205 197 194 68 173 186 105 174 
VALIDITY QUESTIONS                        
1. Was the research question clearly stated? Y Y Y Y Y Y Y Y Y Y Y Y 
2. Was the selection of study subjects/patients free from bias? Y Y Y NA Y Y Y Y NA Y N NA 
3. Were study groups comparable? NA Y NA NA Y NA NA Y NA NA Y NA 
4. Was method of handling withdrawals described? Y NA NA NA NA NA N Y NA NA NA NA 
5. Was blinding used to prevent introduction of bias? NA N NA NA N N Y Y NA N Y NA 
6. Were intervention/therapeutic regimens/exposure factor or procedure and any 
comparison(s) described in detail? Were intervening factors described? 
NA Y Y NA Y Y Y Y U Y Y Y 
7. Were outcomes clearly defined and the measurements valid and reliable? Y Y Y Y Y Y Y Y Y Y Y Y 
8. Was the statistical analysis appropriate for the study design and type of outcome 
indicators? 
Y Y Y Y Y Y Y Y N Y NA Y 
9. Are conclusions supported by results with biases and limitations taken into 
consideration? 
Y Y Y Y Y Y Y Y Y Y Y Y 
10. Is bias due to study’s funding or sponsorship unlikely? Y Y Y Y Y U Y Y Y Y Y Y 
OVERALL QUALITY                         
Negative/Neutral/Positive (−/⊘/+)* + + + ⊘ + ⊘ + + ⊘ + ⊘ ⊘ 
Sum             
Y 7 8 7 5 8 6 8 10 4 7 7 6 
N 0 1 0 0 1 1 1 0 1 1 1 0 
NA 3 1 3 5 1 2 1 0 4 2 2 4 
Unclear  0 0 0 0 0 1 0 0 1 0 0 0 
 
 



















































































































































































Reference number  167 187 175 71 73 69 190 176 185 202 29 74 
VALIDITY QUESTIONS                      
1. Was the research question clearly stated? Y Y Y Y Y Y Y Y Y Y Y Y 
2. Was the selection of study subjects/patients free from bias? U Y NA Y NA Y Y Y U Y Y Y 
3. Were study groups comparable? NA Y NA NA Y Y NA NA U Y Y NA 
4. Was method of handling withdrawals described? N NA NA NA Y NA NA NA N NA NA Y 
5. Was blinding used to prevent introduction of bias? N Y Y Y Y N NA N Y NA Y Y 
6. Were intervention/therapeutic regimens/exposure factor or procedure and any 
comparison(s) described in detail? Were intervening factors described? 
Y Y Y Y Y Y Y Y Y Y Y Y 
7. Were outcomes clearly defined and the measurements valid and reliable? Y Y Y Y Y Y Y Y Y Y Y Y 
8. Was the statistical analysis appropriate for the study design and type of outcome 
indicators? 
Y Y Y U Y Y Y Y N Y Y Y 
9. Are conclusions supported by results with biases and limitations taken into 
consideration? 
Y Y Y Y Y Y Y Y U Y Y Y 
10. Is bias due to study’s funding or sponsorship unlikely? U Y Y Y Y Y Y Y U U Y Y 
OVERALL QUALITY                       
Negative/Neutral/Positive (−/⊘/+)* ⊘ + + + + + + + ⊘ + + + 
Sum             
Y 5 9 7 7 9 8 7 7 4 7 9 9 
N 2 0 0 0 0 1 0 1 2 0 0 0 
NA 1 1 3 2 1 1 3 2 0 2 1 1 
Unclear  2 0 0 1 0 0 0 0 4 1 0 0 
 
 






































































































































































Reference number  103 85 195 198 192 203 193 168 189 196 58 199 
VALIDITY QUESTIONS                      
1. Was the research question clearly stated? Y Y Y Y Y Y Y Y Y Y Y Y 
2. Was the selection of study subjects/patients free from bias? Y Y Y Y N Y Y Y U Y Y U 
3. Were study groups comparable? NA NA NA Y NA NA NA NA NA NA Y NA 
4. Was method of handling withdrawals described? N N N NA Y N Y NA Y Y NA Y 
5. Was blinding used to prevent introduction of bias? U U U N Y NA Y NA NA N Y NA 
6. Were intervention/therapeutic regimens/exposure factor or procedure and any 
comparison(s) described in detail? Were intervening factors described? 
Y Y Y Y Y Y Y Y NA Y Y Y 
7. Were outcomes clearly defined and the measurements valid and reliable? Y Y Y Y Y Y Y Y Y Y Y N 
8. Was the statistical analysis appropriate for the study design and type of outcome 
indicators? 
Y Y Y Y Y Y Y Y Y Y Y N 
9. Are conclusions supported by results with biases and limitations taken into 
consideration? 
Y Y Y Y Y Y Y Y Y Y Y N 
10. Is bias due to study’s funding or sponsorship unlikely? Y Y U Y Y Y Y U Y Y Y U 
OVERALL QUALITY                       
Negative/Neutral/Positive (−/⊘/+)* + + + + + + + ⊘ ⊘ + + ⊘ 
Sum             
Y 7 7 6 8 8 7 9 6 6 8 9 3 
N 1 1 1 1 1 1 0 0 0 1 0 3 
NA 1 1 1 1 1 2 1 3 3 1 1 2 











































































































































































Reference number  55 62 28 200 177 178 179 180 181 201 75 182 
VALIDITY QUESTIONS                         
1. Was the research question clearly stated? Y Y Y Y Y Y Y Y Y Y Y Y 
2. Was the selection of study subjects/patients free from bias? N Y Y Y Y Y Y Y U Y NA Y 
3. Were study groups comparable? NA NA Y NA NA NA NA Y NA Y Y NA 
4. Was method of handling withdrawals described? N NA N NA NA NA NA NA NA NA NA NA 
5. Was blinding used to prevent introduction of bias? Y N NA N N N N Y N N Y N 
6. Were intervention/therapeutic regimens/exposure factor or procedure and any 
comparison(s) described in detail? Were intervening factors described? 
Y Y Y Y Y Y Y Y Y Y Y NA 
7. Were outcomes clearly defined and the measurements valid and reliable? Y Y Y Y Y Y Y Y Y Y Y Y 
8. Was the statistical analysis appropriate for the study design and type of outcome 
indicators? 
Y Y Y Y Y N N Y N N Y Y 
9. Are conclusions supported by results with biases and limitations taken into consideration? 
Y Y Y Y Y Y Y Y N N Y Y 
10. Is bias due to study’s funding or sponsorship unlikely? Y Y Y Y Y Y Y Y Y Y Y Y 
OVERALL QUALITY                          
Negative/Neutral/Positive (−/⊘/+)* + + + + + ⊘ ⊘ + ⊘ ⊘ + ⊘ 
Sum             
Y 7 7 8 7 7 6 6 9 4 6 8 6 
N 2 1 1 1 1 2 2 0 3 3 0 1 
NA 1 2 1 2 2 2 2 1 2 1 2 3 
Unclear  0 0 0 0 0 0 0 0 1 0 0 0 
 
 
































































































































Reference number  183 72 184 188 204 104 169 106 
VALIDITY QUESTIONS                 
1. Was the research question clearly stated? Y Y Y Y Y Y Y Y 
2. Was the selection of study subjects/patients free from bias? Y Y Y Y Y U Y Y 
3. Were study groups comparable? NA Y NA Y Y NA Y NA 
4. Was method of handling withdrawals described? NA N N NA Y N Y U 
5. Was blinding used to prevent introduction of bias? Y Y Y N N Y U Y 
6. Were intervention/therapeutic regimens/exposure factor or procedure and any comparison(s) described 
in detail? Were intervening factors described? 
Y Y Y Y Y NA Y NA 
7. Were outcomes clearly defined and the measurements valid and reliable? Y Y Y Y Y Y Y Y 
8. Was the statistical analysis appropriate for the study design and type of outcome indicators? Y Y Y Y Y Y N NA 
9. Are conclusions supported by results with biases and limitations taken into consideration? Y Y Y Y Y Y Y Y 
10. Is bias due to study’s funding or sponsorship unlikely? Y Y Y Y Y Y Y Y 
OVERALL QUALITY                  
Negative/Neutral/Positive (−/⊘/+)* + + + + + ⊘ + ⊘ 
Sum         
Y 8 9 8 8 9 6 8 6 
N 0 1 1 1 1 1 1 0 
NA 2 0 1 1 0 2 0 3 
Unclear  0 0 0 0 0 1 1 1 
*If most (six or more) of the answers to the above validity questions are “No”, the report should be designated negative. If the answers to validity criteria 2, 3, 6 and 7 do not indicate 
that the study is exceptionally strong, the report should be designated neutral. If most of the answers to the above validity questions are “Yes” (including criteria 2, 3, 6, 7 and at least 
one additional “Yes”), the report should be designated positive. 
 
 







Appendix J: Feasibility survey  
Exploring current data management plans within clinical research trials 
 




Please enter your participant identification (PIO): ________________                                   




I have been provided with the participant information sheet about exploring 
current data management plans within clinical research trials. I have been 
advised of the potential risks and burdens associated with this research, which 
include completing a 10-15 minute online survey. 
 
I understand that my participation in this research is voluntary, I am free to 
refuse to participate and I am free to withdraw from the research at any time. 
If I choose not to participate or withdraw consent it will not affect my 
treatment in anyway and/or my relationship with the University of 
Wollongong. 
 
If I have any enquiries about the research, I can contact Ms Lauren Houston 
(Email: lah993@uowmail.edu.au) who is conducting this research as part of her 
PhD thesis at the University of Wollongong. If I have any concerns or complaints 
regarding the way the research is or has been conducted, I can contact the Ethics 
Officer, Human Research Ethics Committee, Office of Research, University of 
Wollongong on 42213386 or email rso-ethics@uow.edu.au. 
 
By agreeing to the below I am indicating my consent to (please tick):  
 Participate in this online survey 
 
Date: _____________                               




















 Female  
 Male  
 Transgender 
 Prefer not to disclose 
 
 
2. Highest level of completed education 
 Did not complete high school  
 Completed high school  
 College/TAFE course  
 Bachelor degree 
 Master's degree  
 Doctoral degree 
 








(Years (For example, 6 months = O.5 years))  
 
 
5. Appointment (Current job or position) 
 
 Continuing employment (Full or part time basis with no specified end 
date)  
 Fixed-term contract (A specified term or ascertainable period) 
o If yes, Contract duration (Please provide value in years)                                    
______________________________________________________
______________________________________________________ 











The following questions are related to your current procedures and protocols 
for data quality assurance. Please follow instructions and select the most 
appropriate response{s) from the range of options provided. 
 
Question 1 
Does your institution currently have a clinical data management plan in place? 
 Yes  
 No 
 Not applicable  




What type of clinical research does your institute conduct? (Select all that apply) 
 
For definitions of the following types of clinical trials hover mouse/curser over 
words for popup window to display additional information. 
 
 Treatment  
 Prevention  
 Diagnostic  
 Screening  
 Quality of life  
 Genetic studies 
 Epidemiological studies  
 Phase I trials 
 Phase II trials  
 Phase III trials  
 Phase IV trials  
 Other 















Does your institute have any of the following procedures in place to ensure 
high-quality data is produced? (Select all that apply) 
 
For definitions of the following procedures hover mouse/curser over words for 
popup window to display additional information. 
 
 Logic, range and consistency checks  
 Statistical techniques 
 Risk-based targeted monitoring  
 Risk-based triggered monitoring  
 On-site source data verification  
 Remote monitoring 
 Centralised monitoring  
 Don't know 
 Other 













 Amount of data monitored depends on the data point/outcome measured 
(e.g. 10% data monitored from outcome A and 5O% data monitored from 
outcome B) 
o Please explain: 
____________________________________________________ 
 Not applicable  
 Don't know  
 Other 
o Please specify: 














Does your institute have an error acceptance level? 
 0% 
 <5%  
 5-10% 
 10% 
 No (you will be directed to question 7) 
 Not applicable (you will be directed to question 7)  
 Don't know (you will be directed to question 7)  
 Other 





Following on from Question 5, if the error rate is found to be higher than the 
approved acceptance level, does your institute implement further follow-up 
monitoring? 
 No  
 Yes 
o If yes, please explain the procedure. (E.g. further monitor 1OO% 






How often does your institute conduct internal data monitoring? 
 Every month  
 Every 3 months 
 Every 6 months 
 Every 9 months  
 Annually  
 Biannually 
 Follow-up, recommended on data identified with issues of poor quality.  
 Not applicable 
 Don't know  
 Other 





What variables are included in data monitoring? 
 
For definitions of the following variables hover mouse/curser over words for 
popup window to display additional information. 
 
 Critical data points (Key/primary data) 
 
 







 Non-critical data points (non-key/secondary data)  
 Critical and non-critical data 
 All data points (1OO%)  
 Not applicable 
 Don't know  
 Other 





Does your institute use any of the following sampling methods to select what data 
points are monitored? (Select all that apply) 
 
For definitions of the following sampling methods hover mouse/curser over words 
for popup window to display additional information. 
 
 Simple random sampling  
 Systematic sampling  
 Stratified sampling  
 Cluster sampling 
 Multi-stage sampling  
 Not applicable 
 Don't know  
 Other 













Please specify the type of staff training/development you conduct that is devoted 
to data quality for clinical trials. (Select all that apply) 
 One-on-one education and training  
 Group education and training 
 Educate throughout clinical trial (as needed)  
 Educate prior to research 
 Skills training/development 
 International Conference on Harmonisation and Good Clinical Practice 
(ICH-GCP) training Standard Operating Procedure (SOP) training 
 Nil 
 Not applicable  
 Don't know  
 Other 
o Please specify: 
____________________________________________________                                   
 
Please enter the average amount of time spent on staff training/development 
(hours): ___________                                                                             
                       
  
Question 11 
Who reviews the reports of data quality and consistency? (Select all that apply)  
 Chief investigator  
 Sponsor  
 Auditor/Monitor  
 Data manager 
 Senior staff management  
 Data entry staff 
 Data analyst  
 Administration staff  
 No one 
 Don't know  
 Other 


















Appendix K: National survey  
Exploring data quality monitoring in Australian clinical studies survey 
 
Consent 
I have been provided with the participant information sheet (attached below) 
about the project 'Exploring data quality monitoring within Australian clinical 
studies survey'. I have been advised of the potential risks and burdens associated 
with this research, which include completing a 20 to 30 minute online survey. 
 
I understand that my participation in this research is voluntary, I am free to refuse 
to participate and I am free to withdraw from the research at any time. If I choose 
not to participate or withdraw consent it will not affect my treatment in anyway 
and/or my relationship with the University of Wollongong. I acknowledge that 
any responses given by me as part of this survey form my opinions and practices 
not necessarily those of the organisation with whom I am employed. I understand 
that my identifiable responses will not be shared with my organisation or anyone 
outside of the research team. 
 
If I have any enquiries about the research, I can contact Ms Lauren Houston (Ph. 
0430371929 or Email: lah993@uowmail.edu.au) who is conducting this research 
as part of her PhD thesis at the University of Wollongong. If I have any concerns 
or complaints regarding the way the research is or has been conducted, I can 
contact the Ethics Officer, Human Research Ethics Committee, Office of 
Research, University of Wollongong on Ph. (02) 42213386 or Email: rso-
ethics@uow.edu.au. 
 
By agreeing to the below I am indicating my consent (please tick): 













Please follow instructions and select the most appropriate response(s) from the 
range of options or type free text in the box provided for the following questions. 
 
1. Gender 
 Female  
 Male 
 Prefer not to disclose  
 Prefer to self-describe 




2. Highest level of completed education 
 Did not complete high school  
 High school 
 College/TAFE course (e.g. apprenticeship)  
 Bachelor degree (including Honours)  
 Masters/Postgraduate degree 
 Doctoral degree  
 
 




4. Duration of employment with current employer: 
_______________________________ 
(Please provide numeric value to the nearest completed half year, for example, 6 
months = 0.5 years) 
 
 
5. Appointment (Current job or position) 
For definitions hover mouse/cursor directly over words for popup window to 
display additional information. (May take a few seconds to appear) 
 Casual Student  
 Continuing 
 Visiting / Honorary fellow 
 Fixed-term contract  
o Current contract duration: 
___________________________________________  
(Please provide numeric value to the nearest half year, for 
example,  













Clinical research demographics 
 
The following questions relate to the specified clinical study outlined in the 
survey email. 
 
For the purpose of this research a clinical study involves research using 
human volunteers (also called participants) that is intended to add to medical 
knowledge. There are two main types of clinical studies: clinical trials (also 
called interventional studies) and observational studies. 
 
6. What health professionals are part of the clinical study team? (Select all that 
apply) 
 Aboriginal and Torres Strait Islander health practitioner  
 Audiology 
 Chinese Medicine  
 Chiropractic  
 Dentistry  
 Dietetics 
 Exercise physiology  
 Genetic counselling  
 General practice/Physician  
 Medical radiation 
 Nursing  
 Nutrition 
 Occupational therapy  
 Optometry  
 Osteopathy 
 Orthotics  
 Paramedics  
 Pharmacy  
 Physiotherapy  
 Podiatry  
 Prosthetics  
 Psychology  
 Social work 
 Speech pathology  
 Other 
o Please specify: 
____________________________________________________ 












7. Which of the following best describes the organisation(s) that administers 
the clinical study? (Select all that apply) 
 Academic (University)  
 Cooperative group/consortium  
 Government 
 Hospital 
 Independent research institute  
 Industry 
 Non-governmental organisation  
 Not applicable 
 Don't know  
 Other 




8. What is the clinical study type? 




9. If ‘Intervention trial’ in question 8. What type of intervention is the clinical 
trial? (Select one) 
For definitions hover mouse/cursor directly over words for popup window to 
display additional information. (May take a few seconds to appear) 
 Diagnostic  
 Epidemiological  
 Genetic  
 Prevention  
 Quality of Life  




10. What phase is the clinical study? (Select one) 
For definitions hover mouse/cursor over words for popup window to display 
additional information. (This may take a few seconds) 
 Phase 0 (Exploratory)  
 Phase I 
 Phase II  
 Phase III  
 Phase IV  
 Don't know 
 Not applicable 














12. If ‘Multi-site’ in question 11. Number of sites:  








13. If ‘Single-site’ in question 11. In what setting is the data collected? (Select 
one)  
 Health centre 
 Hospital 
 Independent research institute  
 In-home care 
 Private practice  
 University  
 Other 




14. If ‘Multi-site’ in question 11. In what setting(s) are the data collected? (Select 
all that apply) 
 Health centre  
 Hospital 
 Independent research institute  
 In-home care 
 Private practice  
 University  
 Other 




15. If ‘Multi-site’ in question 11, Is the clinical study part of an international 
study? (Select one) 
 Yes 
 No 
16. Number of participants targeted for baseline enrolment in the clinical study? 
(Select one) 


















17. Does the clinical study/organisation employ a person as a data monitor and/or 
data manager? 
Yes No Don’t know  Not applicable  
    
 
 
The following questions are related to data management and are conducted prior to 
the study commencing. Such procedures include identifying data to be collected, 
defining data elements, designing case report forms (CRFs) and research protocols. 
 







18. have a data dictionary?     
19. involve staff in develeoping 
case report forms (CRFs)?     
20. have a defintion for protocol 
deviation and/or violation?     
21. Have a data quality monitoring 
plan or standard operating 
procedure (SOP) for quality 
assurance and quality control? 
    
22. outsource data monitoring to 
another company?     
23. follow national and 
international regulations, guidelines 
and/or standards for data 
monitoring?   












24. If ‘Yes’ or ‘Don’t know’ to question 23. Please select which of the following 
regulations, guidelines and/or standards are followed. (Select all that apply) 
 National Statement on Ethical Conduct and Research 
 The Australian Clinical Trial Handbook - Therapeutic Goods 
Administration (TGA)  
 Good Clinical Practice Guidelines (GCP) - International Conference for 
Harmonisation  
 International Standards Organization (ISO) quality systems standard 
 Food and Drug Authority (FDA)  
 21 CRF part 11 
 Food and Drug Authority (FDA) Monitoring of Clinical Investigations  
 Health Level 7 (HL7) 
 Analysis Data Model (ADaM)  
 Operational Data Model (ODM) 
 Logical Observation Identifiers names and Codes (LOINC)  
 Clinical data acquisition standards harmonization (CDASH) 
 International classification of diseases (ICD): ICD-9 / IDC-10 / ICD-0-3 
Systematized Nomenclature of Medicine -- Clinical Terms (SNOMED-
CT) 
 Study data tabulation model implementation guide for human clinical 
trials (SDTM)  
 Don't know 
 Other 




The following questions relate to the process by which data elements are 
accumulated known as data collection. 
 







25. have a standard operating 
procedure (SOP) specifically for 
data collection? 
    
26. implement procedures to 
overcome missing values in the 
process of data collection?  
    














27. Which data capture instrument(s) are used to record source data? (Select all 
that apply) 
Source data refers to the FIRST time a data value is recorded. Source data is 
contained in source documents, e.g. hospital records, clinical and office charts, 
laboratory notes and recorded data from automated instruments. 
 Paper 
 Mobile or tablet application  
 Electronic case report form (eCRF)  
 Database management software/tool 
 Microsoft Excel spreadsheet/workbook 
 Automated instruments (e.g. pathology, ultrasound, x-ray etc.)  
 Don't know 
 Other 




28. Are any of the following clinical data management tools used to store data? 
(Select all that apply) 
 RAVE  
 MACRO 
 REDCap  
 TRialDB  
 PhOSCo  
 CLINTRIAL 
 openCDMS  
 OpenClinica  
 eClinical Suite  
 ORACLE CLINICAL 
 None 
 Not applicable  
 Don't know  
 Other 













The following questions relate to the processes and systems applied to audit and 
monitor data within the clinical study. 
For definitions hover mouse/cursor directly over words for popup window to 
display additional information. (May take a few seconds to appear) 
 
Does the research team of the clinical study complete any of the following 







29. Logic, range and consistency 
checks      
30. Double data entry      
31. Statistical techniques     
32. Risk-based taregted monitoring     
33. Risk-based triggered 
monitoring      
34. Remote monitoring     
35. Centrlised monitoring     
36. On-site monitoring      
37. Source data verification     
38. Other      















Risk-based targeted monitoring - Focus on certain data points that have been 
identified to have the most risk. 
 
Does the clinical study use a risk-based targeted monitoring procedure to... 







32a. guide centralised monitoring 
visits?     
32b. guide on-site visits?     
32c. completely replace on-site 
visists?     
32d. other     





32e. What types of data does the risk-based monitoring target? (Select all) 
 Safety data 
 Patient visits 
 Clinical data (key data/primary outcome)  
 Not applicable 
 Don't know  
 Other 













Risk-based triggered monitoring - After certain events like a large number of 
adverse events or deviations occur this leads to more detailed monitoring 
 
Does the clinical study use a risk-based triggered monitoring procedure to... 







33a. guide centralised monitoring 
visits?     
33b. guide on-site visits?     
33c. completely replace on-site 
visists?     
33d. other     






33e. Which of the following factors are likely to trigger a non-scheduled site 
monitoring visit? (Select all that apply) 
 Suspected fraud 
 Rate of enrolment  
 Screen failure rate  
 Laboratory data signals  
 Number of data queries 
 Subject dropout/withdrawal  
 Incidence of adverse events  
 Geographical location of site 
 Number of protocol deviations  
 Lack of experience with the site  
 Missing case report forms (CRFs)  
 None 
 Not applicable  
 Other 














33f. What kinds of data are used to trigger a non-scheduled site monitoring visit? 
(Select all that apply) 
 Laboratory data 
 Case report form (CRF) data 
 Data related to performance, e.g. time of day, duration, sequencing of 
study activities  
 External data sets, e.g. national death registry, prescribing data, episode or 
claims data  
 Not applicable 




33g. Which type of data analyses are likely to trigger a non-scheduled site 
monitoring visit? (Select all that apply) 
For examples hover mouse/cursor over words for popup window to display 
additional information. (This may take a few seconds) 
 Missing data  
 Plausibility checks  
 More complex statistics 
 Simple descriptive statistics  
 Multivariate risk assessment  
 None 
 Not applicable  
 Don't know  
 Other 














Remote monitoring - Data monitored off-site, includes delivering documents via 
email, fax or snail mail to monitoring personnel to conduct source data verification. 
 
Does the clinical study use a remote monitoring procedure to... (Select one 







34a. perform periodic site audits 
via tele/video conference?     
34b. perform data reveiew and site 
performance evaluations using 
centrally available data? 
    
34c. other?     











34d. Is there a tracking/reminder 
system for expected case report 
forms (CRFs)? 









34e. Is there a set amount of time 
between data capture and sending 
files/reports? 
    
 
o If yes to question 34e. Please enter the amount of time between data 












Centralised monitoring - Data collected through an electronic data capture and 
queries identified by monitor that may need further attention to alleviate problems. 
 
Does the clinical study use a centralised monitoring procedure to... (Select 







35a. guide on-site visits?     
35b. completely replace on-site 
visists?     
35c. other     











35d. Does the clinical study 
conduct periodic audits of a subset 
of data, sites, centres or 
participants?  
    
 
 
35e. If ‘Yes’ to question 35d. Sample of: (Select one) 
 Data  
 Sites  
 Centres 
 Participants  
 Don't know  
 Other 



















 Depends on the data point/outcome measured. (E.g. 10% data monitoring 
from outcome A and 50% data monitored from outcome B). 
o Please explain: 
______________________________________________________
______________________________________________________ 
 Don't know 
 
 
35g. Which of the following factors are likely to trigger a non-scheduled site 
monitoring visit? (Select all that apply) 
 Suspected fraud  
 Rate of enrolment  
 Screen failure rate 
 Laboratory data signals  
 Number of data queries  
 Subject dropout/withdrawal  
 Incidence of adverse events  
 Geographical location of site  
 Number of protocol deviations 
 Lack of experience with the site  
 Missing case report forms (CRFs)  
 None 
 Not applicable  
 Other 




35h. What kinds of data are used to trigger a non-scheduled site monitoring visit? 
(Select all that apply) 
 Laboratory data 
 Case report form (CRF) data 
 Data related to performance, e.g. time of day, duration, sequencing of 
study activities  
 External data sets, e.g. national death registry, prescribing data, episode or 
claims data  
 Not applicable 
 Don't know  
 Other 













35i. What analyses of centralised data does the clinical study use to trigger a site 
monitoring visit? (Select all that apply) 
For examples hover mouse/cursor over words for popup window to display 
additional information. 
 Missing data  
 Plausibility checks  
 More complex statistics 
 Simple descriptive statistics  
 Multivariate risk assessment  
 Not applicable 
 Don't know  
 Other 














On-site Monitoring - All monitoring activities undertaken at the clinical trial site. 
 
36a. What data variables are included in on-site monitoring? (Select one) 
 All data points (100%) 
 Critical and non-critical data 
 Critical data points (key/primary data)  
 Non-critical (non-key/secondary data)  
 Not applicable 
 Don't know  
 Other 










36b. Does the clinical study 
perform on-site monitoring vistsis 
for only a subset of data, sites, 
centres or participants?  
    
 
 
36c. If ‘Yes’ to question 36b. Sample of: (Select one) 
 Data  
 Sites  
 Centres 
 Participants  
 Don't know  
 Other 



















 Depends on the data point/outcome measured. (E.g. 10% data monitoring 
from outcome A and 50% data monitored from outcome B). 
o Please explain: 
______________________________________________________
______________________________________________________ 
 Don't know 
 
 
36e. If ‘Yes’ to question 36b. How does data monitor select the sample of data, 
sites, centres or participants for on-site monitoring? (Select one) 
 A sampling method 
 A pre-defined set (e.g. first 2 participants)  
o Please explain: 
____________________________________________________ 
 Not applicable 
 Don't know  
 Other 




36f. If ‘A sampling method’ to question 36e. Which of the following 
sampling methods are used? (Select all that apply) 
For definitions hover mouse/cursor over words for popup window to display 
additional information. 
 Cluster sampling  
 Stratified sampling  
 Systematic sampling  
 Multi-stage sampling  
 Simple random sampling  
 Other 




















36g. Is there a minimum frequency 
of on-site monitoring visits for the 
clinical study? 
    
 
 
36h. If ‘Yes’ to question 36g. What is the frequency? (Select one) 
 Annually 
 2-3 times annually (every 4-6 months) 
 4-6 times annually (8-12 weeks) 
 7-11 times annually (every 4-6 weeks)  
 Once per month 
 Once per week  
 Other 




36i. If ‘Yes’ to question 36g. The frequency of on-site monitoring visits is 
most commonly determined by: (Select all that apply) 
 Budget  
 Study design 
 Study population 
 Usual practice of your organisation  
 Monitoring plan specified in protocol  
 Critical study requirement/procedure  
 Pre-defined analyses of potential risks  
 Standard operating procedures (SOPs)  
 Not applicable 
 Other 













Source data verification - Comparing source data (original or certified copy) 
documents to data recorded or entered to a case report form or electronic record or 
database. 
 







37a. source data to electronic 
database     
37b. source data to electronic case 
report form (eCRF) 









37c. Does the clinical study 
complete source data verification 
on all data (100%) points? 
    
 
 







37d. Is there a minimum frequency 
of source data verification visitis 
for the clinical study? 
    
 
 
37e. If ‘Yes’ to question 37d. What is the frequency? (Select one) 
 Annually 
 2-3 times annually (every 4-6 months) 
 4-6 times annually (8-12 weeks) 
 7-11 times annually (every 4-6 weeks)  
 Once per month 
 Once per week  
 Other 













If ‘No, Don’t know or Not applicable’ to question 37c.  
For each of the following records, what proportion are verified? (Select one 













37f. Consent form        
37g. Eligibility criteria       
37h. Critical data points (key 
data/primary outcomes)     
  
37i. Non-critical data points 
(non-key data/secondary 
outcomes) 
    
  
37j. Serious adverse events 
reports     
  
37k. Non-serious adverse 











37l. Does the clinical study 
perform source data verification for 
only a subset of data, sites, centres 
or participants involved in the 
study? 
    
 
 
37m. If ‘Yes’ to question 37l. Sample of: (Select one) 
 Data  
 Sites  
 Centres 
 Participants  
 Don't know  
 Other 



















 Depends on the data point/outcome measured. (E.g. 10% data monitoring 
from outcome A and 50% data monitored from outcome B). 
o Please explain: 
______________________________________________________
______________________________________________________ 
 Don't know 
 
 
37o. If ‘Yes’ to question 37l. How does data monitor select the sample of data, 
sites, centres or participants for on-site monitoring? (Select one) 
 A sampling method 
 A pre-defined set (e.g. first 2 participants)  
o Please explain: 
____________________________________________________ 
 Not applicable 
 Don't know  
 Other 




37p. If ‘Yes’ to question 37l. Which of the following sampling methods are 
used? (Select all that apply) 
For definitions hover mouse/cursor over words for popup window to display 
additional information. 
 Cluster sampling  
 Stratified sampling  
 Systematic sampling  
 Multi-stage sampling  
 Simple random sampling  
 Other 




















37q. Is there a minimum frequency 
of source data verification visitis 
for the clinical study? 
    
 
 
37r. If ‘Yes’ to question 37d. What is the frequency? (Select one) 
 Annually 
 2-3 times annually (every 4-6 months) 
 4-6 times annually (8-12 weeks) 
 7-11 times annually (every 4-6 weeks)  
 Once per month 
 Once per week  
 Other 












The following questions relate to data analysis and the process of translating data 
into meaningful information. 
 







38. a clear definition of ‘poor data 
quality’ or ‘dirty data’?      











39. an error acceptance level?      












40. If yes, and the error rate is 
found to be higher than the 
approved acceptance level, does 
your organisation implement 
further follow-up monitoring? 
    











41. a standard equation and/or 
method used to calculate error?      




















42. data quality and consistency 
reports generated?     
o If ‘Yes’ to question 42. Please specify how often they are generated and/or 





43. If ‘Yes’ to question 42. Who reviews the reports of data quality and 
consistency? (Select all that apply) 
 Sponsor  
 Auditor/Monitor  
 Data entry staff  
 Chief investigator 
 Senior staff management  
 No one 
 Don't know  
 Other 










44. a feedback mechanism in place 
to ensure continuous quality 
improvement? For example, a plan, 
do, check, act cycle.  
    
o If ‘Yes’ to question 44. Please specify how often they are generated and/or 













Education and training 
 







45. achieved a minimum level of 
education?     











46. a minimum level of 
experience?     











47. training/development devoted 
to data quality?     
 
 
48. If ‘Yes’ to question 47. Which of the following areas are data entry staff 
provided training in: (Select all that apply) 
 Monitoring process  
 Protocol procedure  
 Skills development 
 Specific research area investigation 
 Standard Operating Procedure (SOP) 
 International Conference on Harmonisation and Good Clinical Practice 
(ICH-GCP)  
 Don't know 
 Other 













49. If ‘Yes’ to question 47. Please specify how education and training is 
delivered: (Select all that apply) 
 Group 
 One-on-one  
 Online/computer module(s)  
 Other 




50. If ‘Yes’ to question 47. Please specify when education and training is 
delivered: (Select all that apply) 
 Prior to research 
 Throughout 
 Triggered due to a reoccuring event (e.g. incomplete CRFs)  
 Other 












51. achieved a minimum level of 
education?     











52. a minimum level of 
experience?     











53. training/development devoted 
to data quality?     
 
54. If ‘Yes’ to question 53. Which of the following areas is this person 
provided training in: (Select all that apply) 
 Monitoring process  
 
 







 Protocol procedure  
 Skills development 
 Specific research area investigation 
 Standard Operating Procedure (SOP) 
 International Conference on Harmonisation and Good Clinical Practice 
(ICH-GCP)  
 Don't know 
 Other 





55. If ‘Yes’ to question 53. Please specify how education and training is 
delivered: (Select all that apply) 
 Group 
 One-on-one  
 Online/computer module(s)  
 Other 




56. If ‘Yes’ to question 53. Please specify when education and training is 
delivered: (Select all that apply) 
 Prior to research 
 Throughout 
 Triggered due to a reoccurring event (e.g. incomplete CRFs)  
 Other 










57. Are the skills and performance 
of  the person(s) in charge of data 
monitoring assessed via periodic 
on-site evaluations by a third party 
(e.g. manager) during monitoring 
visit(s)? 
    












Participate in further research and comments. 
 
Would you like to further participate in a telephone interview? 
 
The interview will give you the opportunity to discuss your current data 
monitoring plan and opinions to developing best practice for monitoring data 
quality for clinical research trials? 
 
This information remains separate from the previous answers you have given in 
this survey. All answers to the previous questions will remain de-identified. 
 
 No  
 Yes 
 
Please provide an email address or phone number which you will allow us to 
contact you on: 
__________________________________________________________________
    
 

















Appendix L: Responses for national and international regulations, 
guidelines and/or standards 
Table 1: Combined ‘Yes’ and ‘Don’t know’ responses for national and international 






Which of the following regulations, guidelines and/or standards are followed.a,b 
 National Statement on Ethical Conduct and Research 363 (40.2) 86.0 
 Good Clinical Practice Guidelines (GCP) - International 
Conference for Harmonisation 
230 (25.4) 54.5 
 The Australian Clinical Trial Handbook - Therapeutic 
Goods Administration (TGA) 
142 (15.7) 33.6 
 International classification of diseases (ICD) 41 (4.5) 9.7 
 International Standards Organization (ISO) quality 
systems standard 
24 (2.7) 5.7 
 Food and Drug Authority (FDA) 21 CRF part 11 12 (1.3) 2.8 
 Systematized Nomenclature of Medicine -- Clinical 
Terms (SNOMED-CT) 
11 (1.2) 2.6 
 Clinical data acquisition standards harmonization 
(CDASH) 
10 (1.1) 2.4 
 Food and Drug Authority (FDA) Monitoring of Clinical 
Investigations 
8 (0.9) 1.9 
 Operational Data Model (ODM) 6 (0.7) 1.4 
 Analysis Data Model (ADaM) 3 (0.3) 0.7 
 Study data tabulation model implementation guide for 
human clinical trials (SDTM) 
2 (0.2) 0.5 
 Health Level 7 (HL7) 1 (0.1) 0.2 
 Logical Observation Identifiers names and Codes 
(LOINC) 
1 (0.1) 0.2 
 Other 23 (2.5) 5.5 
 Don’t know  22 (2.4) 5.2 
 Missing  4 (0.4) 0.9 
a Multiple response question (select all that apply) 












Appendix M: Data collection and storage tools 
Table 1: Data collection and storage tools (n=547) 
Variable n (%) Percent of 
Cases (%) 
Which data capture instruments are used to record source data?a,b 
 Paper 391 (41.2) 77.0 
 Microsoft excel spreadsheet/workbook 140 (14.7) 27.6 
 Database management software /tool 114 (12.0) 22.4 
 Electronic case report form (eCRF) 91 (9.6) 17.9 
 Automated instrument  
(e.g. pathology, ultrasound, x-ray) 
84 (8.8) 16.5 
 Mobile or tablet application  53 (5.6) 10.4 
 Don’t know 3 (0.3) 0.6 
 Other  35 (3.7) 6.9 
 Missing  39 (4.1) 7.1 
Are any of the following clinical data management tools used to store data?a,c 
 Noned 256 (45.7) 51.7 
 REDCap 87 (15.5) 17.6 
 OpenClinica 13 (2.3) 2.6 
 RAVE 6 (1.1) 1.2 
 ORACLE CLINICAL 4 (0.7) 0.8 
 MACRO 1 (0.2) 0.2 
 Not applicable 26 (4.6) 5.3 
 Don’t know 22 (3.9)  4.4 
 Other  93 (16.6) 18.8 
 Missing  52 (9.3) 9.5 
a Multiple response question (select all that apply) 
b Total n (%)=950 (100.0) 
c Total n (%)=560 (100.0) 
d n=2 respondents answered ‘no’ and ‘not applicable’ due to select all apply survey item. Responses to 












Appendix N: Who reviews the reports of data quality and consistency 






Who reviews the reports of data quality and consistency?a,b 
 Chief investigator 46 (31.1) 63.9 
 Senior staff management 36 (24.3) 50.0 
 Data entry staff 31 (20.9) 43.1 
 Auditor/Monitor 15 (10.1) 20.8 
 Sponsor  9 (6.1) 12.5 
 Other  11 (7.4) 15.3 
 Missing  0 (0) 0 
a Multiple response question (select all that apply) 












Appendix O: Education and training data entry staff and data monitor 
Table 1: Follow-up questions for education and training data entry staff (n=240) and 
data monitor (n=205). 
Is it required that the primary person(s) responsible for data entry have 
training/development devoted to data quality? 
 If yes, which of the following areas are data 




  Protocol procedure 181 (22.2) 79.1 
  SOPs 150 (18.4) 63.0 
  skills development 136 (16.7) 57.1 
  specific research are investigation 116 (14.2) 48.7 
  Monitoring process 111 (13.6) 46.6 
  ICH-GCP 106 (13.0) 44.5  
  Don’t know  5 (0.6) 2.1 
  Other 9 (1.1) 3.8 
  Missing  2 (0.2) 0.8 
 If yes, please specify how education and 
training is delivered:a,c 
 
 
  one-on-one 175 (44.5) 74.5 
  Group 116 (29.5) 49.4 
  online/computer modules(s) 91 (23.2) 38.7 
  Other 6 (1.5) 2.6 
  Missing 5 (1.3) 2.1 
 If yes, please specify when education and 
training is delivered:a,d 
 
 
  Prior to research  199 (44.0) 85.0 
  Throughout 169 (37.4) 72.2 




  Other 4 (0.9) 1.7 
  Missing 6 (1.3) 2.5 
Is it required that the primary person(s) responsible for monitoring the data have 
training/development devoted to data quality.  
If yes, which of the following areas is this person provided training in:a,e 
 Protocol procedure 164 (20.6) 80.8 
 Monitoring process 152 (19.1) 74.9 
 skills development 127 (16.0) 62.2 
 SOPs 126 (15.8) 62.1 
 specific research are investigation 113 (14.2) 55.7 
 ICH-GCP 104 (13.1) 51.2 
 Don’t know  2 (0.3) 1.0 
 Other 5 (0.6) 2.5 
 Missing 2 (0.3) 1.0 
If yes, please specify how education and training is delivered:a,f 
 one-on-one 147 (41.5) 74.2 
 online/computer modules(s) 96 (27.1) 48.5 
 Group 94 (26.6) 47.5 
 Other 10 (2.8) 5.1 
 
 







 Missing 7 (2.0) 3.4 
If yes, please specify when education and training is delivered:a,g 
 Prior to research  168 (45.0) 83.6 
 Throughout 139 (37.3) 69.2 




 Other 5 (1.3) 2.5 
 Missing 4 (1.1) 2.0 
a Multiple response question (select all that apply) 
b Total n (%)=816 (100.0) 
c Total n (%)=393 (100.0) 
d Total n (%)=452 (100.0) 
e Total n (%)=795 (100.0) 
f Total n (%)= 354 (100.0) 











Appendix P: Data points selected for on-site monitoring  




What data variables are included in on-site monitoring? 
 all data points (100%) 141(54.4) 
 critical data points (key/primary data) 52 (20.1) 
 critical and non-critical data 34 (13.1) 
 Non-critical (non-key/secondary data) 0 (0) 
 Not applicable 11 (4.2) 
 Don’t know 10 (3.9) 
 other 3 (1.2) 













Appendix Q: Factors that determine the frequency of on-site 
mentoring  






The frequency of on-site monitoring visits is most commonly determined by:a,b 
 Study design 89 (17.1) 37.1 
 Budget 80 (15.4) 33.3 
 Monitoring plan specified in protocol 74 (14.2) 30.8 
 Usual practice of your organisation 58 (11.2) 24.2 
 Standard operating procedures (SOPs) 47 (9.0) 19.6  
 Study population 43 (8.3) 17.9 
 Critical study requirements/procedure 37 (7.1) 15.4 
 Pre-defined analyses of potential risks 21 (4.0) 8.8 
 Not applicable  41 (7.9) 17.1 
 Other 11 (2.1) 4.6 
 Missing 19 (3.7) 7.3 
a Multiple response question (select all that apply) 











Appendix R: Forwards stepwise model 
Table 1: Forward stepwise (step 1), coefficients of the model predicting whether a clinical study was observational or interventional 
(dependent variable) based on n=179 (32.7%). 
Category Variable  Multivariate analysis 






Lower  Upper  P 
Study set up 
Definition protocol deviation and/or 
violation 
0.889 3.922 2.433 1.009 5.864 0.048 
R2 = .0 (Hosmer & Lemeshow) .021 (Cox & Snell) .038 (Nagelkerke). Model χ2 (1, 179) = 3.797, p=0.051. Correctly classified 86.6% of the cases. 
Abbreviations: CI, confidence interval. 
Definition for protocol deviation and/or violation is compared with ‘no’ as the referent category. 
Independent variables included in multivariate analysis: clinical study demographics (Participants targeted for baseline enrolment); data collection setting 
(hospital, university and other); study set-up (definition for a protocol deviation and/or violation, data quality monitoring plan/SOP QA and QC and follow 
guidelines/regulations); Data monitoring methods (risk-based triggered monitoring, remote monitoring and source data verification); and data representation (a 
feedback mechanism CQI). 
 
   
 
 







Appendix S: Backwards stepwise model  
Table 1: Backwards stepwise (step 9), coefficients of the model predicting whether a clinical study was observational or 
interventional (dependent variable) based on n=179 (32.7%). 
Category Variable  Multivariate analysis  






Lower  Upper  P 
Data collection setting 
University  1.674 2.511 5.332 0.673 42.264 0.113 
Other 1.472 1.943 4.356 0.550 34.503 0.163 
Study set up 
Definition protocol deviation and/or 
violation 
0.971 4.469 2.640 1.073 6.495 0.035 
R2 = .417 (Hosmer & Lemeshow) .054 (Cox & Snell) .100 (Nagelkerke). Model χ2 (5, 179) = 9.997, p=0.075. Correctly classified 86.6% of the cases. 
Abbreviations: CI, confidence interval.  
All variables (university setting, other setting, definition for protocol deviation and/or violation) are compared with ‘no’ as the referent category.  
Independent variables included in multivariate analysis: clinical study demographics (Participants targeted for baseline enrolment); data collection setting 
(hospital, university and other); study set-up (definition for a protocol deviation and/or violation, data quality monitoring plan/SOP QA and QC and follow 
guidelines/regulations); Data monitoring methods (risk-based triggered monitoring, remote monitoring and source data verification); and data representation (a 











Appendix T: COREQ (COnsolidated criteria for REporting 
Qualitative research) Checklist 
A checklist of items that should be included in reports of qualitative research. You 
must report the page number in your manuscript where you consider each of the 
items listed in this checklist. If you have not included this information, either 
revise your manuscript accordingly before submitting or note N/A. 
 
Topic Item No. Guide Questions/Description Reported on 
Page No. 
Domain 1: Research team and reflexivity   
Personal characteristics   
Interviewer/facil
itator  
1  Which author/s conducted the interview or focus 
group?  
166 
Credentials  2  What were the researcher’s credentials? E.g. PhD, MD  166 
Occupation  3  What was their occupation at the time of the study?  166 
Gender  4  Was the researcher male or female?  166 
Experience and 
training  
5  What experience or training did the researcher have?  166 
Relationship with participants   
Relationship 
established  





the interviewer  
7  What did the participants know about the researcher? 




8  What characteristics were reported about the inter 
viewer/facilitator? e.g. Bias, assumptions, reasons and 
interests in the research topic  
166-167 
Domain 2: Study design   




9  What methodological orientation was stated to 
underpin the study? e.g. grounded theory, discourse 
analysis, ethnography, phenomenology, content 
analysis  
165 
Participant selection   
Sampling  10  How were participants selected? e.g. purposive, 




11  How were participants approached? e.g. face-to-face, 
telephone, mail, email  
166 
Sample size  12  How many participants were in the study?  168 
Non-
participation  
13  How many people refused to participate or dropped 
out? Reasons?  
167-168 
Setting   
Setting of data 
collection  










16  What are the important characteristics of the sample? 
e.g. demographic data, date  
169 
Data collection   
Interview guide  17  Were questions, prompts, guides provided by the 
authors? Was it pilot tested?  









19  Did the research use audio or visual recording to 











Field notes  20  Were field notes made during and/or after the 
interview or focus group?  
n/a 
Duration  21  What was the duration of the inter views or focus 
group?  
166 
Data saturation  22  Was data saturation discussed?  167 
Transcripts 
returned  
23  Were transcripts returned to participants for comment 
and/or correction? 
167 
    
Domain 3: analysis and findings  
Data analysis  
Number of data 
coders  
24  How many data coders coded the data? 167 
Description of 
the coding tree  




26  Were themes identified in advance or derived from the 
data? 
167 









29  Were participant quotations presented to illustrate the 
themes/findings? Was each quotation identified? e.g. 
participant number 





30  Was there consistency between the data presented and 
the findings? 
167-178 
Clarity of major 
themes  
31  Were major themes clearly presented in the findings? 168 
Clarity of minor 
themes  
32  Is there a description of diverse cases or discussion of 
minor themes? 
168 
Developed from: Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting 
qualitative research (COREQ): a 32-item checklist for interviews and focus 
groups. International Journal for Quality in Health Care. 2007. Volume 19, 
Number 6: pp. 349 – 357  
 
Once you have completed this checklist, please save a copy and upload it as 
part of your submission. DO NOT include this checklist as part of the main 











Appendix U: Online Semi-Structured Interview Guide 
Introductory Statement  
Hi [name],  
Firstly, thank you very much for taking the time and agreeing to take part in this 
study. As you probably know, my name is Lauren and I am currently completing 
the second year of my PhD at the University of Wollongong, which this research 
is part of.  
I understand that you have already read and signed the Participant Information 
Sheet and Participant Consent Form. Did you have any questions about any of the 
information mentioned in either of those? [pause] 
I will just read you an overview of the plans for today’s interview, so you know 
what to expect. Just to clarify the purpose of this research is to understand how 
clinical researchers experience data quality monitoring in Australia. In particular, 
today’s interview questions will focus on auditing tools and procedures, which 
include staff training. We will also touch on the motivators and barriers to ensure 
quality assurance of clinical research data. 
During our interview, I will be asking you about your experience with the 
monitoring of data quality before, during and after a clinical study. I will ask you 
to describe your experiences that have been successful and/or unsuccessful. I will 
then finish up talking to you about any education and training that you may have 
undertaken related to data quality.  
The findings from this research will be used as part of my PhD thesis, and will be 
published in scientific journals and presented at suitable conferences. Ultimately, 
my research aims to develop a toolkit for clinical researchers to improve data 
quality monitoring in Australia.  
I also just wanted to remind you that we are focusing on your experience in 
monitoring data quality in clinical studies, so this includes both intervention trails 
and observation studies. I am not assessing your knowledge of what is right or 
wrong I am purely trying to work out what is happening in the clinical research 
 
 







space. In addition, to make sure that the privacy of any people or organisations 
you are and or have worked with is protected I will remove these from the 
interview before analysis.  
Before we start, based on what I have just read do you have any questions? 
[pause] Can I confirm that you still agree to participate in this interview? [pause] 
I also want to remind you that your participation today is voluntary and that you 
may stop the interview at any time without any consequence. If you would like to 
stop the interview, or feel like you need to take a break, please just let me know. 
Similarly, if there is a question that you do not feel comfortable answering please 
let me know too. Finally, if there are any technical difficulties and something does 
go wrong, please tell me by sending me an email and hopefully we can fix it for 
you. 
I expect our interview today to take between 30 and 60 minutes. Is that okay with 
you? [pause] I will check with you after 30 minutes to make sure you are okay for 
time.  
Can I also check with you that you are happy to have this interview recorded 
today? [pause]  
[If participant does not agree to recording] Can I check if you are happy about me 
writing notes from today’s interview by hand and sending them by email to you 
for review? [pause]  
[If participant agrees to recording] The recording helps to make sure I can 
transcribe what was said in our interview today. The recording will be stored 
securely at the University of Wollongong and all of the data from this recording, 
including your interview transcript, will be de-identified. We will be using your 
participant code to analyse the data to ensure your privacy. The file that maps 
your code to your name will also be kept securely and separately from the rest of 
the data. My supervisors and I will be the only people who have access to the 
data, and your name will not appear in any transcripts, my thesis, publications or 
presentations.   
 
 







[Recording on] Thank you for agreeing to have this interview recorded, I will start 
recording now [turn on recording devices if participant agrees]. 
[Recording off] Thank you for agreeing to me handwriting notes from this 
interview, I will start taking notes now.  
Do you have any questions you would like to ask before we start? [pause] 
Interview Questions  
[Name] to start with today I’ll be asking you some introductory questions. Firstly, 
it would be great to know about the journey you have had working in clinical 
research.  
Probes: 
 How you came to working in clinical research 
 Drove interest in working in this area 
 Range of clinical research settings / physical environment  
 Range of clinical research type (intervention/observation) 
o Intervention  - type (diagnostic, epidemiological, genetic, 
prevention, quality of life, screening, treatment)  
As I mentioned earlier, I am particularly interested in understanding your 
experience with monitoring data quality. For the purpose of today’s interview, I 
am going to refer to ‘data quality monitoring’ as the oversight and review of 
research processes, procedures, records, data reporting, appropriate conduct and 
ongoing evaluation. How do you feel about this definition? [pause] 
So now, can you think about the clinical research setting/range of settings 
[adapted to suit] you just mentioned that you have work in and could you 
comment broadly on your individual experience with monitoring data quality.  
Probes: 
 Similarities and differences 












So now, the following questions follow on from the answers you provided in the 
online survey earlier this year. Please keep in mind that the survey answers were 
linked to a particular clinical study in which yours was [trial name]. The 
difference today is that this interview aims to understand more in depth your 
personal experiences and points of view.  
Data definition  
From your survey answers, you have told me that you implement/don’t 
implement/follow/don’t follow [adapt to individual survey answer]. It would be 
great if you could describe your experience with such data quality procedures that 
are implemented before a clinical study starts. 
Probes: 
 Reflect on how this experience happened/role in this process 
 Reflect on the setting and context  
 Reflect on successful and not so successful  
 An example of an experience which worked well or didn’t work 
Data collection  
I would now like to move onto data collection, which as you know is the process 
of accumulating data elements. Your survey answers show that the clinical study 
has [adapt to individual survey answer]. Could you describe your experience with 
such procedures over your research career?  
Probes:  
 An example for overcome missing values during data collection 
 Reflect on technology (paper, mobile, electronic) 












In your survey answers, you mentioned that the clinical study implements [adapt 
to individual survey answer] to audit and monitor data. Could you describe your 
involvement with this/these method(s)?  
Probes: 
 Reason why [name method is chosen and completed 
 Reason for implementing more than one method 
 Experience with other methods/reason for change 
 Key factors of method 
Data representation  
Now I would like to focus on your experience with data analysis and translating 
data into information for dissemination. Your survey answers indicate that you 
[adapt to individual survey answer] could you comment on your role and your 
opinion about such procedures.  
Probes:  
 Reflect on a definition for ‘poor data quality’ 
 Reflect on an error acceptance level  
 Reflect on continuous quality improvement  
 Reason why selection of the three most important factors that impact data 
quality answer 
Education and training 
Given what we have spoken about today and hearing about your experiences, I’d 
like you to reflect on any training you have received regarding data entry, data 
quality or data monitoring. Can you tell me about these experience(s)? 
Probes:  
 What the experience involved 
 Usefulness of the training 
 Areas of training (skills, procedures, SOPs, ICH GCP) 













That takes us to the end of our interview. Thank you very much [name] for 
agreeing to be interviewed today. You have given me some great insights into 
your experience with monitoring data quality as a clinical researcher. Before we 
finish up, can I ask if there were anything else, you would like to add. [pause] 
If you have any further questions or think of anything you would like to add 
please do not hesitate to contact me by email after the interview. 
Before you go, I need to remind you that the recording from today’s interview 
will be transcribed. If you would like to review your transcript, I can email it to 
you so you can confirm that you are happy with what has been transcribed.  













Appendix V: Interview Questions 
This document outlines the questions you will be asked during your telephone 
interview by the interviewer, Lauren Houston. You have been provided these 
questions before your scheduled telephone interview to help you in understanding 
what is involved when completing the interview, and to give you some time to 
reflect and develop your responses if you wish, given these questions ask about 
your specific experiences before, during and after a clinical study. 
Please do not hesitate to contact Lauren Houston on [telephone number] or by 
[email address] if you have any questions.  
Data quality monitoring definition 
The oversight and review of research processes, procedures, records, data 
reporting, appropriate conduct and ongoing evaluation. 
 
Interview questions 
1. Could you tell me about your journey you have had working in clinical research? 
2. Could you comment broadly on your individual experience with monitoring data 
quality? 
3. Could you describe to me your experience with data quality procedures that are 
implemented before a clinical study starts? 
4. Could you describe your experience with data quality procedures during the data 
collection phase? 
5. Could you describe to me your involvement with any methods implemented to audit 
and monitor data? 
6. Could you comment on your role and opinion with any data quality procedures you 
have been involved in during data analysis phase and translating data into 
information for dissemination? 
7. Could you reflect on any training you have received regarding data entry, data 












Appendix W: Transcription Protocol  
This protocol follows the outline of the Sample Qualitative Data Preparation and 
Transcription Protocol published in ‘Beyond the Qualitative Interview: Data 
Preparation and Transcription’ by McLellan, MacQueen and Neidig (2003).   
 
Ms Lauren Houston shall transcribe all interview recordings which will be made 
from an audio recording.  
 
1. Text formatting  
General Instructions  
The following format in Microsoft Word will be adhered to by the transcriber for 
all interviews: 
Calibri (Body) font, size 12 
Margins: Top and bottom – 2.5cm, left – 2.5cm, right – 6.0cm  
All text shall begin at the left hand side margin (no indents)  
All text shall be left justified  
Line numbers (excluding coversheet)  
Page numbers in footer and right justified (excluding coversheet) 
Coversheet of interview transcripts 
The interview transcript shall include a coversheet as the first page of the 
document, and include the following information:  
The transcript title ‘Interview Transcript’ in bold text, size 18 
Participant identification code  
Date and time of interview 
Location of interview  
Interviewer name 
Transcriber name  
Reviewer name 
Medium, all interviews conducted via telephone 
Number of interviews with participant  
If transcript approved by the participant (if requested)  
 
 







Date the transcript was originally transcribed 
Date transcript was checked  














Example of transcript coversheet: 
Interview transcript  
 
Participant code: ID-0000 
 
Date and time of interview: 1st January 2018, 12:00pm 
 
Location: 41.309 UoW Science Building 
 
Interviewer name: Lauren Houston  
 
Transcriber name: Lauren Houston 
 
Reviewer name:  John Smith 
 
Medium: Telephone interview 
 
Number of interviews with participant: 1/1 
 
Transcript approved by participant: Not requested  
 
Date transcribed: 01st September 2018  
 
Date transcript checked by transcriber: 14th October 2018 
 
















Start of Transcript 
The transcriber shall indicate the beginning of the interview recording and 
transcript, by typing the words ‘START OF INTERVIEW RECORDING’ at the 
start of a new page immediately after the coversheet. The text will be written in 
uppercase, italic, size 16 and centre justified. 
End of Transcript  
When the interview has reached completion, the transcriber shall indicate by 
typing ‘END OF RECORDED INTERVIEW’ on the last line immediately after the 
last spoken text. The text will be written in uppercase, italic, size 16 and centre 
justified.  
Source Labelling  
The individual participant identification code shall be indicated by ‘ID-’ followed 
by the appropriate four digit code provided in the prior survey to the participant, 
for example ID-0000. The code will be written in uppercase and immediately 
before the spoken text on the same line followed by a colon.  
The interviewer shall be indicated by the code ‘INTERVIEWER’. The code will 
be written in upper case and immediately before the spoken text on the same line 
followed by a colon. 
 
2. Content   
Interview recordings will be transcribed verbatim, to include every recorded 
word, exactly as said and nonverbal or background sounds. This includes the 
following: 
Verbal Content  
All filler words such as ‘um’, ‘ah’, ‘oh’, ‘mm’, ‘mhmm’, ‘yeah’, ‘huh’ will be 
transcribed. 
Mispronounced words will be transcribed as pronounced. If mispronunciation 
results in difficulties with understanding of the text, the correct word shall be 
typed immediately after in square brackets. E.g. I thought that was pretty pacific 
[specific], but they disagree.  
 
 







Any foul language, slang and/or swear words shall be written as said and will not 
be “cleaned up”.  
Unfinished or cut off words will be transcribed and a hyphen shall be inserted at 
the end of the last letter or audible sound. E.g. he wen- he went and did what I 
told him to do).  
Repeated words or phrases shall be transcribed. E.g. so ah for example, I think 
that, that you shouldn’t…  
Obvious shortening of words and informal contractions will be transcribed as 
said. E.g. ‘gonna’ meaning going to.  
Non-Verbal Content  
No non-verbal or background sounds will be transcribed in square brackets. E.g. 
[laugh], [sigh], [cough]. 
Inaudible Information 
Speech that is difficult to be recognised or deciphered as an explicit word or short 
phrase by the transcriber shall indicate as “inaudible” at the point of speech where 
it occurred in square brackets. E.g. what I call a [inaudible] shop is where I go 
shopping.  
Overlapping Speech  
If there is simultaneous speaking or overlapping of speech recorded and the 
transcriber cannot hear clearly or distinguish what each person is saying the 
transcriber shall indicate as “cross talk” at the point of speech where it occurred in 
square brackets. E.g. [cross talk].  
Pauses  
Short pauses between speaking shall be indicated by a comma.  
Longer pauses between 2-5 seconds of speaking shall be indicated at the point of 
speech where it occurred through the use of three ellipse. E.g. Such as then . . . 
um, we would 
Substantial delays shall be transcribed with action or “delay” at the point of 
 
 







speech where it occurred in square bracket. E.g. [toilet break] or [delay].  
Technical issues/Freezing  
If there is a technical issue, prolonged unexplained silence (greater than 10 
seconds) or freeze in the recording it shall be indicated as a “freeze” at the point 
of speech where it occurred in square brackets. E.g. [freeze].  
Sensitive information  
If names of people, locations of work or any other identifiable information are 
spoken of in the discussion, the transcriber shall replace to ensure confidentiality 
at the point of speech where it occurred in square brackets. E.g. [name], 
[location].  
3. Transcript reviewing (quality assurance and control)   
Three stages of transcript reviewing:  
1. The transcriber will check and proof read transcripts against the audio 
recording for accuracy. Any revisions that are required will be made to ensure the 
transcript reflects the audio recording.  
2. A reviewer will then check the transcription against the audio recording for 
accuracy. The second reviewer will use tracked changes in Microsoft Word to 
document any recommended changes. The transcriber and reviewer will discuss 
any discrepancies identified before transcript is amended.  
3. If requested by the participant, the transcript and audio recording will be sent to 
the participant for checking. Any discrepancies or amendments requested by the 
participant will be made in tracked changes to the document and returned to the 
primary researcher.  
A Microsoft Excel spreadsheet will be kept to document all three stages for the 
transcript reviewing process. Documentation will include dates the transcript was 











4. Saving the transcripts   
All transcripts will be saved in a Microsoft Word file. The final copy of the 
transcript approved by the transcriber and reviewer, and if requested by the 
participant will be saved in both a Microsoft Word file and a Portable Document 
Format (PDF).  
All transcript files will be named with the participant code, initials of those who 
have checked the transcript, and the day, month and year of checked transcript 
(DDMMYY). The final version of the transcript will be indicated with the name 
FINAL.  
E.g. 
Unchecked transcript: Transcript ID-0000  
Stage 1: Transcript ID-0000 LH 141018 
Stage 2: Transcript ID-0000 LH 141018 YP 01022019 






















Appendix Y: Secondary themes, sub-themes and representative quotes regarding each of the primary themes 
Table 1: Sub-themes and representative quotes regarding the ‘Education and training’, “Ways of working’ and ‘Working with 
technology’ primary themes. 
Primary 
theme 
Sub-theme Representative quotes  
Education 
and training 
Importance “everybody is referring to the same [Good Clinical Practice] bible” (P3) 
“sticking to ethics registration” (P5) 
“There isn't a common basis for the whole lot. I think if you can get something there and get people really thinking about 
it...I think people are yelling out for it” (P4). 
“If there's more information or more training about data monitoring process or data entry education, to clinical research that 
would be very great.” (P6) 
Staff training “The only difference would of been…filling people in on the changes and then how that’s been incorporated into the 
standard operating procedures and their own unique way into each organisations.” (P2) 
 Pre-implementation “Ah and start to get some familiarity with what this is gonna look like [study procedures and CRFs], once it hits the road and 
so, that would be one kind of way that we did that.” (P2) 
 On-job “So in terms of running clinical trials I learned everything on the job I guess.” (P5) 
Ways of 
working 
Responsibility “we should come up as a team, make sure everybody knows their role that everything's okay” (P7) 
 Additional 
responsibility 
“Once you have a clinician whose super imposing research for which they are not being paid and which their trying to 
squeezed into their usual day that’s when the issues arise.” (P1) 
 “I think you know if you've got um clinicians so you know nurses putting in data they're actually putting in data but they're 
not really aware that that data could be used in other things and they don't they don't necessarily appreciate the importance of 
um that all fields being completed.” (P4) 
Staff engagement  “That’s one very convenient way of engaging with a group of people who perhaps rarely get to play a role in helping put 
these things together…why don’t you review them and give them some comments” (P2). 
 Workplace 
communication  
“We held regular meetings with staff so to ensure that there was any issue and if there were some yes if they’d obviously 
obtained an odd score or not response to a question, we could discuss it.” (P5) 
 Seeking advice  “I’ve talked about that with [boss] as I said even with the studies, I’m doing now I will go back to [boss] and say what do 
you think I should do with this? Um, how do you think I should manage this?” (P3) 
Organisational 
environment 
“Whereas now I guess um I've moved up [laughs] it's more the research assistants who are, who keep, keep an eye on it and 
I’m a little more distanced.” (P5) 
Skills and expertise  “People from several disciplines who were involved so there was a geriatrician who could interpret like the medication lists 






“I mean we used to in the old days, we would actually have to go to the sites to collate the papers that changed to then the 
papers would then be sent to us, so it started to get more about currency of data.” (P2) 
“So, it’s changed over time as I’m sure other participants would have well and truly told you. Um since the 90s when 
 
 







everything was paper based um you had…paper case report forms in duplicate.” (P3) 
“I think if people are collecting um paper and I'm not aware of what the researchers do that.” (P7) 
Quicker and easier “Yes, yes everything is there. So, we can just ah with because of everything is online everything from it is kept it is very easy 
to actually monitor.” (P7) 
Investment “Real time range checking...it wouldn’t prohibit entry of data, but it would certainly require somebody to think about 
whether the number or the word they just put in was indeed the correct one.” (P2) 
Unintended consequences  “Make sure that um all the data had been entered correctly because at one stage you could enter it, but it wouldn't go 
in…there was a glitch in it in the program.” (P4) 
 
 







Table 2: Secondary themes, sub-themes and representative quotes regarding the primary theme ‘Working with data’. 
Secondary 
theme 
Sub-theme Representative quotes  
Monitoring Method and 
frequency 
“doing some regular check, plotting the data, doing some simple stuff” (P5) 
“So, I have been involved in project they have they are very fussy about the data monitoring they have to check every day… probably 
back in the day its paper based…they didn't check until the very end of the trial” (P6). 
“when we say monitoring, we are going to actually start implementing a lot more statistical compliance monitoring in house so we can 
save on travel because we are [name] funded so we don’t have a lot of funds to send people away.” (P3) 
Approach “It depended on whether it was academic, whether it was commercial…investigator-initiated study, or an investigator sponsored study 
or a commercially sponsored study and what the aims of the study were” (P3). 
“I found that it varies from project to project and also ah even within the same setting ah you know different projects different research 
team um depending on their size may have different factors.” (P6) 
“Well, look um I am going to be sort of bold here and say, it’s never really has been different.” (P2) 
“I've always kinda taken the same approach in monitoring data quality.” (P5) 
Detailed plan or 
framework 
“We had to submit to a monitoring plan…this actually should have been submitted with the protocol, but we didn't know at the time” 
(P7). 
No data checking 
or monitoring 
“I guess it's more in my head I suppose… I just knew what I needed to do. I never wrote it down. I kind of just did the difference steps 
over and over” (P5). 
Assumptions or 
opinions 
“They’re not a complicated study it’s not like a drug trial. Drug trials are the ones we have all those sorts of trouble” (P1). 
Errors Error avoidance “We've tried to minimise any bias, or you know introduction of any errors. So, we've always had the same training procedure” (P4). 
Error acceptance “We picked 1% probably arbitrarily…how much error would you begin to feel a bit uncomfortable about in terms of the capacity for 
seriously changing the reported outcome from a study” (P2). 
Human error “Just because with excel there were quite a lot of um of ways things could go wrong like formulas that are set up in several 
spreadsheets or even jumping a line or just entering a wrong number. Just doing a typo which is not always visible straight away.” (P5) 
Audits Being audited “We also, under various funding arrangements were subject to external completely independent compliance checks... we would 
welcome those and work very closely with the people doing it. We didn’t like them.” (P2) 
Missing Identifying 
missing data 




“we would simply use the last value carried forward” (P1) 
“we would give them a call and ask over the phone” (P5) 
“I know that they did manage, that they managed to manipulate the data in such a way that they did get an outcome, but I know I 
remember we were struggling with that. I remember talking at meetings about how we were, how the statisticians were going to 
manage that to, to be able to provide an answer.” (P3) 
 
 







No missing data “Oh, we aren’t going to have any missing data points.” (P1) 
Quality Elements of 
quality 
“Unless you could substantiate claims about data integrity and reliability you really might as well not bother” (P2). 
 Need for 
improvement  
“I remember even her [boss] saying ‘you know we don’t want to leave all this evidence around, sponsors to be looking at um and 
seeing that there’s of lots of dirty data sitting outside’ I don’t know if anyone else has said that to you but it’s something that has 




“the first thing you'd realise then is that CRFs would often lay around uncompleted for considerable periods of time and then there'd be 
a rush to fill them in before people arrived or they were due to be sent and inevitably when you allowed time to elapse between a 
clinical assessment and the forms being filled in there's much greater chance of there being mistakes and errors.” (P2) 
Reporting data 
queries 
“the desire for this kind of unwritten or unspoken ah, rule that if you had lots of queries you don’t want to an auditor to come in behind 




















GCP downfall “I made sure they actually did it [GCP training] although it was pretty tedious… it was like sticking pins in your eyes, but I actually still 
think it made people think about exactly what they're doing and that they're part of a bigger thing. I think if it was slightly tweaked, I 
think that, that it would be actually more instructive.” (P4) 
GCP benefit “It’s all been very repetitive, and it has all been very sensed around the same sort of rules…everything focuses back on GCP, so 
everybody keeps looking back to GCP and saying ok what are the requirements…what’s the bare minimal we can get away with.” (P3) 
Protocol Creation “I just follow the template…this was how it first did my, my first protocol” (P7). 
Implementation 
and adherence 
“That allowed us to adopt a whole range of more or less protocol defined approaches to all the activities relating to the design, 
implementation conduct and reporting of clinical trials.” (P2) 





Creation “No, it was always had a standalone SOP…around monitoring visits and frequency.” (P3) 
Introduction “It seems awfully difficult I don’t quite understand why we would want to do any or all of these things (SOPs). Why can’t we just 
collect a truck load of data and then analyse it. So, um I think that’s an understandable thing um, but it requires a fair amount of work at 
the beginning. Particularly for new people.” (P2) 
Setting “There was a commercial and non-commercial arm at the [location] and initially we had separate SOPs but then they all got moulded 
into one another. So, everything that use to be not quite as strict started to be become stricter and I think there was a lot of resentment 
around that actually in the team, including myself.” (P3) 
 
